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Abstract
G protein-coupled receptor kinases (GRKs) are a family o f serine/threonine kinases 
that phosphorylate and mediate densensitisation o f agonist-occupied G protein- 
coupled receptors (GPCRs). Recent evidence suggests, however, additional cellular 
functions for these enzymes.
The seven mammalian GRKs are divided into the GRK1-, GRK2- and GRK4-like 
subfamilies. I have discovered that GRK4 subfamily members contain functional 
nuclear localisation sequences (NLSs). The location o f the NLSs o f GRK5 and 6  is 
similar whereas the NLS o f GRK4 is more N-terminal. Although all members o f the 
GRK4 subfamily contain NLSs the nuclear localisation o f these kinases is 
differentially regulated by Ca2+/CaM. Furthermore, the NLS o f GRKs 5 and 6 , but 
not GRK4, mediate DNA-binding in vitro, suggesting differential nuclear signalling 
roles for these enzymes.
I investigated structural determinants o f GRK5 required for DNA-binding and 
nuclear localisation. The ability o f GRK5 to bind DNA requires an intact NLS and an 
N-terminally located calmodulin (CaM) binding domain. Additionally, CaM- 
dependent autophosphorylation o f GRK5 reduces the affinity o f GRK5 for DNA. 
Overexpression o f GRK5 in cultured rat neonatal cardiac myocytes rescues 
hypertrophy induced by phenylephrine, an a-adrenergic receptor agonist, or by 
activation of PLC. Hypertrophy is not rescued by over expression o f GRK5 with a 
mutant NLS (GRK5ANLS), mutant N-terminal CaM binding site (GRK5NTPB) or a 
catalytically in active version o f the kinase (GRK5K215R). That GRK5 and
GRK5ANLS show similar kinase activity in vitro suggests that both the kinase 
activity and the DNA-binding ability o f GRK5 contributes to its role in rescuing 
hypertrophy. Since GRK5 rescues hypertrophy induced downstream of adrenergic 
receptors, by PLC activation, GRK5 DNA-binding ability and kinase activity in the 
nucleus would appear to be required for this effect. Clearly, the GRK4 subfamily o f 
GRKs is more diverse than previously appreciated and play a role in cellular 
signalling in the nucleus distinct from GPCR desensitisation.
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Abbreviations used in this thesis
ocAR: a-adrenergic receptor 
ocibAR: aie-adrenergic receptor 
PAR: p-adrenergic receptor 
parr: Parrestin
p-MHC: P-myosin heavy chain
a-M HC: a-myosin heavy chain
7TMRs: seven transmembrane receptors
AC: adenylyl cyclase
ACE: angiotensin converting enzyme
ACh: acetylcholine
ANF: atrial natriuretic factor
Angll: angiotensin II
AnglliAR: angiotensin II type IA receptor
Ao: angiotensinogen
AP: autophosphorylation
aPKC: atypical protein kinase C
AR: adrenergic receptor
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ATP: adenosine triphosphate 
ATR: angiotensin receptor 
bHLH: basic helix-loop-helix 
BSA: bovine serum albumin 
Ca2+/CaM: calcium-calmodulin 
Ca2+: calcium
CALM: clathrin assembly lymphoid myeloid leukemia 
CaM: calmodulin
CaMBP/m: cytosolic CaM binding sequestrant
CaMBP/n: nuclear CaM binding sequestrant
cAMP: cyclic adenosine monophosphate
CAMTA2: calmodulin binding transcription activator 2
CASTing: cyclic amplification of targets
CBP: cAMP response element-binding-protein
CCPs: clathrin coated pits
CCR: chemokine receptor
CDKs: cyclin dependent kinases
cGMP: cyclic guanosine monophosphate
CHF: chronic heart failure
ChIP: chromatin immunoprecipitation 
CHO: Chinese hamster ovary
CHO-M3: Chinese hamster ovary cells expressing muscarinic M3 receptor
cPKC: classical PKC
CRM: chromosomal region maintenance
CsA: cyclosporine A
CSP: calcium sensor protein
CTPB: C-terminal polybasic
CXCR: chemokine receptor
DAG: diacylglycerol
DMEM: Dulbecco’s Modified Eagle Medium
DNA: deoxyribonucleic acid
E. coli: Escherichia coli
EGF: epidermal growth factor
EGFR: epidermal growth factor receptor
ENaCs: epithelial sodium channels
ER: endoplasmic reticulum
ERK: extracellular signal-regulated kinase
ERM: ezrin-radixin-moesin
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ETi: endothelin- 1
ETiR: endothelin-1 receptor
EYFP: enhanced yellow fluorescent protein
FCS: foetal calf serum
G protein: GTP-binding protein
GAP: GTPase activating protein
GEF: guanine nucleotide exchange factor
GIRK: G protein-coupled inwardly rectifying potassium channel
GIT: G protein-coupled receptor kinase-interacting protein
GPCR: G protein-coupled receptor
GRK: G protein-coupled receptor kinase
HATs: histone acetyltransferases
HCC: hepatocellular carcinoma
HD AC: histone deacetylase
HEK-293: human embryonic kidney 293
HEp2: human epithelial 2
HF: heart failure
IP3: 1,4,5-trisphosphate
IkB: inhibitor of kappa B
JAK: janus-family tyrosine kinase 
JNK: c-Jun amino-terminal kinase 
LB: luria broth
M2MR: M2 muscarinic receptor
M3MR: M3 muscarinic receptor
MAPK: mitogen-activated protein kinase
MEF2: myocyte enhancer factor 2
MEK1: MAPK/ERK kinase 1
MK2: MAPK-activated protein kinase 2
MKK: mitogen activated protein kinase kinase
MR: muscarinic receptor
mRNA: messenger ribonucleic acid
NES: nuclear export sequence
NFAT: nuclear factor o f activated T cells
NFkB: nuclear factor kappa B
NHERF: Na+/H+ exchanger regulatory factor
NLS: nuclear localisation sequence
NPC: nuclear pore complex
nPKC: novel PKC
NTPB: N-terminal polybasic
PBS: phosphate-buffered saline
PCR: polymerase chain reaction
PDZ: PSD-95, Dig, ZO-1 homology
PE: phenylephrine
PH: pleckstrin homology
PI3K: phosphoinositide 3-kinases
PIP2 : phosphatidylinositol 4,5-bisphosphate
PIP3 : phosphatidylinositol 3,4,5-trisphosphate
PKA: protein kinase A, cAMP-dependent protein kinase
PKC: protein kinase C or Ca2+-dependent protein kinase
PKI: protein kinase C inhibitor
PLC: phospholipase C
PM A: phorbol ester 12-tetradecanoylphorbol-13 acetate
PMSF: phenylmethanesulfonyl fluoride
RGS: regulator o f G protein signalling
RH: regulator o f G protein signalling homology domain
RNA: ribonucleic acid
RNAi: ribonucleic acid interference
ROS: rod outer segments
RPMI: Roswell Park Memorial Institute
R-Smads: receptor activated smads
RT: room temperature
RTK: receptor tyrosine kinase
SDS: sodium dodecyl sulphate
SDS-PAGE: SDS polyacrylamide gel electrophoresis
SHHF: spontaneously hypertensive heart failure
SR: sarcoplasmic reticulum
SRF: serum response factor
ssDNA: single stranded deoxyribonucleic acid
STAT: signal transducers and activators o f transcription
TEMED: N, N, N ', N'-tetramethyl-ethylenediamine
TF: transcription factor
TPA: 12-o-tetradecanoylphorbol-13 -acetate
TSA: trichostatin A
WT: wildtype
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1. Introduction
1.1. GRKs
G protein-coupled receptor kinases (GRKs) are a seven-member family o f 
serine/threonine kinases, depicted in Figure 1.1. GRKs were originally identified as 
kinases that phosphorylate agonist occupied, or activated, G protein-coupled 
receptors (GPCRs) initiating their desensitisation. However, it is now evident that 
these kinases phosphorylate a range o f receptor and soluble substrates. The 
implications o f this are discussed in Section 1.3.
1.1.1. GRK structure
Based on sequence similarity and functionality, the seven mammalian GRKs have 
been divided into three subfamilies shown in Figure 1.1 (Pitcher et al., 1998; Vatter et 
al., 2005):
• GRK1 subfamily (47% sequence homology)
o GRK1 (rhodopsin kinase) 
o GRK7 (cone opsin kinase)
• GRK2 subfamily (84% sequence homology)
o GRK2 ((3-Adrenergic receptor kinase 1) 
o GRK3 (P-Adrenergic receptor kinase 2)
• GRK4 subfamily (70% sequence homology)
o G R K 4 a ,p ,y ,8  
o GRK5
o GRK6 A, B, C (and D in mouse)
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Figure 1.1 GRK Structure.
The schematic shows the multi-domain structure o f the GRKs along with key regulatory elements and 
sites of protein interactions that have been mapped. The lipid modifications depicted are famesylation 
(GRK1), geranylgeranylation (GRK7) and palmitoylation (GRKs 4 and 6 ). Auto (±), stimulatory or 
inhibitory autophosphorylation sites; CaM, calcium-calmodulin; MAPK, mitogen-activated protein 
kinase; PL, phospholipids; PIP2, phosphatidylinositol 4,5-bisphosphate; PH, pleckstrin homology; 
PKC, protein kinase C; RH, regulator o f G protein signalling homology domain (Reproduced from 
Penela et al., 2003).
As indicated above, GRKs 4 and 6  undergo alternative splicing to give, respectively, 
four and three distinct splice variants (Premont et al., 1996). GRKs are well 
conserved from nematodes (Caenorhabditis elegans) and flies (Drosophila 
melanogaster) to mammals indicating their importance in biological functions 
(Pitcher et al., 1998). GRKs are most related to the protein kinase C (PKC) and
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protein kinase A (PKA) families o f serine/threonine kinases (Penela et al., 2003). 
Generally, the GRKs are ubiquitously expressed except for GRK1 & 7 (almost 
exclusively found in the retina) and 4 (predominantly testes/spermatocytes but also 
lower levels in the brain and kidney) (Penela et al., 2003; Premont et al., 1996; 
Sallese et al., 1994; Sallese et al., 1997; Virion et al., 1998).
GRKs contain a central catalytic domain approximately 260 amino acids in length 
(Figure 1.1). The N-terminus o f the GRKs is well conserved and has thus been 
suggested to meditate receptor recognition (Willets et al., 2003a). The N-terminus 
also contains a regulator o f G protein signalling homology domain (RH domain), 
which has been proposed to regulate GPCR signalling in a phosphorylation- 
independent mechanism by sequestering activated G a  subunits. This has been 
demonstrated for GRK2 which sequesters GaqGTP, suppressing Gaq-mediated 
phospholipase C (PLC)-(3 activation (Carman et al., 1999). RH domain ligands for the 
other GRKs have yet to be identified. However, GRK4 has been reported to promote 
phosphorylation-independent desensitisation of the GABAb receptor (Perroy et al.,
2003). GRK4 catalytic activity is not required for GABAb desensitisation perhaps 
suggesting that GRK4 promotes desensitisation by binding to G o u / o g t p , preventing 
functional coupling o f the receptor to its cognate effector (Perroy et al., 2003). The C- 
terminus of GRKs is more variable and constitutes the major site o f posttranslational 
modifications and protein-protein interactions which act to regulate GRK catalytic 
activity and cellular localisation, discussed further in Section 1.4 (Pitcher et al., 
1998). The crystal structure of two GRK2 and GRK6 , has been determined and 
reveals some interesting insights into their function (Lodowski et al., 2003a;
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Lodowski et al., 2006). The kinase domain o f these GRKs appears to adopt an open 
conformation similar to other kinases such as PKA. The open and presumably 
inactive conformation o f GRKs suggests that GPCR binding may activate these 
kinases by inducing kinase domain closure (Lodowski et al., 2006). However, 
differences between GRK2 and GRK6  3D conformation were noted, highlighting 
potential differences between the GRKs. In particular, the crystal structure o f GRK6  
reveals that it exists as a dimer. Dimerisation does not appear to be required for 
receptor phosphorylation (Lodowski et al., 2006) and a function for GRK6  
dimerisation has yet to be reported.
1.2. GRK function -  GPCR desensitisation
1.2.1. GPCR structure
GPCRS or seven-transmembrane spanning receptors (7TMRs), make up the largest 
family of plasma membrane receptors and the most frequent therapeutic drug target 
(Pierce et al., 2002). There are over 800 genes encoding GPCRs in the human 
genome (Jacoby et al., 2006), many of which are yet to be deorphanised (Lefkowitz,
2004). GPCRs are regulated by a diverse range of agonists from hormones, 
neurotransmitters, chemokines and calcium ions to odorants for bitter and sweet taste 
and light (Lefkowitz, 2004; Pierce et al., 2002).
Based on sequence homology alone, GPCRs have been divided into three 
subfamilies, A, B and C (Pierce et al., 2002). The families share over 25% sequence 
homology in the transmembrane spanning region along with shared motifs and 
conserved amino acids (Pierce et al., 2002). Family A, the largest family, includes
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amongst others retinal light receptors (rhodopsin), adrenergic receptors (ARs, types a  
and p) and olfactory receptors. Family B is made up o f only 25 members including 
receptors for gastrointestinal peptide hormones. The members o f this family appear to 
couple predominantly to the G protein Gs, to activate adenylyl cyclase (AC). Family 
C is comparatively small and contains the metabotropic glutamate receptor family, 
G A B A b , and the calcium (Ca2+) sensing receptors. Family C receptors are typified by 
a large extracellular amino terminus, which seems to be critical for ligand binding 
and activation.
Determination of the crystal structure of rhodopsin (Figure 1.2A) confirmed what 
biochemical experiments had previously indicated, that GPCRs share structural 
features such as the seven a  transmembrane helices which are connected by six loops 
o f differing lengths (Palczewski et al., 2000). The N-terminus of rhodopsin is 
extracellular and includes a conserved disulfide bridge that arranges the seven 
transmembrane helix motifs (Figure 1.2A). The C-terminus o f the receptor is 
intracellular and contains key residues that allow interactions between the 
transmembrane helices and the cytoplasmic surface (Figure 1.2A).
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Figure 1.2 Classical GPCR signalling.
A. 2.8A Crystal structure o f  rhodopsin, the light activated G PCR found in the retina. Rhodopsin is 
represented as a ribbon draw ing parallel to the plane o f  the m em brane (stereoview ) (R eproduced from 
Palczewski et al., 2000). B. C lassic exam ples o f  GPCR signalling. Follow ing agonist binding, a 
conform ational change w ithin the receptor prom otes G DP release from the a  subunit o f  the 
heterotrim eric G protein and G TP loading. This results in G protein activation and dissociation  into a
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subunits and fty dimers, both capable o f activating multiple cellular effectors, some o f which are 
depicted (Adapted from Pierce et al., 2002). CaM, calmodulin; DAG, diacylglycerol; GEF, guanine 
nucleotide exchange factor; GIRK, G protein-coupled inwardly rectifying potassium channels; PIP2 , 
phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A; PI3 K, phosphoinositide 3-kinase; PLC, 
phospholipase C; RGS, regulator o f G protein signalling.
1.2.2. G protein-mediated signalling
Guanine-nucleotide regulatory proteins transmit the signal, which activates a GPCR, 
to cellular effectors (Figure 1.2B). Figure 1.2B shows the heterotrimeric composition 
o f G proteins, which consist o f a , p and y subunits. The a  subunit binds GTP/GDP 
whilst the p and y subunits form a linked complex (Gainetdinov et al., 2004; Pierce et 
al., 2002). There are sixteen human genes encoding twenty-three known a  subunits, 
and five human p and twelve human y subunit genes identified to date (McCudden et 
al., 2005). In its inactive state, the a  subunit o f the G protein is GDP bound and binds 
the Py complex (Figure 1.2B) (Gainetdinov et al., 2004). Agonist occupancy o f a 
GPCR induces a conformational change and the receptor acts as a guanine nucleotide 
exchange factor (GEF), promoting GDP dissociation. Since the intracellular 
concentration o f GTP is higher than that o f GDP, GTP binds to the a  subunit 
resulting in its activation.
G proteins are classified by the a  subunit they contain. Four subfamilies o f a  subunits
are known; Gs proteins which stimulate AC, Gj proteins which inhibit ACs and
activate G protein-coupled inwardly rectifying potassium channels (GIRKs), Gq
proteins which activate PLCp and G 12 proteins which activate Rho GEFs. The Gpy
complex also activates or inhibits a large number o f effectors including but not
limited to GIRKs (Huang et al., 1997; Kunkel and Peralta, 1995), Ca2+ channels
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(Delmas et al., 2000; Kammermeier et al., 2000), ACs (Tang and Gilman, 1991), 
mitogen-activated protein kinases (MAPKs) (Faure et al., 1994), phosphoinositide 3- 
kinases (PI3Ks) (Stephens et al., 1994) and GRK2 (Lodowski et al., 2003b). Gp5 has 
been shown to bind directly to regulator o f G protein signalling (RGS) proteins which 
act to turn off G protein mediated signalling by promoting Ga-mediated GTP 
hydrolysis thereby acting as a GTPase activating protein (GAP) (Levay et al., 1999; 
Snow et al., 1998). Gp5 binding to RGS7, inhibits the ability o f RGS7 to bind to G ao 
and has been suggested to be a RGS7 inhibitor (Levay et al., 1999). It was 
traditionally the view that G a  activation results in its dissociation from the Py 
complex (Gilman, 1987). However, it has emerged that this is not necessarily the case 
for all G a  subunits, certain G ai subunits do not dissociate from the heterotrimeric 
complex but appear to undergo a rearrangement which permits an interaction with 
effector subunits (Frank et al., 2005). Typical signalling pathways regulated by the 
heterotrimeric G proteins are depicted in Figure 1.2B. The combinatorial possibilities 
o f a , p and y subunits and the fact that different heterotrimeric complexes can couple 
to multiple GPCRs, provides huge potential variety in terms of signal propagation 
from GPCRs.
1.2.3. GRK and Parrestin-mediated GPCR desensitisation
An important characteristic o f GPCRs is that continuous stimulation results in
receptor desensitisation. Rapid GPCR desensitisation is mediated, in large part, by
receptor phosphorylation by two distinct classes o f protein kinases. Firstly, second-
messenger regulated kinases such as PKA participate in a feedback mechanism by
which they are activated by GPCRs and then, in turn, phosphorylate the GPCRs,
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inhibiting their coupling to G proteins and terminating signalling (Reviewed 
inFerguson, 2001). Here however I will focus on the second phosphorylation- 
dependent mechanism o f GPCR desensitisation, that mediated by GRKs.
Agonist dependent recruitment o f GRKs to GPCRs leads to specific phosphorylation 
o f serine and threonine residues in the C-terminal tail or third intracellular loop of 
agonist occupied receptors (Ferguson, 2001; Gainetdinov et al., 2004; Willets et al., 
2003a). Arrestins, a family o f adaptor proteins bind GRK phosphorylated GPCRs 
preventing G protein coupling and thus GTP loading o f the a  subunit (Luttrell and 
Lefkowitz, 2002). This terminates further G protein-mediated intracellular signalling 
from this receptor. There are four arrestin family members, rod arrestin (arrestin-1), 
cone arrestin (arrestin 4), Parrestin 1 (arrestin 2 ) and parrestin 2  (arrestin 3), all o f 
which share high sequence homology but as the names suggest, rod arrestin is found 
solely in rod outer segments of the retina in the eye and cone arrestin in the cone 
photoreceptors of the eye and pineal gland (Pierce and Lefkowitz, 2001). p-Arrestin 1 
(Parr-1 ) and p-arrestin 2  (parr-2 ) (shown schematically in Figure 1.3) are 
ubiquitously expressed, with particularly high levels in the brain. There are however, 
some differences in distribution between the two subtypes, parr- 2  being more widely 
distributed in rat brain than parr-1. Conversely, parr-2 is expressed at higher levels 
than parr- 1  in the striatum, hypothalamus and hippocampus whereas Parr- 1  is more 
highly expressed in the olfactory bulb (Pierce and Lefkowitz, 2001). Agonist 
mediated translocation o f parrs to GPCRs defines two major classes o f receptors 
(Oakley et al., 2000). Class A receptors, which bind both biogenic amines and 
peptide ligands, such as the P2 -adrenergic receptor (P2AR), Dopamine D1A receptor
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and the ai B-adrenergic receptor (ccibAR), bind to parr-2 with higher affinity than
parr-1. Conversely, class B receptors, which bind peptide ligands, such as the 
Angiotensin II type IA receptor (AnglliAR) and vasopressin V2 receptor, bind to both 
parr-1 and Parr-2 with similarly high affinity. It appears that residues in the C- 
terminal tail o f  GPCRs determine their classification as either class A or B receptors 
rather than their ligand (Oakley et al., 2000). Thus it might be possible to predict 
which parr isoform will desensitise which GPCRs in a particular cellular
environment.
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Figure 1.3. Parrestin Family.
D om ain architecture o f  the Parrestins (Parrs). The Parrs contain tw o m ajor structural dom ains, the N- 
term inal dom ain (A ) and the C -term inal dom ain (B) separated by a phosphate sensor dom ain (P). It has 
been proposed that the N -term inal dom ain specifically  recognises activated G PC R s w hilst the B 
dom ain provides further receptor-b inding capability. R egulatory dom ains are present at the N- and C- 
term ini o f  parrs. The R2 region contains binding m otifs for clathrin and AP2, com ponents o f  the 
endocytosis m achinery and the p rim ary site o f  parr-1 phosphorylation, S412. O ther m otifs in parrs 
recognise and bind IP6, Src-SH3 and Jnk3. Parrs also bind to a range o f  o ther signalling m olecules not 
show n here including S rc -S H l, A sk l, NSF, M dm 2 and filam in (R eproduced from Luttrell and 
Lefkow itz, 2002).
As well as acting to prevent coupling to G proteins arrestins mediate the
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internalisation o f  GPCRs (Figure 1.4). parrs act as adaptors between the GPCRs and 
clathrin-coated pits (CCPs). parrs bind to clathrin (Goodman et al., 1996) and the P2- 
adaptin subunit o f  the AP2 complex (Laporte et al., 1999). By virtue o f  this ability to 
bind to components o f  CCPs, they recruit GPCRs into such membrane invaginations 
and therefore direct their internalisation (Figure 1.4). GRK2, whilst promoting pan- 
binding to the receptor also recruits PI3K which is required to generate D3- 
phosphoinositides, required for receptor internalisation (Naga Prasad et al., 2001; 
Naga Prasad et al., 2002). As depicted in Figure 1.4, following internalisation o f  
GPCRs into the cell, agonist dissociation and receptor dephosphorylation is proposed 
to occur in acidic endosomes. GPCRs are subsequently either degraded in lysosomes 
(downregulated) or recycled back to the cell surface for further signalling 
(resensitised) (Pierce and Lefkowitz, 2001).
Dynamin
Recycling
Endosome
parrestin binding 
and internalisationGRK
phosphorylation
r
Dearadation
Agonist
Clathrin
Figure 1.4. GPCR homologous desensitisation and trafficking.
A gonist binding to the G PCR  induces a conform ational change w ithin the receptor w hich acts as a
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GEF to activate the G protein. Activation o f the receptor causes the dissociation o f the activated G 
protein a  and |3y subunits, which activate effector substrates in the cell. GRK recruitment to the 
receptor varies. Free py dimers recruit GRKs 2 or 3, GRKs 4 and 6  are permanently tethered to the 
membrane via lipid modifications at their C-termini and GRK5 binds to phospholipids in the plasma 
membrane via a PIP2 binding domain. Recruited GRKs specifically phosphorylate agonist occupied 
GPCRs. This phosphorylation event recruits Parr, which binds to the phosphorylated tail o f the GPCR 
and targets the receptor to a clathrin-coated pit (CCP). The receptor is internalised into acidic 
endosomes, dephosphorylated and then either follows a pathway for degradation or recycling back to 
the cell surface for a further round o f signalling (Reproduced from Pierce et al., 2002).
1.2.4. GPCR desensitisation in  v iv o
Since the discovery o f the GRK subfamily much work has focused on the ability 
these kinases to desensitise specific GPCRs. A multitude o f approaches have been 
employed to answer such questions (Pitcher et al., 1998), including the ability of 
purified GRKs to phosphorylate purified receptors reconstituted in phospholipid 
vesicles (Pitcher et al., 1998). The subtype specificity o f GRKs has also been studied 
using purified plasma membrane or rod outer segment (ROS) preparations in vitro or 
by transiently expressing wildtype or mutant GRK constructs in heterologous cell 
systems (Pitcher et al., 1998). Whilst these in vitro systems yield information about 
potential GRK receptor substrates and the kinetics o f GRK initiation o f GPCR 
desensitisation the likely physiological substrates for the GRKs in vivo has been 
defined more convincingly using GRK transgenic and knock-out animals. Table 1.1 
and a Review by Metaye and colleagues lists recent studies which have gone some 
way to identify the physiological substrates and functional consequences o f GRK- 
mediated desensitisation in vivo (Metaye et al., 2005).
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Table 1.1: GRK-mediated regulation of GPCRs i n  v iv o
(Adapted from Metaye et al., 2005)
GRK
Subfamily
GRK
subfamily
member
GRK Genetic 
Alteration
Targeted GPCR Functional Implication Reference
GRK1 GRK1 Knockout Rhodopsin •  Prolonged rhodopsin responsiveness
•  Retinal apoptotic degeneration
(Chen et al., 1999; 
Lyubarsky et al., 2000)
• Lethal phenotype identical to ‘thin (Jaber et al., 1996)
myocardium syndrome’ observed in mice 
with inactive transcription factors RXRa,
N -myc, TEF-1 and WT-1
Heterozygous
knockout
Chemokine receptor 
(CCR5)
• Enhanced T cell chemotaxis (Vroon et al., 2004a)
Heterozygous
knockout
P-Adrenergic 
receptors (P-AR)
•  Increase in P-AR stimulated cardiac 
contractility
(Rockman et al., 1998b)
Vascular smooth 
muscle
overexpression
p-ARs • Attenuated P-AR stimulated vasodilation, 
elevated blood pressure and hypertrophy
(Eckhart et al., 2002)
Cardiac
overexpression
p-ARs • Diminished P-AR stimulated ventricular 
contraction
(Koch et al., 1995)
GRK2 GRK2 Homozygous N/A 
knockout
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GRK GRK GRK Genetic Targeted GPCR Functional Implication Reference
Subfamily subfamily
member
Alteration
GRK2 GRK2 Cardiac Angiotensin-II type • Diminished Angiotensin-II stimulated (Rockman et al., 1996)
(Cont.) overexpression IA receptor 
(AngII1AR)
cardiac contraction and heart rate
Cardiac ais-Adrenergic • No effect compared to controls (Eckhart et al., 2000)
overexpression receptor (ociB-AR)
GRK3 Knockout M2/M3 Muscarinic 
receptors
•  Enhanced cholinergic stimulation o f  
airway responses
(Walker et al., 1999)
Knockout K-opioid receptor •  Loss o f Kappa opioid tolerance (Xu et al., 2004)
Cardiac P-AR • No cardiac effect compared to controls (Iaccarino et al., 1998a)
overexpression
Cardiac AngIIiAR • No cardiac effect compared to controls (Iaccarino et al., 1998a)
overexpression
Cardiac (Xib-AR •  Diminished (Xib-AR  cardiac signalling (Eckhart et al., 2000)
overexpression
Cardiac Thrombin receptor •  Attenuated MAPK p42/p44 signalling via (Iaccarino et al., 1998a)
overexpression the Thrombin receptor
GRK4 GRK4y
(A142V)
Overexpression Dopamine-Dl
receptor
•  Hypertension as a result o f attenuation o f  
renal DIR  regulation o f fluid and 
electrolyte balance
(Felder et al., 2002)
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GRK GRK GRK Genetic Targeted GPCR Functional Implication Reference
Subfamily subfamily
member
Alteration
GRK4 GRK5 Knockout Dopamine D1/D2 • No effect on locomotion compared to (Gainetdinov et al., 1999)
(Cont.) receptors controls
Knockout M2/M3 Muscarinic 
receptors
• Excessive muscarinic receptor-mediated 
opposition o f airway smooth muscle 
relaxation
• Enhanced hypothermia, hypoactivity, 
tremor, salivation following muscarinic 
stimulation (oxotremorine)
(Gainetdinov et al., 1999; 
Walker et al., 2004)
Knockout Serotonin type IA 
receptor
•  No effect compared to controls (Gainetdinov et al., 1999)
Knockout Chemokine receptor 
(CXCR4)
•  No effect on chemotactic responses (Fong et al., 2002)
Knockout N/A • Age-dependent increase in hippocampal 
defects, extracellular (3-amyloid fibrillar 
deposits, degenerating axons, loss o f  
synaptic proteins and consistent selective 
working memory impairment
(Suo et al., 2006)
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GRK GRK GRK Genetic Targeted GPCR Functional Implication Reference
Subfamily subfamily
member
Alteration
GRK4 GRK5 Knockout N/A •  Decreased PDGF-stimulated PDGFRP (Wu et al., 2006)
(Cont.) serine phosphorylation in smooth muscle 
cells compared to wildtype with a 
concomitant increase in PI hydrolysis and 
thymidine incorporation.
•  Decreased PDGFRP association with the 
phosphatase Shp2 and Src activation
Cardiac P-ARs • Diminished P-AR stimulated cardiac (Rockman et al., 1996)
overexpression contraction
Cardiac AngIIiAR • No cardiac effect compared to controls (Rockman et al., 3 996)
overexpression
Cardiac (Xib-AR •  Partially diminished cardiac a 1B-AR (Eckhart et al., 2000)
overexpression signalling
GRK6 Knockout Dopamine D2-like 
receptors
•  Supersensitivity to cocaine and 
amphetamine stimulated locomotion
(Gainetdinov et al., 2003)
Knockout Chemokine receptor 
(CXCR4)
•  Impaired T cell chemotaxis
•  Enhanced chemotaxis o f  bone marrow 
derived neutrophils and impaired 
neutrophil mobilisation
(Fong et al., 2002; Vroon et 
al., 2004b)
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1.3. GRK function -  signalling roles
GRKs are best known for their role in promoting desensitisation o f GPCRs however 
it is evident from the number o f non-receptor substrates and binding partners that 
have been identified for these kinases that they perform additional signalling 
functions (Penela et al., 2006; Penela et al., 2003). Non-receptor substrates and 
binding partners o f GRK2, the most intensively studied member o f the GRK family, 
are shown in Figure 1.5. The functional relevance of many o f the GRK2-mediated 
non-GPCR phosphorylation events shown in Figure 1.5 remains somewhat unclear. 
GRK2-mediated phosphorylation o f the inhibitory gamma subunit o f cyclic 
guanosine monophosphate (cGMP) phosphodiesterase stimulates epidermal growth 
factor receptor (EGFR)-mediated activation o f p42/p44 MAPK in human embryonic 
kidney cells (HEK-293 cells) (Wan et al., 2001; Wan et al., 2003). GRK2-mediated 
epithelial Na2+ channel (ENaC) phosphorylation inhibits Nedd4-2-mediated Na+ 
channel ubiquitination and internalisation (Dinudom et al., 2004). Phosphorylation of 
phosducins by GRK2 inhibits an interaction between phosducins and Gpy thereby 
promoting Gpy signalling (Ruiz-Gomez et al., 2000).
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(Cant and Pitcher, 2005)
(Cant and Pitcher, 2005; 
Carman et al., 1998; Haga 
et al., 1998)
(Haendeler et al., 2003; 
Premont et al., 1998; Yin 
et al., 2004; Yin et al., 
2005)
(Ruiz-Gomez et al., 2000)
(Dinudom et al., 2004)
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(Ho et al., 2005)
(Wan et al., 2001; Wan et 
al., 2003)
Figure 1.5. GRK2 non-receptor substrates and binding partners.
G R K 2 is involved in a w ide range o f  in tracellu lar signalling  pathw ays d istinct from  its role in desensitiz ing  G PC R s. G RK 2 phosphory lates (P) and binds to (B) a 
w ide range o f  m olecules. G R K 2 substrates are show n in blue, w hilst b inding partners are show n in purple. The resu lts o f  either o f  these actions can prom ote 
(green arrow ) or inhibit (red  inhib ito ry  arrow ) various signalling  pathw ays including cytoskeletal o rganisation , cytosolic signalling  and nuclear signalling. 
U nconfirm ed steps are indicated  w ith a ‘? \  B, binding; P, phosphorylation; TF, transcrip tion  factor.
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A role for GRK2 in mediating cytoskeletal organisation has also emerged. 
Phosphorylation o f ezrin, a member o f the ezrin-radixin-moesin (ERM) protein 
family, by GRK2 results in activation o f this protein and promotes GPCR-dependent 
cytoskeletal reorganization. GRK2-mediated activation of Ezrin is required for P2AR 
internalisation (Cant and Pitcher, 2005). GRK2 also phosphorylates tubulin, but the 
significance o f this phosphorylation event has not been reported (Carman et al., 1998; 
Haga et al., 1998). GRK2-mediated phosphorylation o f ribosomal subunit P2 appears 
to promote translation, marking GRK2 as a positive regulator o f gene transcription 
(Freeman et al., 2002).
Evidence o f the ability o f GRK2 to indirectly modulate nuclear signalling pathways is 
also growing (Penela et al., 2006). The cytokine, transforming growth factor- 
13, promotes GRK2 association with receptor regulated-smads (R-smads) which 
regulate transcription in the nucleus. GRK2 association with R-smads results in 
GRK2-mediated R-Smad phosphorylation inhibiting R-Smad activation by type-1 
receptor kinases. Consequently, nuclear translocation of Smad complexes and Smad- 
mediated antiproliferative and apoptotic related transcription is inhibited (Ho et al., 
2005). A second potential example o f indirect modulation of gene transcription by the 
GRKs is via GRK2-mediated phosphorylation o f the non-receptor substrates a -  and 
p-synuclein (Chen and Feany, 2005; Pronin et al., 2000). GRK2 phosphorylation o f 
a-synuclein enhances a-synuclein aggregate formation in a Drosophila model of 
Parkinson disease (Chen and Feany, 2005). Although the function o f a-synuclein is 
not completely understood it has been shown to inhibit ERK2-mediated 
phosphorylation and activation o f the transcription factor Elk-1 (Iwata et al., 2001a;
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Iwata et al., 2001b). Furthermore, GRK5 was also found to phosphorylate a- 
synuclein, suggesting that this signalling pathway might be modulated by more than 
one GRK (Pronin et al., 2000).
Binding partners o f the GRKs are also increasing in number. GRK2 has been shown 
to bind to and recruit G protein coupled receptor kinase-interacting protein 1 (GIT1) 
to the plasma membrane (Premont et al., 1998). GIT’s have multiple cellular 
functions (Hoefen and Berk, 2006), but o f particular importance to GRK signalling is 
the ability of GIT-1 (G protein coupled receptor kinase-interacting protein-1) to act as 
an ARF-GAP inhibiting receptor internalisation mediated by the small GTPase Arf6  
(Premont et al., 1998). GIT-1 also interacts with and activates PLC, promoting 
phosphatidylinositol 4,5-bisphophate (PIP2) hydrolysis and promotes MAPK/ERK 
kinase 1 (MEK1) activation of extracellular signal-regulated kinase (ERK)-l/2 
(Hoefen and Berk, 2006). It is unclear if  GRK2-dependent translocation o f GIT-1 to 
the plasma membrane actively promotes all o f these GIT-1 mediated processes but as 
GRK2 is localised to GPCRs where activation o f these pathways is initiated, it might 
not be unreasonable to think that GRK2 promotes more than one o f G IT -l’s 
signalling functions. In vitro GRK5 binds to and phosphorylates the NFkBI (nuclear 
factor kBI) precursor, p i 05, and appears to negatively regulate lipopolysaccharide- 
stimulated ERK activation (Parameswaran et al., 2006). The relevance o f these 
findings, in relation to toll-like receptor signalling which regulates innate and 
adaptive immunity, are yet to be fully explored.
Evidence for cellular signalling roles o f the GRKs has focused particularly on GRK2 
but other members o f the GRK family might also have roles similar to GRK2 in
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regulating cellular signalling.
1.4. Regulation of GRK activity
GRKs are subject to a wide range o f regulatory mechanisms including alteration of 
their expression levels, subcellular localisation and interactions with other cellular 
proteins, all o f which affect their cellular activity (Reviewed in Penela et al., 2003).
1.4.1. Regulation of GRKs by calcium binding proteins
Ca plays a major role in intracellular signalling, activating calcium-sensor proteins 
(CSPs) which, either directly or indirectly, activate other target molecules that 
regulate biochemical changes within the cell. (Ikura et al., 2002; Santella et al., 2005). 
Calmodulin (CaM) is a universal and well-studied CSP (Chin and Means, 2000). 
CaM is expressed in all eukaryotic cells and regulates a range of effectors including 
the CaM-dependent ACs (Ferguson and Storm, 2004), PLC (McCullar et al., 2003) 
and protein kinases including but not limited to the CaM kinases (Sheng et al., 1991), 
sphingosine kinase (Young et al., 2003), the cyclin dependent protein kinases (Agell 
et al., 1998) and the GRKs (Sallese et al., 2000a). CaM also regulates receptors at the 
plasma membrane including ion channels (Chin and Means, 2000). In addition, CaM 
has a number o f nuclear roles including regulation o f transcription factors, 
particularly the basic helix-loop-helix (bHLH) group o f transcription factors (Agell et 
al., 1998; Hermann et al., 1998). Thus, activation o f CaM by increasing Ca2+ 
intracellular concentration has wide ranging effects.
1.4.1.1. Regulation o f the GRK1 subfamily by Recoverin
CSP regulation o f GRKs was first identified in studies o f retinal phototransduction.
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Ca2+ activated Recoverin, a CSP expressed primarily in vertebrate photoreceptor cells 
binds to and inhibits GRK1 (rhodopsin kinase) catalytic activity (Figure 1.1) (Chen et 
al., 1995; Klenchin et al., 1995). In the dark, when rhodopsin is inactive, basal Ca2+ 
levels are high and thus Recoverin is activated. Recoverin binds to GRK1 and inhibits 
its catalytic activity and thus rhodopsin phosphorylation. Recoverin mediated
inhibition o f GRK1 is relieved upon light exposure when Ca2+ levels decrease,
permitting GRK1 to phosphorylate rhodopsin and initiate its desensitisation (Kohout 
and Lefkowitz, 2003). The effect o f Recoverin on GRK7 activity has not been 
reported.
1.4.1.2. Regulation o f the GRK2 subfamily by CaM
The ubiquitous CSP, CaM, inhibits the kinase activity o f the non-retinal GRKs 
(Figure 1.1) (Sallese et al., 2000a). Ca2+/CaM inhibits GRK2 and 3 mediated 
phosphorylation o f rhodopsin in vitro with an IC50 of 2pM (Chuang et al., 1996; Haga 
et al., 1997; Pronin et al., 1997). GRK2 and 3 contain an N-terminal CaM binding site 
between residues 18-37 (shown in Figure 1.1) and bind Ca2+/CaM directly (Pronin et 
al., 1997).
1.4.1.3. Regulation o f the GRK4 subfamily by CaM
Analysis o f the regulation o f the GRK4 subfamily by Ca2+/CaM reveals that GRK4, 5 
and 6 exhibit different affinities for Ca2+/CaM. Purified GRK5 kinase activity, as 
assessed by rhodopsin phosphorylation, is inhibited by Ca2+/CaM with an IC50 of 
approximately 40-50nM (Haga et al., 1997; Pronin et al., 1997). Ca2+/CaM is 
therefore approximately fourty- to fifty-fold more potent in inhibiting GRK5-
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mediated rhodopsin phosphorylation than that of GRKs 2 and 3 (Iacovelli et al., 
1999).
Ca2+/CaM has been shown to bind to GRK5 directly with a Kd o f approximately 
lOnM (Iacovelli et al., 1999; Pronin et al., 1997). Two Ca2+/CaM binding sites have 
been identified in GRK5 (shown in Figure 1.1), one in the N-terminus between 
residues 20-39 and one in the C-terminus between residues 547-562 (Pronin et al., 
1998; Pronin et al., 1997). Ca2+/CaM binding at the N-terminus o f GRK5 prevents 
GRK5 from binding to and phosphorylating receptor substrates rather than inhibiting 
its kinase activity directly since Ca2+/CaM bound GRK5 can phosphorylate soluble 
substrates such as casein (Chuang et al., 1996). The N-terminal Ca2+/CaM binding 
site of GRK5 is coincident with the PIP2 -binding site o f this kinase (shown in Figure
1.1) (Kunapuli et al., 1994; Pronin et al., 1997). PIP2 binding to the N-terminal 
polybasic domain of GRK5 promotes receptor but inhibits soluble substrate 
phosphorylation (Freeman et al., 2000; Pitcher et al., 1996). In contrast, CaM or a - 
actinin binding to this same region inhibits specifically GRK5 plasma membrane 
localisation and GRK5-mediated GPCR phosphorylation but does not affect catalytic 
activity. Thus, CaM or a-actinin bound GRK5 phosphorylates exclusively soluble 
substrates (Freeman et al., 2000). Finally, actin binding to the N-terminal polybasic 
domain o f GRK5 inhibits its catalytic activity (Freeman et al., 1998). So GRK5 
activity can be completely inhibited by binding o f actin, but can be targeted towards 
receptor or soluble substrates by binding o f PIP2 or CaM/a-actinin respectively. The 
interplay between these cytosolic molecules in determining GRK5 kinase activity and 
subcellular localisation are not yet fully understood and might be expected to be
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complex.
Ca2+/CaM binding to the C-terminus o f GRK5 induces GRK5 inhibitory 
autophosphorylation at distinct sites within the kinase (serine 579, serine 583 and 
serine 584), shown in Figure 1.1, which serves to inactivate catalytic activity of 
GRK5 (Levay et al., 1998; Pronin et al., 1998; Pronin et al., 1997). So whilst
Ca2+/CaM binding at the N-terminus primarily inhibits GRK5-mediated receptor
2 +
phosphorylation by directly competing with the receptor to bind to GRK5, Ca /CaM
2 +
binding at the C-terminus also directly inactivates GRK5s kinase activity. Ca /CaM- 
mediated autophosphorylation of GRK5 will prolong GRK5 catalytic inactivity long 
after Ca2+/CaM dissociation and presumably GRK5 kinase activity is reactivated 
following de-phosphorylation o f these sites.
The catalytic activity o f GRKs 4 and 6  is also inhibited by Ca2+/CaM binding.
Partially purified GRK4a-mediated phosphorylation o f rhodopsin, the only splice
2+
variant demonstrated to phosphorylate rhodopsin in vitro, is inhibited by Ca /CaM 
with an IC50 o f approximately 80nM (Sallese et al., 1997). The IC50 o f Ca2+/CaM 
inhibition o f GRK6 catalytic activity, determined using lysates from COS cells 
overexpressing GRK6, is 0.7pM (Pronin et al., 1997). These measurements reveal 
that GRKs 4 and 6 are less sensitive than GRK5 to Ca2+/CaM-mediated kinase
•y I
inhibition but are still thirty-fold more sensitive to Ca /CaM than GRKs 2 and 3 
(Iacovelli et al., 1999). The N-terminal CaM binding site of GRK5 is well conserved 
within the GRK4 subfamily members but is absent in GRK4(3 and 8 since the CaM 
binding site lies within an alternatively spliced exon o f these splice variants (shown in 
Figure 1.1) (Iacovelli et al., 1999; Sallese et al., 1997). Like GRK5, GRK4a binds to
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CaM directly as determined using CaM-conjugated Sepharose 4B (Sallese et al., 
1997). However, GRK4p, y and 8 did not bind to CaM in the same experiment, 
perhaps suggesting that these splice variants are not regulated by Ca2+/CaM (Sallese 
et al., 1997). The N-terminal high affinity Ca2+/CaM binding site o f GRK5 is not as 
well conserved in GRKs 2 and 3 suggesting a potential explanation for the reduced 
affinity o f GRK2 and 3 for Ca2+/CaM compared to GRK5 (Iacovelli et al., 1999). The
I
C-terminal Ca /CaM binding site o f GRK5 appears to be at least partially conserved 
in GRKs 4a, 4(3 and 6 but the significance o f this binding site has not been 
thoroughly investigated. The fact that GRK4p does not bind CaM in vitro suggests 
that at least in this kinase the binding site is not functional although this has not been 
definitively investigated (Sallese et al., 1997).
' j i
The functional implications o f Ca /CaM inhibition of GRK-mediated receptor 
phosphorylation are potentially far reaching. Ca2+/CaM binding to GRK5 has already 
been demonstrated to inhibit receptor phosphorylation and perhaps therefore promote 
kinase activity towards soluble substrates (Chuang et al., 1996; Freeman et al., 2000). 
Ca2+/CaM-mediated inhibition o f GRKs can be envisaged in other cellular settings, 
for example, a rise in intracellular Ca2+ mediated by activation o f a Gq-coupled 
receptor would ultimately inhibit GRK activity. This might provide a feedback 
mechanism to inhibit GRK-mediated GPCR desensitisation. Indeed, GRK2-mediated 
agonist-dependent internalisation o f the M2 Muscarinic receptor (M2MR) in Chinese 
hamster ovary (CHO) cells was inhibited after treatment with a Ca2+ ionophore (Haga 
et al., 1997). It seems likely, due to the ubiquitous nature o f Ca2+ signalling, that the 
roles of Ca2+/CaM-dependent inhibition o f GRKs has not yet been fully elucidated.
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1.4.2. Regulation of GRK cellular localisation
The ability of GRKs to phosphorylate and desensitise receptors depends on their 
localisation at the plasma membrane in close proximity to the GPCR. Various C- 
terminal modifications play an important role in regulating how GRKs interact with 
GPCRs at the plasma membrane during receptor signalling. GRKs have variable C- 
termini and utilise distinct mechanisms for binding to the plasma membrane (shown 
in Figure 1.1). Some o f the GRK family members are post-translationally modified at 
their C-termini. GRKs 1 and 7 contain a C-terminal CAAX motif which directs 
isoprenylation of these kinases which is essential for light-dependent membrane 
association (Figure 1.1) (Chen et al., 1999). GRK4a, p, y, 8 and GRK6A are all C- 
terminally modified by palmitoylation, a reversible post-translational modification 
(Figure 1.1) (Premont et al., 1996; Stoffel et al., 1994). GRK6A contains three C- 
terminal cysteine residues (561, 562, 565), mutation o f which prevents GRK6A 
palmitoylation (Figure 1.1) (Stoffel et al., 1994). Thus, palmitoylation of GRK6A 
occurs at one or more o f these cysteine residues. The exact location of the site of 
palmitoylation of GRK4 is not definitively established but all GRK4 splice variants 
contain a C-terminal cysteine residue (a: C563, p: C531, y: C517 and 8: C485) 
homologous to C561 in GRK6A, as well as a second cysteine residue at the very C- 
terminus o f all splice variants. These represent potential sites o f palmitoylation in 
GRK4. GRK5 contains two lipid-binding sites, one at its N-terminus (residues 22-29) 
and one at its C-terminus (547-560) (Figure 1.1) (Pitcher et al., 1996). GRKs 4a , 4y 
and 6A, B and C all appear to contain the N-terminal lipid binding site present in 
GRK5, suggesting that these kinases might also be regulated by lipid binding (Figure
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1.1) (Pitcher et al., 1996). The C-terminal lipid-binding site o f GRK5 does not show 
strict lipid specificity and this interaction induces intramolecular stimulatory 
autophosphorylation, primarily at serine 484 and threonine 485 (Kunapuli et al., 
1994). This autophosphorylation increases GRK5 catalytic activity towards receptor 
but not soluble substrates. GRKs 2 and 3 are not posttranslationally modified at their 
C-terminus, but instead possess a phospholipid (PIP2) binding pleckstrin homology 
domain (PH domain) that extends into the Gpy binding domain o f these kinases 
(Figure 1.1). Following GPCR activation, Gpy subunits are released from the 
heterotrimeric G protein complex and bind to GRKs 2 and 3, recruiting these kinases 
to the plasma membrane (Pitcher et al., 1992; Pitcher et al., 1995). Thus, GRK2 and 3 
are cytosolic kinases that are only present at the membrane following GPCR 
stimulation.
1.4.3. Regulation of GRKs by other kinases
Several kinases have been shown to regulate GRKs by phosphorylation, although 
work has generally focused on regulatory phosphorylations affecting the activity o f 
GRKs 2 and 5. Here I will discuss regulation o f GRKs by PKC which is most 
relevant to this thesis.
PKC is activated by intracellular Ca2+ release, such as that stimulated by Gq-coupled 
GPCRs. PKC phosphorylates GRK2 and GRK5 in vitro (Figure 1.1) (Chuang et al., 
1995; Krasel et al., 2001; Pronin and Benovic, 1997; Winstel et al., 1996). PKC 
phosphorylation o f GRK2 at serine 29 enhances its phosphorylation o f GPCRs 
without affecting GRK2-mediated phosphorylation of soluble substrates implying 
that PKC phosphorylation promotes membrane association o f GRK2 without
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impairing its catalytic activity (Krasel et al., 2001). Phosphorylation at serine 29 
within the N-terminal CaM binding region of GRK2 relieves the inhibitory 
interaction between GRK2 and CaM (Krasel et al., 2001). Conversely, 
phosphorylation o f GRK5 by PKC inhibits its catalytic activity towards both receptor 
and soluble substrates (Pronin and Benovic, 1997; Pronin et al., 1998). Inhibitory 
PKC phosphorylation o f GRK5 occurs at its C-terminus (ser-566, ser-568, ser-572) in 
the same region that CaM induces inhibitory autophosphorylation o f GRK5 (Figure
1.1) (Pronin et al., 1998). PKC thus seems to have opposing effects, activating GRK2 
while inhibiting GRK5.
1.4.4. Regulation of GRK expression
GRKs appear to be expressed at relatively low levels, such that their expression is 
limiting for agonist-dependent desensitisation o f GPCRs (Penn and Benovic, 1994). 
Regulation of GRK expression during times o f persistent GPCR signalling is required 
to prevent chronic activation of GPCRs. Relatively little is understood about the 
regulation o f GRK gene transcription. However, it appears that varying signals can 
alter expression levels o f GRKs depending on the signal and cell type. Increased 
circulation o f catecholamines and stimulation o f pARs correlates with an increase in 
GRK2 expression in the heart (Iaccarino et al., 1998b). In aortic smooth muscle cells, 
induction o f physiological vasoconstriction and hypertrophy by agents such as 
phorphol esters or Gq activation results in increased transcriptional activity at the 
GRK2 promoter, whilst proinflammatory cytokines decrease transcriptional activity 
at the GRK2 promoter (Ramos-Ruiz et al., 2000). This suggests that GRK2 
expression might be modulated by cell type specific signalling pathways. Recently, it
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has been reported that GRK2 translation is downregulated in C6 rat glioma cells 
following exposure to hydrogen peroxide, the full mechanism o f which is yet to be 
determined but appears to involve activation o f cyclin dependent kinases (CDKs) 
(Cobelens et al., 2006). Further work is required to elucidate the regulatory 
mechanisms controlling GRK expression under both normal and disease states.
Regulating protein stability is another mechanism by which the function o f GRKs 
may be modulated. GRK2, for example, has a short half-life o f approximately 1 hour 
(Penela et al., 1998). Persistent isoproterenol stimulation o f the P2AR in HEK-293 
cells, stimulates polyubiquitination of GRK2, continuously promoting its degradation 
by the proteasome (Penela et al., 1998). Kinase activity appears to be required for 
GRK degradation since the catalytically inactive mutant of GRK shows greater 
stability than wildtype (Penela et al., 1998). In this heterologous system, Parr-1 or -2 
recruits c-Src to GRK2 which phosphorylates tyrosine residues within the kinase 
marking it for degradation via the proteasome (Penela et al., 2001). This mechanism 
causes downregulation o f steady-state kinase levels. Regulation o f GRK stability is 
yet to be fully understood.
1.5. GRKs and disease
GPCRs are the largest class of cell surface receptors and their dysfunction has been 
implicated in a number o f human disease states (Johnson and Lima, 2003). GRK- 
mediated GPCR desensitisation regulates the number and function o f GPCRs at the 
plasma membrane and thus GRKs have the potential to influence cellular signalling- 
mediated by these receptors in disease. Additionally, as discussed in Section 1.2.5, 
studies using transgenic animals not only reveal physiological receptor substrates for
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the GRKs but also their potentially direct involvement in disease progression. 
Naturally occurring alterations in the expression o f GRKs has also revealed the 
importance of GRKs in maintaining normal cellular function.
In patients suffering from Oguchi disease, point mutations in the catalytic region o f 
GRK1, deletions at the C-terminus and deletion o f the entire o f exon 5 have been 
reported (Cideciyan et al., 1998; Khani et al., 1998). The absence of GRK-mediated 
rhodopsin desensitisation results in enhanced rhodopsin signalling causing Oguchi 
disease, an autosomal recessive form of retinitis pigmentosa apparent as night 
blindness (Cideciyan et al., 1998; Khani et al., 1998). Sufferers experience prolonged 
dark adaptation, abnormal sensitivity to light and, with excessive light exposure, 
retinal degeneration (Metaye et al., 2005).
Alterations in the expression o f the ubiquitous GRKs have been observed in a number 
o f human pathologies, o f which I will only discuss a few (Metaye et al., 2005). In 
patients with rheumatoid arthritis a significant decrease in GRK2 (-55% ) and GRK6 
(-60% ) expression was observed in peripheral blood mononuclear cells (Lombardi et 
al., 1999). Reduction in the expression of these GRKs likely results in increased 
sensitivity of P2ARS in these cells, as administration of p2AR antagonists in murine 
models o f rheumatoid arthritis delays the onset o f the disease (Levine et al., 1988; 
Lombardi et al., 1999).
Changes in the expression levels o f GRKs in a number o f human cancers has also 
been reported (Metaye et al., 2005). In human differentiated thyroid carcinoma a 
decrease in GRK5 expression is observed which correlates with increased signalling 
from the thyrotropin receptor (Metaye et al., 2002), suggesting an inhibitory role for
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GRK5 in hormonal-mediated cell proliferation.
Chronic treatment o f rats with mood stabilisers such as lithium or carbamazepine 
results in a significant increase in membrane association o f GRK3 in the frontal 
cortex. Membrane association of GRK3 is correlated with increased activity. Mood 
stabiliser treatments may thus promote GRK3 mediated GPCR desensitisation 
correcting supersensitivity o f D2 dopaminergic receptors and other GPCRs seen in 
bipolar disorder (Ertley et al., 2006). A single nucleotide polymorphism in the 
promoter of GRK3 is linked with a susceptibility locus for bipolar disorder (Barrett et 
al., 2003). The P-5 SNP had an estimated allele frequency of 3% in bipolar subjects 
suggesting that dysregulation in GRK3 expression and thus GPCR desensitisation 
predisposes to onset o f bipolar disorder.
Abnormalities in GRK2 function and expression are observed in a mouse model of 
Alzheimer’s disease (Suo et al., 2004). Treatment of microglial cells with p-amyloid, 
the component that is deposited in the brains of sufferers, reduces the amount of 
GRKs 2 and 5 associated with the membrane in microglial cells, inhibiting 
desensitisation of thrombin receptors in this model, perhaps marking these GRKs as 
potential therapeutic targets in Alzheimer’s disease (Suo et al., 2004).
Although GRK4 shows limited tissue distribution, aberrant expression o f this kinase 
in kidney has been found to contribute to essential hypertension. Single nucleotide 
polymorphisms in GRK4y have been shown to enhance GRK4y kinase activity, 
against receptor substrates such as the Dopamine-Dl receptor in the renal proximal 
tubule, impairing the ability o f D IR  to regulate fluid and electrolyte balance which 
results in genetic hypertension (Felder et al., 2002; Speirs et al., 2004; Williams et al.,
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2004).
The strongest evidence supporting a causative role for the GRKs in disease 
progression come from studies investigating their role in heart failure (HF) and 
cardiac hypertrophy discussed in the next Section, 1.6.
1.6. Heart failure and cardiac hypertrophy
HF has reached epidemic proportions in the western world and the lifetime risk for 
developing HF is one in five for both men and women (Lloyd-Jones et al., 2002). In 
HF the heart is unable to meet the metabolic demands o f the peripheral tissues (Ritter 
and Neyses, 2003). The disease is typified by a progression o f events, which begins 
when part o f the heart is damaged, for example by hypoxia, myocardial infarction 
(necrosis o f heart tissue due to lack of blood supply) or hypertension (increased blood 
pressure due to narrowed arteries containing fatty deposits). Initially, the heart can 
generally preserve function but slowly over time the rest o f the heart begins to fail. 
Death ensues when the heart develops fatal rhythm disorders and stops pumping 
oxygenated blood to the body (Ritter and Neyses, 2003).
Generally, pathological cardiac hypertrophy is a prerequisite for the development o f 
HF. Hypertrophy is an adaptive mechanism in which the heart increases its mass in 
response to signals initiated by biomechanical stress. Although hypertrophy initially 
compensates for the lack of wall tension in the heart, it is ultimately a maladaptive 
process which is generally associated with progression into decompensated HF 
(Mathew et al., 2001; Vakili et al., 2001).
In order to cope with increased biomechanical stress the cardiac muscle must increase
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its capacity. Since myocytes cannot divide, hypertrophic signalling results in an 
increase in cardiac myocyte size by altering transcription o f contractile and 
extracellular matrix proteins and increasing their rate o f protein synthesis (Frey et al., 
2004). Heightened organisation o f the sarcomere occurs, chiefly by altering the 
composition of the myosin subunit. Transcription of a-M HC (myosin heavy chain) is 
downregulated whilst transcription o f p-MHC is upregulated (Schwartz et al., 1993). 
This switch ultimately results in increased heart muscle contractility (Morano, 1999). 
These transcriptional changes represent induction o f the fetal gene program and 
initiate cellular changes that lead to development of cardiac hypertrophy.
1.6.1. Chromatin modification
Nuclear deoxyribonucleic acid (DNA) is packaged into chromatin by proteins called 
histones (Figure 1.6). Chromatin is made up of nucleosomes which comprises 146 
base pairs of DNA wrapped around a histone octamer (two copies each o f histones 
H2A, H2B, H3 and H4) (Backs and Olson, 2006). Nucleosomes condense DNA, 
limiting access o f transcription factors, and therefore acting to regulate gene 
transcription. Residues within the tails of histones are postranslationally modified by 
acetylation, methylation and phosphorylation creating a ‘histone code’ which 
determines if a region of chromatin is transcriptionally active or silent (Jenuwein and 
Allis, 2001). Acetylation o f lysine residues in histone tails by histone 
acetyltransferases (HATs) is commonly associated with activation o f gene 
transcription (Figure 1.6). Histone acetylation destabilises the chromatin structure 
allowing access to gene promoters. In contrast histone deacetylases (HDACs) remove 
acetyl modifications repressing transcription (Figure 1.6).
54
HDACs
Histone Deacetyiation
HATs 
— — — ►
HDACs
Gene Repression Gene Activation
Figure 1.6. Generalised model of histone acetylation and deacetyiation.
DNA and chrom atin are assem bled into nucleosom es. HATs and H DA Cs are recruited to D NA by 
association with transcrip tion  factors (TFs). A cetylation o f  histone tails results in chrom atin relaxation 
and gene activation. D eacetyiation opposes transcriptional activation by prom oting chrom atin 
condensation (A dapted from B acks and O lson, 2006).
1 .6 .2 . H A T s
There are at least five families o f  HATs (Roth et al., 2001). The most extensively 
studied HATs are p300 and its associated cofactor cAMP response element-binding 
protein (CBP) (Backs and Olson, 2006). p300 has inherent HAT activity and is 
capable o f modifying both chromatin and transcription factors to promote gene 
transcription. p300 is essential for cardiac development since mice in which p300 is 
ablated die early during gestation due to inadequate expression o f  muscle structural 
proteins including (3-MHC and a-actinin (Yao et al., 1998). p300-mediated 
promotion o f transcription is enhanced following stimulation o f  a-ARs with 
phenylephrine (PE), which induces hypertrophy in cultured myocytes (Gusterson et 
al., 2002). Furthermore, PE-induced hypertrophy is stimulated by overexpression o f  
CBP/p300 and blocked by overexpression o f p300/CBP dominant negative mutants 
or antisense (Gusterson et al., 2002; Gusterson et al., 2003). The ability o f  cardiac 
transcription factors such as MEF2 (myocyte enhancer factor 2), NFAT (nuclear
Histone Acetylation
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activator o f activated T cells), GATA4, STATs (signal transducers and activators of 
transcription), NFkB and the serum response factor (SRF) to upregulate genes 
associated with induction o f hypertrophy relies on their ability to associate with 
HATs such as p300 (Akazawa and Komuro, 2003; Frey and Olson, 2003; McKinsey 
and Olson, 2004; Purcell et al., 2001).
1.6.3. HDACs
HATs are opposed by HDACs, o f which there are three classes, I, II and III 
(Thiagalingam et al., 2003). Intriguingly, the nuclear class I HDACs have been 
reported to promote hypertrophic growth (Antos et al., 2003) whilst the class II 
family, which is localised throughout the nucleus and cytoplasm, are strongly linked 
to repression of hypertrophic growth (Zhang et al., 2002). The class II HDACs have a 
large N-terminal extension not present in class I HDACs which serves to mediate 
interactions with transcriptional repressors or activators as well as being a site for 
regulatory phosphorylation events which promote their nuclear export (Verdin et al., 
2003). The role of class III HDACs in regulating cardiac transcription is yet to be 
fully explored (Backs and Olson, 2006).
Mice in which the prototypical class II HDACs such as HDAC5 or HDAC9 are 
ablated develop spontaneous cardiac hypertrophy aged six months induced via a 
calcineurin-dependent pathway (discussed in Section 1.6.4.4). This suggests these 
HDACs participate in specific Ca2+-dependent signalling pathways that act to repress 
cardiac growth (Chang et al., 2004; Zhang et al., 2002). Class II HDACs are shuttled 
from the nucleus to the cytoplasm in response to stress signals promoting cardiac 
growth (Harrison et al., 2004; Vega et al., 2004). The nuclear export o f HDAC 5 and
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9 frees cardiac transcription factors, which associate with HATs, increasing local 
acetylation and induction o f hypertrophic gene transcription (Zhang et al., 2002). 
Indeed, MEF2 binds class II HDACs and HATs competitively and is thus able to 
respond to both positive and negative hypertrophic transcriptional signals (McKinsey 
et al., 2001; McKinsey et al., 2002). Class II HDACs also regulate the transcriptional 
cofactor calmodulin binding transcription activator 2 (CAMTA2) (Song et al., 
2006b). Recruitment o f CAMTA2 to the atrial natriuertic factor (ANF) promoter 
occurs via an interaction with the homeodomain-containing cardiac transcription 
factor Nkx2-5 where it acts as a coactivator of Nkx2-5-mediated transcription (Song 
et al., 2006b). Nkx2-5 is essential in mice for normal cardiac development (Prall et 
al., 2002). The Class II HDAC, HDAC5 binds to CAMTA2, preventing its interaction 
with Nkx2-5 (Song et al., 2006b). Phosphorylation of HDAC5 by PKC or PKD 
results in its nuclear export which relieves HDAC5-mediated repression of CAMTA2 
(Song et al., 2006b). Overexpression o f CAMTA2 in myocytes in culture or in the 
hearts of mice results in hypertrophy and HF. Notably, hypertrophy is not observed 
following overexpression o f a mutant CAMTA2 which cannot associate with Nkx2-5 
(Song et al., 2006b). Since CAMTA2 is activated by CaM, activation o f this 
coactivator is likely to be linked to Ca2+ excitation coupling which is required for the 
induction of hypertrophy. These findings support the proposed role for class II 
HDACs as inhibitors o f hypertrophy. Paradoxically however, general inhibitors o f 
HDACs such as trichostatin A (TSA) do not promote hypertrophy, but promote a 
dose dependent blockade of hypertrophy, improving cardiac function (Antos et al., 
2003). These reports suggest that the function o f Class I HDACs in promoting
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hypertrophy may suppress the inhibitory effects of the Class II HDACs. Clearly, the 
role of histone modification in regulating the fetal gene program and cardiac 
hypertrophy is a complex but important avenue for research in understanding the 
regulation o f cardiac growth.
1.6.4. Signalling pathways which regulate hypertrophy
GPCRs play an important role in the regulation o f cardiac function, particularly the 
a -  and P-ARs, angiotensin receptors (ATRs) and muscarinic receptors (MRs). 
Agonist stimulation o f these receptors regulates cardiac contractility and promotes 
gene transcription, particularly those o f the fetal gene program, illustrated in Figure 
1.7. In this section I briefly describe the signalling pathways downstream o f cardiac 
GPCRs that have been implicated in regulating cardiac hypertrophy and progression 
to HF. The role o f the GRKs in regulating the signalling cascades is also discussed.
/. 6.4.1. Gq/Gji signalling
In the heart, ATRs, Endothelin-I receptors (ETiRs) and otARs (aiA and am in
2+
myocytes) all couple to G q /G n , activating PLC, thereby increasing intracellular Ca 
in myocytes (Figure 1.7) (Ritter and Neyses, 2003). Moreover, stimulation o f these 
receptors results in activation of the transcription factor, NFkB, which promotes 
hypertrophic growth in cardiac myocytes (Figure 1.7) (Hirotani et al., 2002; Purcell et 
al., 2 0 0 1 ).
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Figure 1.7. Signalling pathways in myocardial hypertrophy.
Biom echanical pressure activates calcium  channels, receptor tyrosine kinases (R TK ) and G -protein- 
coupled receptors (G PC Rs) inducing activation o f  intracellular signalling cascades including the JA K - 
STAT, M APK, C alcineurin-N FA T , PLC and adenylyl cyclase (A C) pathw ays. A ctivation o f  these 
intracellular signalling pathw ays results in hypertrophic gene transcription, w hich m ediates an increase 
in cellular grow th. A bbreviations: AC, adenylyl cyclase; ERK, extracellu lar-signal-regulated  kinase; 
JA K, Janus kinase; JN K , Jun N -term inal kinase; M A PK K K , m itogen-activated protein k inase kinase 
kinase; NF-AT, nuclear factor o f  activated T cells; p38, p38 kinase; PKA, protein kinase A; PKC, 
protein kinase C; PLC, phospholipase C; STAT, signal transducer and activator o f  transcription 
(R eproduced from R itter and N eyses, 2003).
In rodents, activation o f ATRs, ETiRs and ociARs has been shown to be sufficient to 
induce hypertrophy (Ichikawa et al., 1996; Keys and Koch, 2004; Rockman et al., 
2002; Shah and Catt, 2003). Overexpression of ATRs, ETiRs, ociARs or Gq itself also 
results in hypertrophy in rodents (D'Angelo et al., 1997; Koch et al., 2000; Paradis et 
al., 2000; Sakata et al., 1998). Consistent with these observations, overexpression of a
5 9
peptide in mice which blocks Gq-coupling to GPCRs, thereby inhibiting its function, 
results in inhibition o f hypertrophy indicating the critical importance o f Gq signalling 
in regulating hypertrophic growth (Akhter et al., 1998; Esposito et al., 2001). 
Furthermore, in patients with cardiomyopathy, treatment with drugs such as ATR 
antagonists and ACE (angiotensin converting enzyme) inhibitors, which decrease 
ATR signalling, prevent cardiac remodeling associated with the development of 
hypertrophy, indicating the importance o f these receptors in the clinic (Yusuf et al., 
2000).
1.6.4.2. Gs and Gt signalling
The role of the pARs (pi-, p2 - and p 3 -ARs) in cardiovascular disease has been the 
subject of much investigation (Rockman et al., 2002). Acute pAR stimulation is a 
powerful mechanism by which cardiac output is increased but chronic stimulation 
leads to hypertrophic cardiac remodeling and myocyte apoptosis. The piAR is the 
predominant subtype expressed in heart representing 75-80% of the total pAR present 
(Rockman et al., 2002). Both p i-a n d  p2-A R s couple to Gs and activate AC and PKA 
(Figure 1.7), regulating cardiac contractility and heart rate (Keys and Koch, 2004), 
but the p2 receptor can also couple to Gi (Daaka et al., 1997), inhibiting AC whilst 
activating MAPK cascades, adding an extra layer of regulation to the cardiac system.
Most piAR knockout mice die prenatally, those that do survive to adulthood have a 
dysfunctional cardiac response to exercise (Rohrer et al., 1996). There is no P~ 
agonist-dependent change in cardiac function in these mice suggesting that the PiAR 
controls heart rate. Consistent with this observation, overexpression of PiAR in hearts
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of transgenic mice increases cardiac contractility and responsiveness to the pAR 
agonist isoproterenol (Bisognano et al., 2000; Engelhardt et al., 2002). Eventually 
however, these mice exhibit a progressive loss in cardiac function and hypertrophy.
P2AR knockout mice have no defect in cardiac physiology indicating that the P2AR 
does not contribute to cardiac function under normal conditions in mice (Rohrer, 
1998). P2AR overexpression in transgenic mice, however, results in increased 
contractility and heart rate although there is little pathology observed in these mice 
upon ageing (Koch et al., 2000).
Cardiac overexpression o f Gag in mice results in increased cardiac contractility and 
development of HF with age (Geng et al., 1999). This suggests that acute stimulation 
of the P-adrenergic system could contribute to cardiac failure. Mice overexpressing a 
novel GoCi coupled receptor (R ol) exhibit, as might be predicted, impaired cardiac 
contractility. Since Gi is up-regulated in human HF, this indicates a role for Gaj 
signalling in development of HF (Baker et al., 2001; Eschenhagen et al., 1992).
1. 6.4.3. Calcineurin-NFA T signalling
Ca signalling plays a vital role in hypertrophic growth in response to biomechanical 
pressure (Bers and Guo, 2005). Increases in intracellular Ca2+ results in the activation 
of an array of Ca2+ sensor proteins. One major hypertrophic signalling pathway 
activated by the increase in intracellular Ca2+ is the calcineurin-NFAT pathway 
(Figure 1.7). Calcineurin is a serine-threonine phosphatase activated by Ca2+/CaM 
(Frey and Olson, 2003; Schulz and Yutzey, 2004). Calcineurin dephosphorylates 
transcription factors from the NFAT family, causing exposure o f their nuclear
localisation sequence (NLS) and activating their ability to translocate to the nucleus 
and turn on gene transcription. Constitutive activation of calcineurin in the hearts of 
mice results in HF (Molkentin et al., 1998). Inhibition o f calcineurin with 
Cyclosporine A (CsA) results in inhibition of Angiotensin II (Angll)- or PE- 
dependent hypertrophy in rodents (Olson and Williams, 2000). Transgenic mice 
expressing a constitutively active nuclear mutant o f NFAT3 also develop HF, 
indicating this transcription factor regulates induction o f cardiac hypertrophy (Figure
1.7) (Molkentin et al., 1998). NFAT signalling is regulated by a range o f other 
molecules, including MAPKs, suggesting that this significant pathway may represent 
a point of intersection for many hypertrophic signals (Figure 1.7) (Crabtree and 
Olson, 2002).
/. 6.4.4. PI3K/Akt/GSK-3-dependent signalling
PI3Ks phosphorylate both proteins and lipids and are involved in a wide array of 
signalling functions including cell metabolism and survival along with gene 
expression (Cantley, 2002). PI3Ks are activated by many receptors including the ARs 
(Schluter et al., 1998; Zhu et al., 2001). PI3Ky is specifically activated during 
pressure overload hypertrophy in mouse heart by G(3y released from activated G aq 
(Naga Prasad et al., 2000). Consistent with this observation, overexpression o f a 
constitutively active mutant o f PI3K in mice results in cardiac hypertrophy (Figure
1.7) (Shioi et al., 2000). As discussed in Section 1.6.4.2, PAR dysfunction observed 
in HF is proposed, at least in part, to arise as a consequence of enhanced GRK 
expression and GRK-mediated pAR desensitisation. GRK2/PI3K complex formation 
is required for parr-mediated pAR internalisation (Naga Prasad et al., 2005). The
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agonist-dependent recruitment o f GRK2 to activated pARs targets PI3K to the 
receptor where it produces D3 phosphatidylinositols. Phosphatidylinositol 3,4,5- 
trisphosphate (PIP3) recruits endocytic proteins including parrs, to the receptor to 
facilitate receptor internalisation (Naga Prasad et al., 2002). Overexpressing a 
catalytically inactive form of PI3Ky inhibits this interaction in a murine model o f HF 
induced by overexpression o f calsequestrin, and results in normalised pAR levels and 
preserved pARs responsiveness to the adrenergic agonist isoproterenol (Perrino et al., 
2005). This defines PI3K as a potential therapeutic target for inhibition o f GRK- 
mediated downregulation o f pARs.
Akt, a PI3K effector, is a serine/threonine kinase which promotes protein translation 
by phosphorylating and inhibiting GSK-3p and stimulates gene transcription by 
phosphorylation and activating the NFAT transcription factors (Frey and Olson, 
2003). GSK-3P inhibits cardiac hypertrophy when overexpressed in mice (Antos et 
al., 2002). In cardiac myocytes in culture, pAR stimulation of ANF transcription 
mediated by the GATA4 transcription factor was inhibited by GSK-3P (Akazawa and 
Komuro, 2003). Confirmation that GSK-3p suppresses cardiac hypertrophy by 
preventing upregulation o f the fetal gene program in vivo is yet to be explored.
2.6.4.5. MAPK signalling
MAPKs provide a major pathway for relaying signals from the plasma membrane to 
the nucleus. Three main MAPK pathways exist, the ERKs, c-Jun amino-terminal 
kinases (JNKs) and the p38 MAPKs (Johnson and Lapadat, 2002). The latter two 
cascades are responsive not only to signals from receptors such as GPCRs but by
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stress stimulants such as ischemia (Sugden and Clerk, 1998). A major role for these 
pathways in promoting cardiac hypertrophy was demonstrated by inhibiting all three 
cascades by adenoviral transfer o f MAPK phosphatase-1, a phosphatase which 
inhibits all MAPK cascades (Bueno et al., 2001). Isoproterenol stimulation or 
pressure overload aortic banding of these mice does not induce cardiac growth 
suggesting that MAPK cascades positively regulate cardiac hypertrophy (Bueno et 
al., 2 0 0 1 ).
Each of the MAPK pathways appears to have distinct signalling functions during 
induction of hypertrophy. Overexpression o f MEK1, an activator o f ERK1/2, but not 
JNKs or p38 MAPKs in mice promotes cardiac hypertrophy (Bueno et al., 2000). 
Moreover, ERK can activate GATA4 cardiac transcription factors which regulate 
expression o f a range o f fetal program genes including a-M HC and ANF (Akazawa 
and Komuro, 2003).
The role of p38 in the regulation of hypertrophy is somewhat unclear as different 
results have been obtained in cultured myocytes versus studies in transgenic animals. 
Overexpression of activated MAP kinase kinase-(MKK)-3 or -6 , upstream activators 
of p38, induces hypertrophy and ANF expression in cultured cardiac myocytes 
(Wang et al., 1998a). Different isoforms o f p38 have been attributed different 
signalling roles, that o f p38a in promoting myocyte apoptosis whilst p38(3 promotes 
hypertrophy (Wang et al., 1998a). However, studies o f p38 in transgenic animals, 
have suggested that p38 does not promote hypertrophy (Liang and Molkentin, 2003) 
since overexpression o f dominant negative mutants o f MKK3, MKK6  and 
p38a develop cardiac hypertrophy following pressure-overload or with increasing
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age (Braz et al., 2003). The discordance between in vitro and in vivo results requires 
further investigation.
JNK is activated in cardiac myocytes by mechanical stretching or agonist stimulation 
by ETi, PE or Angll (Choukroun et al., 1998; Ramirez et al., 1997; Yano et al., 
1998). In a similar fashion to p38, there is some controversy as to the function o f JNK 
in the development o f hypertrophy. Overexpression o f MKK7, an upstream activator 
o f JNK in cultured myocytes results in JNK activation and development o f 
hypertrophy (Wang et al., 1998b). However, mice expressing activated MKK7 in the 
heart did not develop hypertrophy but lethal juvenile cardiomyopathy (Petrich et al., 
2003).
Whilst a role for ERK in promoting cardiac hypertrophy has been demonstrated, the 
role o f the p38 and JNK MAPKs in juvenile (e.g. neonatal myocytes) versus adult 
cardiac tissue (transgenic or knock-out mice) remains controversial.
1.6.4.6. PKC signalling
The PKC family consists of at least twelve serine/threonine kinases which are 
grouped into three subfamilies, classical (cPKC.a, (3 and y), novel (nPKC: 8 , e, t | and 
0) and atypical (aPKC: p, ^ and t) (Salamanca and Khalil, 2005). cPKC enzymes are 
activated by Ca2+ and diacylglycerol (DAG), aPKC by DAG, and nPKC 
independently o f Ca2+ or DAG possibly by other PKCs (Salamanca and Khalil, 
2005).
PKC regulation of hypertrophy is complex since the PKC isoforms vary in expression 
level in different cardiac cell types and at different developmental stages (Bowling et
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al., 1999; Sabri and Steinberg, 2003). In cultured myocytes, constitutively active 
PKC-p stimulates promoters o f the P-MHC gene, which is upregulated during cardiac 
hypertrophy (Kariya et al., 1994).
1.6,4.7. JAK-S TA T signalling
JAK (janus-family tyrosine kinase) activation results in their tyrosine- 
phosphorylation and activation o f a family o f latent cytoplasmic transcription factors 
called STATs. Activated STATs dimerise via a intermolecular SH2-phosphotyrosine 
interaction and then translocate to the nucleus to regulate gene expression (Kunisada 
et al., 2000). Cardiac-specific overexpression of STAT3 in mice results in 
hypertrophy (Hoshijima and Chien, 2002). Gpl30, a promiscuous cytokine receptor 
which activates both MAPK and STAT3, has also been linked to development of 
hypertrophy in mice overexpressing IL - 6  and IL- 6  receptors (Mascareno et al., 1998). 
Increased STAT activity has been reported in the myocardium of the spontaneously 
hypertensive rat, in particular STAT3, STAT5a and STAT6  binding to the 
Angiotensinogen (Ao) promoter (Booz et al., 2002). Ao is the precursor of Angll and 
therefore STAT signalling produces a hypertrophic phenotype by generating Angll. 
Production of Ao by hypertrophic Angll signalling thus represents an autocrine loop 
further enhancing the hypertrophic phenotype (Liu et al., 1997). Interestingly though, 
STAT3 and STAT1 appear to have opposing actions in determining cardiac myocyte 
survival (Booz et al., 2002). Ischemia induces STAT1 and apoptosis whereas STAT3 
is cardioprotective in this setting (Hattori et al., 2001; Stephanou et al., 2000; 
Stephanou et al., 2001). JAK-STAT signalling in cardiac muscle is complex since it 
participates in hypertrophic growth, cell survival and apoptotic pathways.
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1.6.4.8. The role o f GRKs in cardiac hypertrophy
GRKs, like GPCRs play a role in cardiac function. GRKs 2, 3 and 5 are the 
predominant subtypes expressed in human heart and are all significantly upregulated 
in a range o f cardiomyopathies (Dzimiri et al., 2004; Ungerer et al., 1993; Vinge et 
al., 2001; Yi et al., 2002). GRK2 protein is upregulated 3-fold and GRK5 protein 2.6- 
fold in the myocardium of rats with congestive heart failure (Vinge et al., 2001). 
Interestingly, upregulation of GRKs often occurs before detectable onset of clinical 
HF and in this capacity represents a novel marker of cardiac function with the 
potential to indicate for therapeutic intervention before complete HF ensues (Hata et 
al., 2006; Iaccarino et al., 2005).
As described earlier, GRK2 knockout mice are embryonic lethal and exhibit major 
cardiac abnormalities indicating an important role for this GRK in regulating cardiac 
development (Jaber et al., 1996). The cardiac failure observed during development of 
GRK2 knockout mice is also seen in mice that have targeted knockdown of cardiac 
transcription factors (Jaber et al., 1996). GRK2 is upregulated in human chronic 
heart failure (CHF) (Ungerer et al., 1993; Ungerer et al., 1994). Overexpression o f 
GRK2 in the heart o f mice during adulthood results in diminished left ventricular 
contractility in response to isoproterenol stimulation (Koch et al., 1995). Consistent 
with these results, inhibition of GRK2 activity by overexpression of an inhibitory C- 
terminal construct, corresponding to 194 amino acids of GRK2 which contains the 
Gpy binding domain (GRK2ct), in mice results in prevention o f cardiac failure (Koch 
et al., 1995). These results suggest that upregulation o f myocardial GRK2 is 
detrimental to cardiac function whereas inhibition o f GRK2 enhances cardiac
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contractility (Petrofski and Koch, 2003). Indeed, transfection o f GRK2ct into a 
genetic model of murine HF (termed MLP- ') significantly improves heart 
contractility in these mice and prevents development of cardiomyopathy (Rockman et 
al., 1998a). Similarly, mating transgenic mice overexpressing GRK2ct with 
transgenic mice with severe cardiomyopathy due to overexpression of calsequestrin, a 
sarcoplasmic reticulum (SR)-Ca2+-binding protein, results in an increased survival 
age with significantly improved cardiac function (Harding et al., 2001). Hence, 
GRK2 is a potential therapeutic target for correcting cardiac function. However, 
whilst GRK2ct has been delivered successfully to the hearts of rats and rabbits, this 
method of delivery in human patients is not practical.
GRK5 messenger RNA (mRNA) is significantly increased in the left-ventricle of 
patients with volume overload and dilated cardiomyopathy (Dzimiri et al., 2004). 
Consistent with this observation, cardiac overexpression o f GRK5 in mice results in 
impaired cardiac function (cardiac output and contractility) (Chen et al., 2001) and 
GRK5 expression (mRNA and protein levels) is upregulated in rat models of CHF 
(Oyama et al., 2005; Vinge et al., 2001). This suggests GRK5, as well as GRK2, 
regulates cardiac function and the progression of hypertrophy to HF. Interestingly, in 
a rat model o f CHF, GRK2 and GRK5 display a distinct and differential distribution 
following myocardial infarction (Vinge et al., 2001). GRK2 is detected in the 
ischemic region, primarily in endothelial cells, whereas GRK5 is found in several cell 
types, but principally in myocytes. This points towards distinct functions for GRKs 2 
and 5 in cardiac tissue (Vinge et al., 2001).
Based on a wealth o f data it is therefore hypothesised that the loss of adrenergic
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signalling in cardiac tissue associated with HF is due, at least in part to increased 
GRK-mediated desensitisation and later downregulation o f receptors. Currently, 
blockers of pAR function (p-blockers) are used widely to inhibit myocardial disease 
with significant improvement in patient survival (Rockman et al., 2002). Whilst 
upregulation of PAR signalling initially compensates for an increase in 
biomechanical pressure, chronic stimulation ultimately leads to cardiac failure and so 
blockers of pAR function are thought to maintain normal heart function by 
preventing GRK-mediated desensitisation and downregulation of adrenergic receptors 
(Koch and Rockman, 1999). Clearly the role of GRKs in disease, certainly heart 
disease, is complicated and requires further investigation.
1.6.5. Cardiac hypertrophy -  therapeutic opportunities
It is clear that initiation and inhibition o f cardiac hypertrophy involves a multitude of 
signalling pathways that form an intricate and integrated web. Certainly new 
therapeutic approaches developed to tackle cardiac hypertrophy will have to consider 
a plethora o f signalling molecules and targets.
Work in animal models has revealed a wealth of information about the action o f 
pharmacological agents. ACE inhibitors and AR antagonists prevent ventricular 
remodeling, improve cardiac function and increase survival rates in models of 
myocardial infarction (Liu et al., 1997). pAR blockers such as propranolol and 
bisprolol and Ca2+ antagonists have also been shown to improve cardiac function 
(Leitch et al., 1998; Sharpe, 1996). These drugs are currently approved for use in 
treatment o f HF in the clinic. It is anticipated that a more detailed understanding of
the molecular events leading to hypertrophy and decompensated HF will reveal new 
targets for pharmaceutical intervention. It seems reasonable that the GRKs and GRK- 
binding proteins might prove useful therapeutic targets for the prevention of 
hypertrophy.
1.7. Nuclear trafficking
One of the major characteristics o f eukaryotic cells is the presence o f intracellular 
compartments or organelles such as the nucleus. This allowed eukaryotic cells to 
become more complex, signalling molecules and their functions could be localised to 
specific intracellular compartments, increasing cellular efficiency. A pertinent 
example o f this is the compartmentalisation o f the genetic contents o f the cell into the 
nucleus. The nucleus is a defined organelle with its own double membrane, the 
nuclear envelope. Central to cellular function is macromolecular transport into and 
out o f the nucleus via protein channels called the nuclear pore complex (NPC) 
(Figure 1.8A). This allows the cell to respond to cues generated at the plasma 
membrane and transmitted through the cytosol, by initiating gene expression from 
which instructions are sent back out to the cytosol. Nuclear trafficking is thus a 
regulated and complicated process. It is possible for small molecules up to 40 kDa to 
diffuse through the nuclear pores along a concentration gradient but molecules larger 
than this require active transport into the nucleus (Yoneda, 2 0 0 0 ).
1.7.1. Nuclear targeting of cellular molecules
Active nuclear import and export o f proteins larger than 40-60 kDa is regulated by
the presence of defined amino acid motifs within the molecule called NLSs or nuclear
export sequences (NESs). In order for a protein to be directly imported or exported
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from the nucleus, it must possess one o f these signals. O f course, it is possible for 
proteins, which do not contain such motifs, to enter the nucleus but they must first 
associate with a molecule which contains this structural code.
1. 7.7. 7. Nuclear localisation sequences
The first ‘classical’ NLS was characterised as a cluster o f basic amino acids in the 
SV40 large T-antigen (Yoneda, 2000). The importance of NLSs was realised when 
ablation of certain residues in molecules caused their nuclear exclusion while addition 
of NLSs to proteins resulted in their nuclear localisation (Cokol et al., 2000). NLSs 
are classified as monopartite or bipartite (Boulikas, 1993). Characteristically a 
monopartite motif is a cluster o f basic residues following a helix-breaking residue. A 
bipartite motif is similar but contains two clusters of basic residues separated by nine 
to twelve amino acids (Cokol et al., 2000). However, many NLSs have been 
identified that do not conform to these general rules. Interestingly, a quarter o f all 
known NLS sequences bind DNA (Cokol et al., 2000). NLSs must show appropriate 
3D conformation and be accessible for nuclear import to occur. Thus NLS exposure 
is a common mechanism whereby the nuclear localisation of proteins is modulated. 
For example, phosphorylation near to a NLS can prevent nuclear import. Mutation of 
a putative PKA site adjacent to the NLS in adenomatous polyposis coli protein 
inhibits nuclear import in vitro (Zhang et al., 2000). Cell cycle-regulated 
phosphorylation of the Saccharomyces cerevisiae transcription factor, Swi6 , regulates 
its nuclear import (Sidorova et al., 1995). Hypophosphorylation o f Swi6  during late 
mitosis phase through to G1 permits Swi6  nuclear localisation whereas 
hyperphosphorylation imparts cytoplasmic localisation during the remainder o f the
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cycle (Sidorova et al., 1995). In vitro it has been shown that phosphorylation in the 
vicinity o f a NLS prevents the NLS interacting with a-importins, thus preventing 
nuclear import (Harreman et al., 2004).
1. 7.1.2. Nuclear export sequences
NESs are a more recent discovery than NLSs (la Cour et al., 2004). NESs are 
typically composed o f four or five hydrophobic residues within a region o f about ten 
residues. In contrast to NLSs, NESs are hydrophobic rich amino acid motifs with a 
high proportion of leucine or isoleucine amino acids, although, NESs also commonly 
contain isoleucine, valine, methionine and phenylalanine residues (Yoneda, 2000). 
The leucine residues at the C-terminus (rather than the N-terminus) o f the motif are 
most highly conserved and deemed most important for NES function (Schneider and 
Stephens, 1990; Wen et al., 1995). The flanking residues of a NES may also 
contribute to the ability o f a NES to mediate nuclear import (Kutay and Guttinger,
2005). In the same way that NLSs do not all conform to a single consensus sequence, 
only 36% of NES conform to the classical L-x(2,3)-[LIVFM]-x(2,3)-L-x-[LI] 
consensus sequence (where x = any amino acid and numbers indicate the number of 
amino acids) (Kutay and Guttinger, 2005; la Cour et al., 2004). Leucine rich NESs 
were originally identified in the HIV rev protein and PKA inhibitor (PKJ) (Fischer et 
al., 1995; W enetal., 1995).
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Figure 1.8. Nuclear trafficking via the NPC.
A. Schem atic representation o f  the structure o f  the NPC. The N PC  sits in the nuclear envelope 
m em brane and consists o f  a central pore (dark b lue) with cytoplasm ic rings either side in the 
cytoplasm  and nucleus. The cytoplasm ic side contains cytoplasm ic filam ents and the nuclear side a 
nuclear basket. B. M echanism  o f  nuclear im port and export via the NPC. D uring im port, a cargo 
containing a NLS is recognised by the im portin com plex w hich directs travel through the pore into the 
nucleus. In the nucleus, R anG TP binds to the com plex, releasing the cargo and initiating recycling o f  
the im portin back to the cytosol v ia the N PC. In the cytosol, a Ran G A P prom otes Ran G TPase activity 
readying the im portin for a further round o f  nuclear im port. In a sim ilar fashion to im portins, exportins
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regulate nuclear export o f NES containing cargos. RanGTP-dependent activation o f exportin is 
required for cargo transport through the NPC to the cytosol. Here the RanGAP promotes RanGTPase 
activity causing dissociation of the complex and release of the cargo into the cytoplasm. Exportins are 
then recycled back to the nucleus to undergo further rounds o f nuclear export (Adapted from Tran and 
Wente, 2006; Yoneda, 2000).
1.7.2. Nuclear import mechanism
In order to enter the nucleus, cargo must travel through the NPC which is made up of 
three major parts, the nuclear basket, the central core and the cytoplasmic fibrils 
(Figure 1.8A) (Tran and Wente, 2006). To traverse the nuclear membrane the cargo 
must either directly interact with the NPC or more commonly chaperone transport 
receptors (Tran and Wente, 2006). The predominant class of transport receptors is the 
karyopherins which include importins (a  and (3), exportins and transportins 
(Pemberton and Paschal, 2005; Tran and Wente, 2006). Importin a  recognises the 
cargo via the NLS and binds to importin p at its N-terminus (Figure 1.8B) (Gorlich et 
al., 1996a). Importin p interacts with the NPC and steers the cargo complex through 
the pore. In the nucleus RanGTP binds to the Ran-binding domain o f importin p 
causing dissociation and release o f the cargo into the nucleus (Figure 1.8 B) (Gorlich 
et al., 1996b). RanGTP-bound importin p is exported back through the NPC to the 
cytoplasm (Figure 1.8B). Importin a  must form a trimeric complex with CAS, an 
importin p related molecule, and RanGTP to traverse the NPC to the cytoplasm 
(Kutay et al., 1997). In the cytoplasm, RanGTP-bound importin is hydrolysed 
preparing the carrier for further rounds o f nuclear import (Figure 1.8B).
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1.7.3. Nuclear export mechanism
In a similar manner to nuclear import, cargo molecules are exported from the nucleus 
by an active mechanism (Figure 1.8B). Cargo proteins containing NESs are 
complexed with an export receptor, CRM1 (chromosomal region maintenance), also 
called exportin 1, and RanGTP in the nuclear compartment (Yoneda, 2000). Exportin 
1 behaves essentially as importin (3 does during the import process. Exportin 1 binds 
the NES containing cargo and RanGTP in the nucleus and directs the complex 
through the NPC to the cytoplasm where again, RanGTP hydrolysis dissociates the 
complex (Figure 1.8B) (Fomerod et al., 1997; Fukuda et al., 1997; Stade et al., 1997).
1.7.4. The role of Ran in nucleocytoplasmic trafficking
Ran is critically required for crossing the NPC as it provides directionality to the 
pore. Ran exhibits a low intrinsic activity o f GDP/GTP exchange and hydrolysis and 
so its activation state is regulated by GEFs and GAPs (Yoneda, 2000). RanGEF, 
which loads Ran with GTP is restricted to the nucleus, and thus it is here that it is in 
its active form, ready for cargo unloading and initiation of nuclear export in the 
nucleus (Figure 1.8B). Furthermore, since there is substantially more GTP in the cell 
than GDP, this exchange occurs readily in the nucleus. RanGAPs contain NESs and 
are thus permanently excluded from the nucleus, only allowing RanGTP hydrolysis in 
the cytosol (Figure 1.8B). RanGAPs are localised to the cytoplasmic fibrils o f the 
NPC (Figure 1.8A) which provides an efficient mechanism for rapid hydrolysis and 
therefore, cargo release once the nuclear export complex reaches the cytoplasm 
(Figure 1.8B) (Yoneda, 2000). Consequently, a RanGDP/RanGTP gradient exists 
across the nuclear membrane and provides directionality for nuclear transport.
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1.7.5. Regulation of nuclear protein localisation
Whilst NLSs and NESs directly mediate nuclear import and export via the NPC, 
mechanisms exist to regulate the nuclear localisation of a protein under certain 
conditions.
1. 7.5.1. Phosphorylation
Phosphorylation of proteins has been shown to regulate their nuclear localisation. 
STATI transcription factor activation requires dimerisation mediated by tyrosine 
phosphorylation. This structural change allows nuclear import and DNA binding. The 
NES o f these transcription factors, is found in the DNA binding region and is hidden 
when bound to DNA. Crystal structure data indicates that dephosphorylation of the 
tyrosine residues might unmask the NES and promote nuclear export o f the STATs 
(Reich and Liu, 2006). p42/p44 MAPK phosphorylation of serine 641 or serine 643 in 
H IF-la promotes its nuclear accumulation and transcriptional activity (Mylonis et al.,
2006). MAPK phosphorylation promotes nuclear localisation o f H IFla by inhibiting 
its CRM 1-dependent nuclear export. Similarly, growth factor mediated translocation 
o f the nuclear kinase Akt is mediated by PI3K activation. AKT phosphorylation via a 
PI3K-dependent mechanism promotes AKT nuclear translocation (Xuan Nguyen et 
al., 2006). In contrast, the nuclear export o f the ribosomal S6  kinases is promoted by 
phosphorylation. Phosphorylation of S6K-1 at serine 17 by CK2 and S6K(3-II 
phosphorylation at serine 486 by PKC results in nuclear export o f these kinases 
(Panasyuk et al., 2006; Valovka et al., 2003).
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1.7.5.2. Calmodulin
CaM has been shown to promote the nuclear import o f the cell cycle inhibitor p21 
(Rodriguez-Vilarrupla et al., 2005). PKC phosphorylation o f p21 retains this inhibitor 
in the cytosol whilst CaM binding prevents this phosphorylation and allows p21 
nuclear import (Rodriguez-Vilarrupla et al., 2005). Conversely, Ca2+/CaM can bind to 
the NFicB/Rel transcription factor c-Rel and inhibits its nuclear localisation 
(Antonsson et al., 2003). CaM therefore has the capability to both promote and inhibit 
nuclear localisation.
1.8. Aims of this thesis
An emerging trend over recent years has been the multiplicity of functions that
components of the GPCR desensitisation machinery perform. Those o f the parrs have
been studied in most depth, parrs act as scaffolds facilitating the agonist-dependent
recruitment o f a multiplicity of binding partners to activated GPCRs (Lefkowitz and
Whalen, 2004). Perhaps the best-characterised scaffold function o f the Parrs is their
ability to bind multiple components o f MAPK cascades promoting efficient GPCR-
mediated activation o f ERK1/2 (extracellular signal-regulated kinase 1/2), JNK3 (c-
Jun amino-terminal kinase 3) and p38 (Lefkowitz and Whalen, 2004). Parr-dependent
GPCR-mediated MAPK activation results in the cytoplasmic retention of the
activated kinase, indirectly regulating MAPK-dependent gene transcription and
presumably facilitating phosphorylation of cytoplasmic substrates. Furthermore, Parrs
can act as adaptors for non-receptor tyrosine kinase, c-Src, initiating MAPK
signalling (Lefkowitz and Shenoy, 2005). parr-2, but not parr-1, contains a NES at
its C-terminus (Scott et al., 2002; Wang et al., 2003) and is actively imported into the
77
nucleus, indicating that parr-2 is capable o f nucleocytoplasmic shuttling (Scott et al., 
2002; Wang et al., 2003). Trafficking through the nucleus results in the cytoplasmic 
retention o f Parr-2 binding partners such as Mdm2, activated ERK and JNK3 (Luttrell 
et al., 2001; McDonald et al., 2000; Scott et al., 2002; Wang et al., 2003), thereby 
indirectly regulating nuclear signalling pathways. Both parr-1 and 2 inhibit activation 
o f the transcription factor NF-kB. parr binding to IkB, the inhibitory protein that 
regulates NF-kB activity, preventing its degradation and thereby inhibiting NF-kB- 
mediated transcription (Gao et al., 2004; Witherow et al., 2004). Recently a more 
direct nuclear function for Parr-1 has been described. Following activation of the 8 - 
opioid receptor parr-1 accumulates in the nucleus o f HEK293 cells where it is found 
in a complex with histone acetylase, p300 at specific promoters (Kang et al., 2005). 
Parr-1 -dependent recruitment o f p300 promotes local histone H4 acetylation and gene 
transcription (Kang et al., 2005).
Cell signalling functions for the GRKs have been less well documented although the 
literature hints towards roles for the GRKs similar to those of the parrs (discussed in 
Section 1.3). The list o f soluble substrates for the GRKs is growing and includes 
synucleins and AKT (Penela et al., 2003) suggesting roles for the GRKs other than 
desensitisation of GPCRs. Indirect links between GRKs and nuclear functions, such 
as regulation of gene transcription have also been reported, including for example, 
GRK2 phosphorylation o f R-Smads which inhibits their nuclear localisation and 
therefore their ability to regulate gene transcription (Ho et al., 2005). However, to 
date, no direct nuclear functions for the GRKs have been described.
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My aim in this thesis was to investigate the observation that the GRK4 subfamily of 
GRKs is present in the nucleus when transfected in tissue culture cell lines, whereas 
GRK2 subfamily members are cytosolic. To do this I determined if  nuclear 
localisation was regulated and o f any relevant functional significance. Chapter 2 
outlines the methods utilised in this thesis.
Chapter 3 describes the identification o f a functional NLS and NES in the most 
studied member o f the GRK4 subfamily, GRK5. The nuclear localisation of GRK5 is 
regulated by Ca2+ signalling activated by the Gq-coupled M3 muscarinic receptor 
(M3MR), or by activation o f the Ca2+ sensor, CaM. CaM binding to the N-terminus 
o f GRK5 results in nuclear export o f this kinase. Furthermore, in Chapter 3, I 
discover that GRK5 binds directly and specifically to DNA in vitro, hinting for the 
first time, o f a potential nuclear function for GRK5.
Chapter 4 focuses on a comparison o f the GRK4 subfamily in terms o f the regulation 
o f their nuclear localisation and DNA-binding ability. Data in this Chapter reveals 
diversity among the GRK4 subfamily members. Whilst all subfamily members are 
localised to the nucleus o f human epithelial cells (HEp2 cells), GRKs 5 and 6  but not 
GRK4 bind to DNA. What is more, the nuclear localisation o f GRK6  splice variants 
are differentially regulated by Ca2+.
Chapter 5 investigates a possible nuclear function for GRK5; inhibition o f cardiac 
hypertrophy in rat neonatal myocytes. Using mutants of GRK5 I determine the 
structural features o f GRK5 which regulate in vitro DNA-binding and nuclear export 
of this kinase. I demonstrate ex vivo that GRK5 overexpression in rat neonatal cardiac 
myocytes rescues PE induced cardiac hypertrophy as has previously been described
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by Eckhart and colleagues (Eckhart et al., 2000). Furthermore, I provide evidence to 
suggest that rescue of cardiac hypertrophy by overexpression o f GRK5 is not due to 
desensitisation of GPCRs but due to its activity as a nuclear kinase and its ability to 
bind DNA. These findings show for the first time, that GRK5 has nuclear functions. 
The findings from Chapters 3 - 5  will be discussed in detail in Chapter 6 .
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2. Materials & Methods
Tissue culture dishes were obtained from Nunc, culture medium from Gibco BRL, 
plasticware from Falcon or Sterilin and other reagents from Sigma, unless otherwise 
specified. All kits were used according to the manufacturers’ instructions and 
solutions made with MilliQ deionised water. Buffer ingredients, cDNAs and 
antibodies referred to in this Chapter are listed in Tables 2.1, 2.2 and 2.3-2.6 
respectively.
2.1. Cell culture
2.1.1. Cell lines
CHO cells stably expressing M3MR (CHO-M3, a generous gift from Dr Andrew 
Tobin, University o f Leicester, UK) were maintained in modified Eagle medium 
alpha (a-MEM) without nucleosides containing 10% foetal calf serum (FCS),
250pg/ml G418 sulphate and penicillin and streptomycin (100 IU penicillin and
lOOjig o f streptomycin/ml). HEp2, HeLa, HEK-293 and Cos-7 were maintained in 
Dulbecco’s modified Eagle medium (DMEM) containing 10% calf serum and 
penicillin and streptomycin (100 IU penicillin and lOOjag of streptomycin/ml). Cells 
were maintained in a humidified incubator at 37°C, 5% CO2 . Confluent monolayers 
were passaged every 3-4 days by trypsinising and replating at a ratio o f 1:10.
2.1.2. Cell freezing
To freeze cell stocks, cells were taken from two plates o f 70% confluency and 
resuspended in 1ml cold freezing medium on ice. Cells were frozen at -70  °C for 1
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week and subsequently transferred to liquid nitrogen.
2.1.3. Cell thawing
To recover cells stored in liquid nitrogen, aliquots were rapidly thawed at 37°C, the 
cells diluted in 10 ml culture medium and split equally into two 9cm dishes 
containing 5ml o f the appropriate media. Cells were maintained in a humidified 
incubator at 37°C, 5% CO2 .
2.1.4. Electroporation of DNA into HEp2 cells
HEp2 cells were transiently transfected using electroporation as this method gave 
approximately 70% transfection efficiency compared to Fugene transfection which 
gave approximately 50% transfection efficiency. HEp2 cells that had been plated 24h 
previously (75% confluency) were trypsinised, washed from the plate with DMEM 
and spun down at 1500 rpm for 3 min (Sorvall TC 6  centrifuge). The supernatant was 
discarded and the cell pellet was then washed in 10ml HEBS buffer. Washed cells 
were recovered by centrifugation as before, resuspended in 250pl HEBS buffer, and 
transferred to a 0.4cm3 electroporation cuvette. Unless otherwise stated, ljig  DNA 
was added to the cuvette and the cells mixed gently by hand. Using the Gene 
Electropulser II (BioRad), cells were electroporated with 2 pulses o f 420V, 125pF, 
ohms. Cells were subsequently incubated at room temperature (RT) for 5 minutes 
before being plated onto coverslips in a 5 cm tissue culture dish and left to express the 
construct(s) for up to 48h.
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2.1.5. Transfection of DNA into Cos-7, HeLa, CHO-M3 and HEK- 
293
Cos-7, HeLa, CHO-M3 and HEK-293 cells were transiently transfected using Fugene 
or GeneJuice as these methods gave approximately 60-70% transfection efficiency 
and was practically simpler to perform than electroporation. 3 pi o f GeneJuice 
(Novagen) or Fugene (Roche) transfection reagent for every lp g  of DNA to be 
transfected was added to lOOpl serum-free DMEM. The media was mixed and 
incubated at RT for 5 minutes. This mixture was then added to another 1.5ml tube 
containing the appropriate DNA, mixed gently by hand and incubated at RT for 30 
minutes. The media/DNA mixture was then dropped onto 70% confluent cells that 
had been plated 24h previously in appropriate media. The cell media was mixed by 
gentle agitation and the cells were left to express the transfected construct(s) for up to 
48h.
2.1.6. Cell lysate preparation and determination of concentration
Untransfected cells or transfected cells were washed twice with cold phosphate 
buffered saline (PBS) on ice. Cells were lysed by addition o f 300pl of the appropriate 
cold lysis buffer and scraped with a cell scraper. Cell lysates were sonicated twice for 
15s (Branson Sonifier 450, setting 6 ) and cleared by centrifugation at 13,000 rpm 
(Heltich bench top centrifuge Mikro 20) for 5min. Cell lysates were transferred to a 
clean tube and protein concentration was determined using the BioRad protein assay. 
BioRad Protein Assay Dye Reagent Concentrate (BioRad) was diluted 1:5 in water. 
2.5pl of cell lysate was added to 1ml o f reagent and vortexed to mix. The A 595 of 
samples was measured using an Ultraspec 2000 spectrophotometer and protein
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concentration determined by comparison with a standard curve obtained by 
measuring the A595 of known amounts of bovine serum albumin (BSA, First Link UK 
Ltd.). Lysates were stored at -20°C.
2.1.7. Preparation of neonatal rat cardiac myocytes
All procedures involving animals were performed in accordance with institutional 
guidelines for the care and use o f laboratory animals. Hearts removed from 1- to 2- 
day-old neonatal Wistar rats were minced and digested with oxygenated digestion 
buffer. Eight to twelve incubations of the heart tissue in digestion buffer were 
performed at 37°C for 15min. 2mls calf serum were added to each incubation to stop 
digestion and cells recovered by centrifugation at 1000 rpm for 4min (Sorvall TC 6 
centrifuge). 4ml calf serum was added to the pellet o f cells and then incubated at 
37°C, 5% CO2 . The cells from all digestions were subsequently pooled and 
centrifuged as before. Cells were resuspended in an appropriate amount of plating 
media (Roswell Park Memorial Institute medium (RPMI), 15% calf serum and 
penicillin and streptomycin (100 IU penicillin and lOOpg o f streptomycin/ml) and 
plated in 175cm flasks for 1 hour at 37°C to remove fibroblasts and enrich the 
myocyte population in the suspension. Cells were transfected with cDNA by 
nucleofection (Amaxa, described in Section 2.1.8) and plated onto coverslips that had 
been coated with 1% gelatin/PBS ( lh  at 37°C). The following day, cells were washed 
three times with maintenance media (RPMI, 1% calf serum and penicillin and 
streptomycin (100 IU penicillin and lOOjug o f streptomycin/ml) and left in 
maintenance media for 48h with or without treatment as described in Section 2.3.3.
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2.1.8. Transfection of neonatal rat cardiac myocytes
Cardiac myocytes are difficult to transfect efficiently. Transfection using the rat 
cardiomyocyte-neonatal nucleofector kit (Amaxa) gave approximately 50% 
transfection efficiency compared to less than 5% transfection efficiency using Fugene 
and was therefore deemed the most appropriate transfection method for cardiac 
myocytes. Cardiac myocytes were transfected using a rat cardiomyocyte-neonatal 
nucleofector kit (Amaxa) according to manufacturer’s instructions with the following 
adjustments. Cells were nucleofected using program G-0012 and subsequently plated 
in RPMI containing 15% calf serum, penicillin and streptomycin (100 IU penicillin 
and lOOpg of streptomycin/ml).
2.2. DNA manipulation
2.2.1. cDNA constructs
Table 2.2 lists DNA constructs used in this thesis and their suppliers. Constructs were 
stored at -20°C.
2.2.2. Generation of GRKANLS and GRK5ANES constructs
Putative NLSs in GRKs 4, 5 and 6 were identified using an automated tool for the 
analysis and determination o f NLSs (Cokol et al., 2000). Putative NESs were 
identified using the NetNES 1.1 server which predicts leucine-rich NES in eukaryotic 
proteins (la Cour et al., 2004). Predicted putative localisation sequences are listed in 
Table 2.7.
In order to generate mutants o f GRK5 in which putative NLS and NES sequences are 
ablated, primers were designed which converted selected residues in the protein
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sequence (see Table 2.7) to alanine (see Section 2.2.3).
2.2.3. PCR
All reagents were from Promega unless otherwise stated. Primers were custom made 
by Invitrogen.
2.2.3. L Site directed mutagenesis
The Quikchange® site-directed mutagenesis kit (Stratagene) was used according to 
manufacturer’s instructions to make point mutants in the putative NLS and NES of 
various GRKs as detailed in Table 2.7.
pRK5-GRK5 (bovine) was used as template to create GRK5ANLS. Basic residues 
located between amino acids 388 to 394 were mutated to alanine residues using the 
following primers; sense primer 5 ’ -C CAG TCG CCC TTC CGC GGC GCT GCT 
GAG GCT GTG G CT G CT GAG GAG GTG GAC CGC CGG- 3’, anti-sense 
primer 5’ -CCG GCG GTC CAC CTC CTC AGC AGC CAC AGC CTC AGC 
AGC GCC GCG GAA GGG CGA CTG G- 3’. Nucleotides in bold encode the 
mutated amino acids. The introduced mutation was screened by a loss of a Notl 
restriction site.
pRK5-GRK5 (bovine) was used as a template to create GRK5ANES. Basic residues 
located between residues 259 and 265 were mutated to alanine residues using the 
following primers; sense primer 5’ -GCC TAC GAG ACC A AG GAT GCC GCG 
TGT GCA G ’CT GCT ACC G CC ATG AAC GGC GGG GAC C- 3’, anti-sense 
primer 5’ -G GTC CCC GCC GTT CAT GGC GGT AGC A G 'C  TGC AC A CGC 
GGC ATC CTT GGT CTC GTA GG- 3’. Nucleotides in bold encode the mutated
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amino acids. The introduction o f the mutation was screened by the addition o f a PvuII 
site (as indicated b y ').
pRK5-GRK4a, p, y  and 8 (human) were used as templates to create GRK4ANLS. 
Basic residues between 221-225 (G RK a and y) or 189-193 (GRKJ3 and 8) were 
mutated to alanine residues using the following primers; sense primer 5’ -GCC TGC 
AAA AAG CTA CAA AAA G CT AGA ATA G 'C T G CT AGG AAA GGT GAA 
GCT ATG GC- 3’, anti-sense primer 5’ -  GC CAT AGC TTC ACC TTT CCT AG'C 
AGC TAT TCT AGC TTT TTG TAG CTT TTT GCA GGC -  3’. Nucleotides in 
bold encode the mutated amino acids. The introduction o f the mutation was screened 
by addition o f an ApeKI restriction site (as indicated b y ').
pBKA-GRK6A, B and C (human) and pBKA-GRK6A-flag, B-flag and C-flag were 
used as templates to create GRK6ANLS. Basic residues between 389-391 were 
mutated to alanine residues using the following primers; sense primer 5’ -CG CCC 
TTC CAG CAG AGG GCA G 'C T  G CT ATC AAG CGG GAG GAG GTG GAG 
CGG C- 3’, anti-sense primer 5 ’ -G  CCG CTC CAC CTC CTC CCG CTT GAT 
AGC A G'C TGC CCT CTG CTG GAA GGG C G - 3’. Nucleotides in bold encode 
the mutated amino acids. The introduction o f the mutation was screened by the 
addition o f a PvuII site (as indicated b y ').
Polymerase chain reactions were carried out as follows:
2pl Template (10ng)
5 pi 10X Primer Reaction Buffer 
1.25pl Sense Primer (lOOng/pl)
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1 .25jll1 Anti-sense Primer (100ng/pl)
1 j L i l  dNTPs (lOmM) 
ljul Pfu Polymerase
38.5 dH20 
50pl
PCRs were cycled in a PTC-2000 Peltier Thermal Cycler (MJ Research) as follows:
1. 95°C, 30 sec
2. 95°, 30 sec
3. 55°C, 60 sec
4. 68°C, l l m i n
5. Return to step 2 for 17 more cycles then step 6.
6. 4°C.
Following PCR, lp l Dpnl was added to the reaction and incubated at 37°C for 1 hour 
to cleave methylated parent DNA. 5pi o f each PCR reaction was then transformed 
into competent Escherichia coli (E. coli) as detailed in Section 2.2.4.
2.2.4. Bacterial transformation and plasmid DNA extraction
TOP 10 (Invitrogen) or D H 5a ultracompetent (Invitrogen) E. coli were thawed on ice 
and mixed by hand. 50pl were aliquoted into a pre-chilled 1.5ml Eppendorf tube and 
20ng of DNA or 5pi o f a PCR reaction added. The cells were swirled and incubated
on ice for 30 minutes before being heat shocked at 42°C for 30 seconds. The bacteria 
were then incubated on ice for 2 minutes. 0.9ml pre-warmed SOC medium 
(Invitrogen) was added and the cells incubated at 37°C for lh  with shaking at 250 
rpm (Kuhner ISF-l-W  bacterial incubator). Bacteria were then plated onto Luria 
Broth (LB) agar plates containing lOOjag/ml ampicillin or 25|xg/ml kanamycin as 
appropriate and incubated at 37°C overnight.
Single colonies were picked from the plate and grown in either 5ml or 500ml of LB 
medium, containing 100pg/ml ampicillin or 25jag/ml kanamycin as appropriate, 
overnight at 37°C with shaking at 250 rpm (Kuhner ISF-l-W  bacterial incubator). 
The next day, bacteria were pelleted and the plasmid DNA was extracted using either 
a QIAprep Spin Miniprep or Maxiprep kit (QIAGEN). To test whether the plasmid 
contained an insert o f the right size, a restriction digest was performed using 2pl of 
the relevant restriction enzyme (Promega) for lh  at 37°C. Digested products were 
analysed on a 1% agarose tris-borate (TBE) gel containing ethidium bromide and 
their size determined using the lkb Plus DNA ladder. The concentration o f the 
plasmid DNA was determined using an Ultraspec 2000 spectrophotometer 
(Pharmacia Biotech).
2.2.5. DNA sequencing
Sequencing was performed by MWG Biotech (Germany) to confirm introduction of 
desired mutations and the integrity o f the remaining sequence. Primers used to 
sequence constructs are listed in Table 2.8 and 2.9. The sequences obtained were 
compared to the published sequences o f the protein using the Gene Jockey II
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Sequence Processor program (Biosoft).
2.3. Immunofluorescence techniques
2.3.1. HEp2 cells - ionophore treatment
24-48h post-transfection cells were treated as described in the figure legends. Cells 
treated with Ca2+ ionophore were incubated with 25pM A23187 (Calbiochem) for 
15min, unless otherwise indicated, in medium supplemented with 2mM CaCI2 at 
37°C, 5% C 0 2.
2.3.2. CHO-M3MR cells - drug treatment
24-48h post-transfection cells were treated as described in the figure legends. CHO- 
M3 expressing cells were treated with the muscarinic agonist acetylcholine (ACh, 
Sigma) at a concentration o f lOOjaM in CHO-M3 eagle medium (see Section 2.1.1) 
for 5 min, unless otherwise stated, at 37°C, 5% CO2 . The phospholipase-C inhibitor 
U73122 (1 -[6-(( 17b-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1 H-pyrrole- 
2,5-dione, Calbiochem) was used at a concentration o f lpM  for lh.
2.3.3. Induction of hypertrophy in rat neonatal cardiac myocytes
The day following preparation cardiac myocytes were treated with 200pM PE 
(Sigma), 167nM Epidermal Growth Factor (EGF) (Sigma), 200nM Angll (Sigma) or 
lOOnM PLC activator m-3M3FBS (Calbiochem) in RPMI, 1% calf serum and 
penicillin and streptomycin (100 IU penicillin and lOOjug o f streptomycin/ml) for 
48h. Other stimulants o f cardiac hypertrophy were also trialed, including Endothelin- 
1 (ETi) (lOOnM) and Phorbol ester 12-tetradecanoylphorbol-13 acetate (PMA,
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200nM). These agents failed to produce reproducible myocyte hypertrophy, as 
assessed by an increase in cell area and thus ETj and PMA were not used during 
these studies.
2.3.4. Immunofluorescent labelling
2.3.4.1. Cell lines
Cells were fixed in 4% paraformaldehyde (TAAB)/PBS for 20min and quenched for 
10 min in 0.27% NH4Cl/0.37% glycine in PBS. 1% BSA (First Link UK Ltd.)/0.2% 
saponin/PBS was subsequently used to block and permeabilise fixed cells. Primary 
antibody incubations were performed for lh  at RT or at 4°C overnight. Cells were 
subsequently washed with l%BSA/0.2% Saponin/PBS and incubated with an 
appropriate secondary antibody for 45min at RT. YFP constructs were not subject to 
immunostaining. Nuclei were visualised by staining DNA with Hoechst (1/10,000 in 
PBS; Sigma). After washing, coverslips were mounted on slides in 90% glycerol 
(Sigma)/PBS/3% N-propyl-galate (Sigma). Essentially the same protocol was used 
for the detection o f endogenous GRK5 in HEp2 cells except the fluorescently labelled 
secondary antibodies described above were replaced with a tyramide signal 
amplification kit (Molecular Probes) that was used according to the manufacturers 
instructions. To block anti-GRK5 C20 antibody before use in immunofluorescent 
labeling, the antibody was preincubated with o f 10 times more blocking peptide 
(Santa Cruz, sc-565) than antibody (e.g. lOpg antibody: lOOpg blocking peptide) for 
30 min on ice.
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2,3.4.2. Neonatal rat cardiac myocytes
Immunofluorescent labelling o f cardiac myocytes was carried out as for cell lines 
described in Section 2.3.4.1 with the following modifications. Cells were 
permeabilised using 0.5% Triton X-l00/PBS for 20 min. Cells were washed with 
wash buffer (0.5% BSA/0.1% glycine/PBS); and blocked in wash buffer containing 
5% calf serum for 45 min. Primary antibody incubations were performed for lh  at 
RT. GRK5 was detected using the polyclonal GRK5 antibody (Santa Cruz) listed in 
Table 2.3 and myocytes were identified by labelling a-actinin with the monoclonal 
antibody (Sigma) listed in Table 2.3. Secondary antibody labelling and coverslip 
mounting was carried out as described in Section 2.3.4.1.
2.3.5. Confocal microscopy
Confocal images were taken at RT. Nikon Plan Apo 40x and 60x oil immersion 
lenses and a BioRad 1024 MRC confocal were used with a Nikon microscope and 
BioRad Lasersharp 2000 software to acquire the images. Images were optimised for 
contrast in Adobe Photoshop but no further manipulations were made.
2.3.6. Analysis of GRK nuclear export
To quantify ionophore-dependent nuclear export o f GRKs, at least 50 appropriately 
transfected cells were counted and GRK distribution scored as nuclear or cytosolic. 
Cells were deemed to show a cytosolic distribution if  no transfected protein was 
detected in the nucleus. At least three separate GRK transfections were scored per 
experiment.
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2.3.7. Analysis of cardiac hypertrophy
Rat cardiac myocytes were assessed for induction of hypertrophy by measuring the 
change in cell area between untreated and treated samples. Following 
immunofluorescent staining, cells were viewed using a Zeiss Axioplan2 microscope 
using a Nikon plan apo 40x oil immersion lens and the cell areas of a minimum of 50 
cells from three independent experiments were measured and averaged for each 
condition. Myocytes were identified by staining for a-actinin. Where myocytes were 
transfected, transfected cells were identified by appropriate immunofluorescent 
staining. Untransfected cells on the same coverslips were identified by a lack of 
immunofluorescence and measured as an internal control. Cell areas were measured 
by drawing around the outline o f each cell visualised by a-actinin and/or GRK5 
(Santa Cruz anti-GRK5 C20; see Section 2.5) staining using Improvision openlab 
software. Statistical differences were determined by performing a Student’s t-test.
2.4. Other techniques
2.4.1. Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE)
SDS-PAGE was performed using the Laemmli method (Laemmli, 1970) with a
discontinuous SDS-PAGE and the Hoefer Scientific Instruments (HSI) vertical slab
gel unit SE 600 gel system. 10% SDS-PAGE resolving gel was cast between two
glass plates by polymerising 30% (v/v) acrylamide in 0.375M Tris-HCl pH8.8 and
1% sodium dodecyl sulphate (SDS), using 0.3% (v/v) ammonium persulphate and
0.07% (v/v) N, N, N ', N'-tetramethyl-ethylenediamine (TEMED). A 4% stacking gel
was cast above the resolving gel by polymerising 4% (v/v) acrylamide in 0.12M Tris-
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HC1 pH6.8 and 1% SDS, using 0.1% (v/v) ammonium persulphate and 0.1% (v/v) 
TEMED.
The polymerised gel was placed in an HSI SE 600 cell and covered with gel running 
buffer. An appropriate volume o f SDS reducing buffer was added to known 
concentrations o f samples prior to heating at 60°C for 10 minutes. Samples were 
briefly centrifuged to collect the entire sample and then loaded onto the gel. Rainbow 
coloured protein molecular weight markers (14.3 - 220kD, Amersham Biosciences) 
were loaded to indicate the molecular weights o f sample proteins. The gel was 
subject to a constant voltage o f 200-300V until the dye front ran off the gel.
2.4.2. Coomassie staining of SDS-PAGE gels
To detect proteins, the gel was covered in Coomassie stain, heated for 1 minute at 
750W in a microwave and then allowed to cool at RT on a shaker. The gel was then 
destained using Coomassie de-stain until proteins were visible and identifiable by 
comparison to molecular weight markers. The gel was scanned using a densitometer 
(BioRad) and the intensity o f the appropriate purified protein band determined as a 
percentage o f total protein present. An empty lane was scanned to determine 
background staining.
2.4.3. Western blotting and immunodetection
Proteins separated on the 10% SDS-PAGE were transferred onto nitrocellulose 
membrane (Hybond-ECL, Amersham) using a semi-dry electrophoretic transfer 
method. The stacking gel was discarded and the resolving gel and nitrocellulose 
membrane were soaked in transfer buffer and placed between 6 sheets o f filter paper
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that had also been soaked in transfer buffer. Horizontal electrophoretic transfer was 
performed in the SCIE-PLAS semi-dry electroblotting unit V20-SDB with a constant 
current o f 0.8mA per cm2 o f nitrocellulose membrane applied for lh  45min. Transfer 
was considered complete if  visual transfer o f the molecular weight standards to the 
nitrocellulose membrane had occurred.
The nitrocellulose membrane to which the proteins had been transferred was 
incubated in blocking buffer for lh  at RT. The immobilised proteins were subject to 
immunoblotting with a primary antibody diluted in blocking buffer for lh  at RT or 
overnight at 4°C. Following five washes over a 30 min period in TTBS a horseradish 
peroxidase-conjugated secondary antibody (Amersham) diluted in TTBS was added 
to the immunoblots for lh  at RT. The blots were then washed as before.
Sufficient ECL reagent was added to cover the protein side o f the blot and incubated 
at RT for 1 minute with vigorous shaking (ECL Western Blotting Detection Reagents, 
Amersham Biosciences). Bound antibody was detected by exposing the immunoblot 
to film (Biomax ML, Kodak) for the required time and the film was developed using 
an Agfa automatic film processor and quantified using a densitometer (BioRad).
2.4.4. Purification of GRK5 & 6
GRK5 and GRK6 were overexpressed in baculovirus-infected SF9 cells by Dr Julie 
Pitcher. Cell pellets were thawed, supplemented with fresh protease inhibitors 
(40pg/ml phenylmethanesulfonyl fluoride (PMSF), lmM  benzamidine), and 
homogenised with 10 strokes o f a tightglass Dounce homogeniser on ice. All 
subsequent manipulations were performed at 4°C, and all buffers contained protease
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inhibitors as above. The homogenate was spun at 17,000 rpm (JA-17 rotor, Beckman 
Coulter Avanti J-25 centrifuge) for 20 min. The resulting pellet was re-homogenised 
with 50 ml o f purification buffer with 20 mM NaCl and spun as before. The two 
supernatants were pooled and passed through a 10-ml column o f S-Sepharose 
(Pharmacia) at a flow rate of 1 ml/min. Most proteins failed to bind to the resin. The 
column was washed with 50 ml o f purification buffer with 20 mM NaCl and eluted 
with a linear 100-ml gradient o f 20-750 mM NaCl in purification buffer. Fractions 
were assessed for GRK5 or 6 content by coomassie staining of 10% SDS-PAGE gels 
or by Western blotting and those fractions containing GRK5 or 6 and the fewest 
protein contaminants were pooled. Pooled fractions (20 ml) were diluted with 
purification buffer to below 100 mM N aC l, and applied to a 10-ml column of 
heparin-Sepharose (Pharmacia) at 1 ml/min. The column was washed with 50 ml of 
purification buffer with 150 mM NaCl and eluted with a linear 100-ml gradient of 15- 
1500 mM NaCl in purification buffer with 0.02% Triton X-100. Fractions containing 
purified GRK5 or 6 as assessed by SDS-PAGE gel coomassie staining were pooled 
and concentrated to 1 ml in a Centriprep 30 spin concentrator (Amicon). Purified 
GRKs were stored at 4°C or at -2 0 °C in 50% glycerol. Final purity o f purified GRKs 
was assessed by staining the proteins in a SDS-PAGE gel with coomassie stain as 
described in Section 2.4.2.
2.4.5. DNA-binding assay
Cos-7 cells expressing GRKs were lysed in 300(il cold DNA-binding buffer and 
lysates clarified by centrifugation at 13,000 rpm (Heltich bench top centrifuge Mikro 
20) for 8 min. Protein concentration of the clarified lysates was determined using the
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BioRad protein assay. Cell lysate was diluted 1:40 in BioRad protein assay reagent 
(previously diluted 1:5 in water). The A595 of samples was measured using an 
Ultraspec 2000 spectrophotometer and the protein concentration of samples 
determined by comparison to a standard curve obtained by measuring the A595 of 
known amounts o f BSA. Cell lysates (~10|ig) or purified GRK (150ng, see Section 
2.4.4) were incubated with 25(il o f native DNA-cellulose (~10p.g DNA, Amersham), 
single stranded DNA-cellulose (~10p,g DNA, Sigma), poly(A)-sepharose 4B 
(Amersham) or cellulose (Sigmacell Cellulose type 50, Sigma) in lOOpl cold DNA- 
binding buffer for lh  at 4°C. For competition assays, GRKs 5 or 6 were pre-incubated 
with the stated amounts o f DNA (sonicated, calf thymus, Amersham) or ribonucleic 
acid (RNA, calf liver type IV, Sigma) for 30 min on ice and then added to 25pl native 
DNA-cellulose. Following incubation the resin was washed four times with 1ml 
binding buffer (at 4°C) and the amount of GRK retained on the resin determined by 
Western blot analysis and immunodetection as described in Section 2.4.3. 
Autoradiographs were subsequently quantified using a densitometer (BioRad) 
Significance was determined by performing a t-test.
2.4.6. Purification of rod outer segments (ROS)
ROS were prepared from dark adapted bovine retinas. 50 retinas were suspended in 
50 ml o f ROS buffer A, homogenised on ice and centrifuged at 4,000 rpm (JA-17 
rotor, Beckman Coulter Avanti J-25 centrifuge) for 5 min. The supernatant, 
containing the ROS, was diluted with 2 volumes o f lOmM Tris-acetate, pH 7.4, and 
centrifuged as above. The crude ROS pellets were resuspended in -3 0  ml o f ROS
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buffer B (4°C), homogenised, and then further purified on a sucrose gradient (See 
ROS sucrose gradient in buffers table 2.1) by centrifugation in a SW-28 swinging 
bucket rotor at 26,000 rpm (Beckman Coulter Optima LE-80K Ultracentrifuge). The 
interface between the 0.84 and l.OOM sucrose layers was collected and diluted 1:1 
with ROS buffer A without sucrose, and sedimented at 17,000 rpm (JA-17 rotor, 
Beckman Coulter Avanti J-25 centrifuge) for 30 min. This pellet was resuspended in 
10ml ROS buffer A without sucrose and centrifuged as before. The pellet was 
resuspended in 10ml ROS buffer A, centrifuged at 23,000 rpm (JA-25.5 rotor, 
Beckman Coulter Avanti J-25 centrifuge), and the recovered ROS resuspended in 
15ml 4M urea in lOmM Hepes (pH7.0) and left on ice for 20 min to remove 
endogenous GRK1. The ROS were then diluted with four volumes o f ROS buffer C 
and centrifuged as before. The pelleted ROS were resuspended in lOmM Hepes 
(pH7.0) and re-centrifuged as before. The final pellet o f purified ROS were 
resuspended in 10ml lOmM Hepes (pH7.0) and homogenised. ROS protein 
concentration was determined using the BioRad protein assay as described in Section
2.4.5 and diluted to 2mg/ml with lOmM Hepes (pH7.0). ROS were aliquoted (50pl) 
under safe light, wrapped in foil and stored in liquid nitrogen. ROS are approximately 
90% pure at the end o f this procedure.
2.4.7. GRK5 kinase assays
Kinase assays were performed in kinase assay buffer containing 50jliM adenosine 
triphosphate (ATP) (~6000cpm/pmol) in a total volume o f 25 p i  Purified rod outer 
segments (ROS, lpg), or purified tubulin (Cytoskeleton, lOpig) were included as 
GRK substrates as indicated.
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When measuring DNA/RNA-mediated inhibition o f GRK5 or GRK5ANLS activity 
transfected Cos-7 cell lysates were used as the source o f GRK5. Cos-7 cells were 
transfected with 2pg o f the appropriate cDNA. 24h post-transfection, cells were lysed 
in 1ml o f kinase assay lysis buffer by homogenisation (two 15sec pulses, Branson 
Sonifier 450, setting 6) and lysates clarified by centrifugation at 13,000 rpm (Heltich 
bench top centrifuge Mikro 20) for lOmin. Equivalent rhodopsin kinase activities of 
GRK5 and GRK5ANLS were used in the assays, corresponding to respectively, -0.6 
and -1 .Omg o f total protein. For each assay condition the kinase activity present in an 
equivalent amount o f protein from a mock-transfected lysate was determined and 
subtracted from that obtained with the GRK5 expressing lysate.
The activity comparison o f GRK5, GRK5ANLS, GRK5NTPB, GRK5CTPB and 
GRK5K215R was performed using partially purified transfected Cos-7 cell extracts. 
GRK5NTPB is expressed at approximately 20% o f the level o f the other GRK5 
constructs and detecting GRK5NTPB-mediated tubulin phosphorylation above a 
background o f endogenous kinases proved difficult without this enrichment step. 
Cells transfected with the appropriate cDNA were lysed as described above. Lysates 
(~2mg o f protein) were diluted 2-fold in kinase assay dilutant buffer and loaded onto 
0.5ml S-Sepharose columns by gravity flow. The columns were washed sequentially 
with 2.5ml o f kinase assay dilutant buffer, kinase assay dilutant buffer + 400mM 
NaCl and kinase assay dilutant buffer + 1M NaCl. Wild type GRK5 and mutant 
kinases eluted in the 1M NaCl wash were subsequently desalted and concentrated in 
Nanosep 3OK centrifugal devices (Pall Life Sciences). In total three separate 
transfections and three S-Sepharose columns were run for each enzyme. Before
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assaying activity the individual purifications were pooled and the amount of 
GRK5/unit volume quantified by western blot analysis. The amount o f total protein 
assayed was adjusted such that equivalent amounts o f each kinase were used in the 
reactions. This ranged between 200-300ng o f protein with the exception of 
GRK5NTPB expressing lysates where approximately 5 times more protein was used. 
Assays using equivalent amounts o f protein derived from a partially purified mock- 
transfected lysate were used to determine endogenous kinase activity, which was 
subsequently subtracted from the relevant kinase expressing lysate activity value.
Where purified GRK was used in kinase assays, 75ng o f purified GRK5 was used in 
each assay. All reactions were incubated at 30°C for lOmin. When rhodopsin was 
used as a substrate samples were illuminated during this incubation period. Reactions 
were stopped by addition o f an equal volume o f SDS reducing buffer, and 
electrophoresed on 10% SDS-PAGE gels. The dried gels were analysed and 
quantified using a phosphorimager (BioRad) and significance was determined by 
performing a Student’s t-test.
2.4.8. NHERF-1 overlays
His/S-tagged full length Na+/H+ exchanger regulatory factor-1 (NHERF-1) was 
expressed in bacteria (BL-21, Stratagene) and purified using a His-tag purification kit 
(Novagen). GRK6A and GRK6A-flag were expressed in Cos-7 cells and lysates 
made as described for the DNA-binding assay. The lysates (25 pg/lane) were run on 
10% SDS-PAGE gels and subject to western blot analysis. The blots were overlaid 
with lOOnM fusion protein in buffer (2% milk, 0.1% Tween 20, 10 mM HEPES, pH 
7.4, 50 mM NaCl) for 1 h at RT. All subsequent steps were performed in Western
100
blot blocking buffer. The blots were washed three times, incubated for lh  at room 
temperature with a horseradish peroxidase-conjugated anti-S-Tag antibody 
(Novagen), washed three more times, and visualised via chemiluminescence.
2.5. Antibodies & Tagged-Conjugates
Tables 23-2 .6  list antibodies and tagged-conjugates used in this thesis, their 
concentrations and suppliers. Commercial antibodies were stored at 4°C, -20°C  or 
-80°C  according to manufacturers’ instructions. Non-commercial antibodies were 
stored at -80°C.
2.6. Statistical analysis
Results were analysed using the student’s two-sample T-test to determine whether 
measurements made on two populations were different from each other (Ennos, 
1999). The null hypothesis proposed that the two populations were the same in every 
case.
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Table 2.1: Buffers
Blocking buffer (Western blot) 4% skimmed milk powder 
made up in TTBS
Blocking buffer (rat cardiac 5% calf serum
myocytes) made up in wash buffer
Coomassie de-stain 40% MeOH 
10% acetic acid
Coomassie stain 40% MeOH 
10% acetic acid 
0.05% Brilliant Blue R
Digestion buffer 100ml isolation buffer
250mg collagenase type II CLS2 (Worthington) 
25mg pancreatin from porcine pancreas
DNA-binding buffer lOmM Hepes pH7.4 
ImM MgCl2 
0.1% Triton X-100  
3mM DTT 
O.lM NaCl 
0.5mM EDTA 
40pg/ml PMSF 
1 mM benzamidine
Freezing medium 20% FCS 
10% DMSO 
made up in DMEM
Gel running buffer 2M glycine 
0.25M Tris 
0.03M SDS
HEBS buffer 137mM NaCl 
20mM Hepes 
6mM D-glucose 
5mM KC1 
0.7mM Na2H P04 
pH adjusted to pH7.05
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Isolation buffer 116mM NaCl 
20mM Hepes 
0.77mM NaH2P 0 4 
5.5mM glucose 
5.4mM KC1 
0.4mM M gS 04 
pH adjusted to pH7.35
Kinase assay buffer 20mM Tris-HCl, pH 7.5 
2.0mM EDTA 
lOmM MgCl2 
ImM DTT
Kinase assay lysis buffer 20mM Hepes, pH7.2 
250mM NaCl 
lOmM EDTA 
0.02% Triton X-100 
40pg/ml PMSF 
1 mM benzamidine
Kinase assay dilutant buffer 20mM Hepes pH7.2 
2mM EDTA 
40|ig/ml PMSF 
1 mM benzamidine
Lysis buffer (cell lysates) 150mM NaCl 
50mM Tris pH8 
2mM EDTA 
1 mM benzamidine 
1% Triton X-100 
10% glycerol 
40fig/ml PMSF
Mountant 90% glycerol
3% N-propyl-galate
made up in PBS
Stored at 4°C, away from light
Immunofluorescence 1% BSA
permeabilisation/block/wash 0.2% saponin
buffer (cell lines) made up in PBS
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Immunofluorescence 
permeabilisation buffer (rat 
cardiac myocytes)
0.5% Triton X-100 
made up in PBS
Purification buffer 20 mM HEPES 
2 mM EDTA  
pH 7.2
Quench buffer 0.37% glycine 
0.27% NH4C1 
0.05% azide 
made up in PBS
ROS buffer A 34% sucrose (w/w)
65 mM NaCl 
2 mM M gC l2
10 mM Tris-acetate buffer, pH 7.4 
0.1 mM EDTA 
500|iM PMSF 
1 |lLM Leupeptin 
1 pM Pepstatin
ROS buffer B 0.77M sucrose 
1 mM MgCl2
lOmM Tris-acetate, pH 7.4
ROS buffer C lOmM Hepes, pH 7.0 
1 mM MgCl2
ROS sucrose gradient 10ml:
0.84 M sucrose 
2mM MgCl2
lOmM Tris acetate, pH 7.4 
0.1 mM EDTA
15ml:
1M sucrose 
2mM MgCl2
lOmM Tris acetate, pH 7.4 
0.1 mM EDTA
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SDS reducing buffer 25mM Tris pH6.5 
10% glycerol 
8% SDS
5% p-mercaptoethanol 
a few grains o f  Brilliant Blue G
TBE 890mM Tris
890mM boric acid
20mM EDTA
pH 8.3
Transfer buffer 0.05M Tris
0.04M glycine
0 .01M SDS
20% MeOH
TTBS 50mM NaCl
20mM Tris
0.05% Tween-20
Wash buffer (rat cardiac 0.5% BSA
myocytes) 0.1% glycine
made up in PBS
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Table 2.2: cDNA constructs
Construct name cDNA Supplier Reference
GRK5 GRK5-pRK5 Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
(Pitcher et 
al., 1996)
GRK5NTPB GRK5NTPB-pRK5 Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
(Pitcher et 
al., 1996)
GRK5CTPB GRK5CTPB-pRK5 Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
(Pitcher et 
al., 1996)
GRK5K215R GRK5 K 215R-pRK5 Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
GRK5AP GRK5ST/AA-pRK5 Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
(Kunapuli et 
al., 1994)
GRK5ANLS GRK5ANLS-pRK5 Constructed by Laura 
Johnson.
(Johnson et 
al., 2004)
GRK5ANES GRK5ANES-pRK5 Constructed by Laura 
Johnson.
GRK2 GRK2-pRK5 Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
(Pitcher et 
al., 1999)
GRK3 GRK3-pcDNAl Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US.
(Menard et 
al., 1996)
106
Construct name cDNA Supplier Reference
GRK4oc, p, y, 8 GRK4-a, -p, -y, -8-pRK5 Dr Richard Premont, 
Duke University, US.
(Premont et 
al., 1996)
GRK4-OANLS, - 
pANLS, -yANLS, 
-8ANLS
GRK4aANLS, pANLS, 
yANLS, 8ANLS pRK5
Constructed by Laura 
Johnson.
GRK6-A, -B, -C GRK6-A, -B, -C-pBK(A) Dr Mario Tiberi, 
Universite de 
Montreal, Canada.
GRK6-AANLS, - 
BANLS, -CANLS
GRK6A-ANLS, -BANLS, - 
CANLS -pBK(A)
Constructed by Laura 
Johnson.
GRK6A-Flag GRK6A-pBK(A)-Flag Dr Mario Tiberi, 
Universite de 
Montreal, Canada.
GRK6A-3C3A GRK6A-3C3A-pCMV5 Dr Richard Premont, 
Duke University.
I39E, F527D,
I39E/I165E,
I165E/F527D
GRK6-I39E, -1165E, -F527D, - 
I39E/I165E, -I165E/F527D -  
pcDNA3
Prof. John Tesmer, 
University o f Texas
(Lodowski 
et al., 2006)
S-tag-NHERF-1 6xHis/S-tag-NHERF-l -pET30a Dr Robert Lefkowitz, 
HHMI/Duke 
University Medical 
Center, US. & Dr 
Randy Hall, Emory 
University School o f 
Medicine, US.
(Weinman 
et al., 1998)
CaMBP/m CaMBP/m-pEYFP Dr Marcia A.
Kaetzel, University 
of Cincinnati, US; 
Prof John Dedman, 
University o f  
Cincinnati, US; Prof 
David Sacks, Harvard 
Medical School, US.
(Li et al., 
2003)
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Construct name cDNA Supplier Reference
CaMBP/n CaMBP/n-pEYFP Dr Marcia A.
Kaetzel, University 
of Cincinnati, US; 
Prof John Dedman, 
University of 
Cincinnati, US; Prof 
David Sacks, Harvard 
Medical School, US.
(Wang et 
al., 1995)
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Table 2.3: Primary antibodies used in immunofluorescence
Antigen Antibody Name Species & Isotype Dilution Supplier
GRK2 Anti-GRK2/3 Mouse IgG2aK 1:300 Upstate
Biotechnology
GRK5 Anti-GRK4-6 Mouse
IgGlK
1:300 Upstate
Biotechnology
Anti-GRK5 C20 Rabbit IgG 1:50 Santa Cruz
Anti-GRK5 C20 
blocking peptide
N/A 1 OX more 
than
antibody
Santa Cruz
GRK4 Anti-GRK4-6 Mouse
IgGlK
1:300 Upstate
Biotechnology
GRK6 Anti-GRK4-6 Mouse
IgGlK
1:300 Upstate
Biotechnology
a-Actinin Anti-a-actinin Mouse IgGl 1:200 Sigma
Muscarinic-M3
receptor
Anti-M3 Rabbit IgG 1:50 Dr Andrew Tobin, 
University o f  
Leicester
Acetyl-histone H3 Anti-AcH3 Rabbit IgG 1:300 Upstate
Biotechnology
Acetyl-histone H4 Anti-AcH4 Rabbit IgG 1:300 Upstate
Biotechnology
Phospho-histone H3 Anti-P-H3 Rabbit IgG 1:300 Upstate
Biotechnology
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Table 2.4: Secondary antibodies used in immunofluorescence
Antigen Antibody Name Species & Isotype Dilution Supplier
Mouse IgG Alexa Fluor 488 
anti-mouse
Donkey 1:700 Molecular
Probes
Alexa Fluor 594 
anti-mouse
Donkey 1:700 Molecular
Probes
Rabbit IgG Alexa Fluor 488 
anti-rabbit
Donkey 1:700 Molecular
Probes
Alexa Fluor 594 
anti-rabbit
Donkey 1:700 Molecular
Probes
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Table 2.5: Primary antibodies/tagged conjugates used in western
blotting and immunodetection
Antigen Antibody/T agged 
Conjugate Name
Species & Isotype Dilution Supplier
GRK2 Anti-GRK2/3 Mouse IgG2aK 1:300 Upstate
Biotechnology
GRK5 Anti-GRK4-6 Mouse
IgGlK
1:300 Upstate
Biotechnology
Anti-GRK5 C20 Rabbit IgG 1:500 Santa Cruz
GRK4 Anti-GRK.4-6 Mouse
IgGlK
1:300 Upstate
Biotechnology
Anti-GRK4 (H64) Rabbit IgG 1:500 Santa Cruz
GRK6 Anti-GRK4-6 Mouse
IgGlK
1:300 Upstate
Biotechnology
Anti-GRK6 (C20) Rabbit IgG 1:500 Santa Cruz
S-protein S-protein-HRP N/A 1:5000 Novagen
111
Table 2.6: Secondary antibodies used in western blotting and
immunodetection
Antigen Antibody Name Species & Isotype Dilution Supplier
Mouse IgG Anti-Mouse IgG Sheep 1:2000 Amersham
Biosciences
Rabbit IgG Anti-Rabbit IgG Sheep 1:2000 Amersham
Biosciences
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GRK Predicted 
localisation Seq.
Species Protein Sequence and location DNA sequence and location
GRK5 NLS Bovine WT: 388-RKEKVKRE-395 
Mutant: 388-AAEAVAAE-395
WT: 1162-CGC AAG GAG AAG GTG AAG CGG GAG-1185 
Mutant: 1162- GCT GCT GAG GCT GTG GCT GCT GAG-1185
NES Bovine WT: 259-LCLVLTI-265 
Mutant: 259-ACAAATI-265
WT: 775-CTG TGT TTG GTC CTG ACC ATC-795 
Mutant: 775- GCG TGT GCA GCT GCT ACC GCC-795
GRK4 NLS Human WT: QKKRIKKRK 
Mutant: QKARIAARK 
a,y: 219-227 
p,5: 187-195
WT: CAA AAA AAA AGA ATA AAG AAG AGG AAA  
Mutant: CAA AAA GCT AGA ATA GCT GCT AGG AAA  
a,y: 655-681 
P,8 : 558-585
NES Human WT: LCLVLTI 
a ,y: 260-266  
p,5: 228-234
Mutant not constructed
GRK6 NLS Human WT: 387-QRKKKIKRE-395 
Mutant: 387-QRAAAIKRE-395
WT: 1159-CAG AGG AAG AAG AAG ATC AAG CGG GAG-1185 
Mutant: 1159-CAG AGG GCA GCT GCT ATC AAG CGG GAG-1185
NES Human WT: 259-LCLVLT-264 Mutant not constructed
Table 
2.7: Putative 
nuclear 
localisation 
sequences
Table 2.8: Custom sequencing primers
Primers synthesised by Invitrogen were designed to sequence both the sense (F) and 
anti-sense (R) strands in stages from 5’ to 3 ’ in order to check that mutagenesis was 
as desired.
Target
sequence
Primer Name
(F-sense,
R-antisense)
Primer Sequence and location (5’-3’ on sense 
strand)
GRK5 GRK5seqFl 1ATGG AGCTGG AAA ACATCGT'U
(bovine) GRK5seqF2 ^C T T C  AG AAACCCTGC A AAG A4 1 9
GRK5seqF3 814 A AGTTCC AC ATTTAC A AC AT833
GRK5seqF4 1201GTGTTGGAG AC AG AGG AGGT1220
GRK5seqF5 1556AGTGCTTT AAGG AGCTG AAC 1575
GRK5seqRl 1754TG AGGTGGCCTT CGTCG ATC 1773
GRK5seqR2 ,2 7 0GAGTGGTTTCTACGTTTCGT1289
GRK5seqR3 91 °GTACTCTTGT AAC AC ATGTC833
GRK5seqR4 4 3 9g t c a g a c a g g t g c t g a t g g a 458
GRK5seqR5 2 3 2c t c a g g a t g t a a g t c a a g g a 251
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Target
sequence
Primer Name
(F-sense,
R-antisense)
Primer Sequence and location (5’-3’ on sense 
strand)
GRK4 HGRK4DSEQ1F ATGGAGCTCGAGAACATCGT
(human) ( c t ,p ,y , 6 : l - 2 0 )
HGRK4DSEQ2F CATATTTTTCTCAGTTTTTACAATGGAA 
(a , y: 497-524, p, 6 : 401-428)
HGRK4DSEQ3F CTTGGAAGATTTACAGAGGGAAAG 
(a , y: 897-920, p, 6 : 801-824)
HGRK4DSEQ4F CTGGGCTGCAGGGG
(a , y: 1297-1214, p, 6:1201-1214)
HGRK4DSEQ1R CACTGTCTTACATCTAACCCTGAC 
(a , y: 376-399, P, 6 : 280-303)
HGRK4DSEQ2R CACGAACCACGAGTGGTAAT 
(a , y: 780-799, p, 6 : 684-703)
HGRK4DSEQ3R TTACCCTCCTCCAGCTAGT 
(a , y: 1181-1199, p, 5:1085-1103)
HGRK4DSEQ4R CTTGGGTTCGTTACGACT
(a: 1720-1737, p: 1085-1103, y: 1181-1199, 6 : 14
86-1503)
GRK6 MGRK6ASEQF1 ‘ATGGAGCTCGAGAACATCGT1 0
(human) HGRK6ASEQF2 401AGC AGGGTCCCTGC AA A 4 17
HGRK6ASEQF3 ^CGGGGGCGACCTCA 8 1 4
HGRK6ASEQF4 1 201g t g a a g g a g g t c c c c g a 1217
MGRK6ASEQF5 1601c c c c a g a c c t g g a c t g g a 1618
MGRK6ASEQR5 (A & B GGGGTGGGCGGAGATC
only) (A: 1715-1731, B: 1718-1733)
MGRK6CSEQR5 
(C only)
1664a g a a g t c a g c g g t t t c c a c t 1683
HGRK6ASEQR1 113 TGTAGTCGGTCACGCTTCT1 3 1
HGRK6ASEQR3 9 1 5c g c g t a g c a c a t g t c c c 931
HGRK6ASEQR4 1316 GGGCGCTCCACTTCCT1331
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Table 2.9: MWG supplied primers
MWG supplied primers were used to check cloning junctions.
Target
sequence
Primer Name Primer Sequence and location (5’-3’ on sense strand)
pcDNA3.1™ T7 promoter/ “6JTAA TAC GAC TCA CTA TAG GGmz
3.1//wyc-His(-)A, priming site (5 ’
B (Invitrogen) Cloning Junction)
BGH reverse 
priming site 
(3 ’ Cloning 
Junction)
,1I3TAG AAG GCA CAG TCG AGG 1130
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3. GRK5 contains a DNA-binding nuclear 
localisation sequence and nuclear export
sequence
The role o f GRKs in regulating desensitisation o f GPCRs is well understood, 
however evidence has emerged to suggest that in addition to this established role 
GRKs also have additional cellular functions (summarised in Section 1.3). Following 
the observation made by Dr. Julie Pitcher that the GRK4 subfamily, but not the 
GRK2 subfamily, are present in the nucleus in HEp2 cells, I investigated the 
possibility that the GRK4 subfamily o f GRKs might have nuclear functions. GRK5 
represents the most intensively studied, and thus, best characterised member o f the 
GRK4 subfamily. I thus sought to determine if  nuclear localisation was a universal 
feature o f GRK5 in a range o f cell lines and to identify motifs within the kinase that 
may account for its subcellular localisation. I additionally describe experiments aimed 
at establishing whether the nuclear localisation o f GRK5 is regulated and to explore 
potential functional consequences o f this localisation.
3.1. Endogenous and overexpressed GRK5 is present in the 
nucleus of various cell lines
Overexpression o f GRK5 in a variety o f mammalian cell lines (Figure 3.1 A); HEp2 
(a), HeLa (b), HEK-293 (c) and Cos-7 (d), and GRK2 in HEp2 (e), reveals distinct 
cellular distributions for these two related kinases. GRK2, a member o f the GRK2 
subfamily, is cytoplasmic and is excluded from the nucleus in HEp2 cells (Figure
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3.1A(e)) whereas GRK5, a member o f  the GRK4 subfamily, is ubiquitously 
distributed throughout the cell, including the nucleus (Figure 3.1 A).
A.
GRK5 GRK2
H Ep2
B.
A4cSfr
^
&
WB a4  
WB a5  
WB a6  
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GRK5
Endogenous 
G RK 5 +
B locking 
Peptide
D.
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Figure 3.1. GRK5 is localised in the nucleus of cells.
A. C onfocal m icroscopy o f  G R K 5 transien tly  transfected  into a. H Ep2, b. HeLa, c. HEK and d. Cos-7 
cell lines and e. G RK 2 in H Ep2 cells. Scale bars, 10pM . B ackground sta in ing  o f  un transfected  cells 
can be seen in panels a, b and c. B. W estern  b lo t show ing that the anti-G R K 5 antibody  (S an ta  C ruz a5  
(5 C 20)) specifically  detects G R K 5 overexpressed  in C os-7 cells. The presence o f  expressed G R K 4
HEp2 H eLa H EK  COS-7
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and 6  in the appropriate cell lysates is also demonstrated. C. Endogenous GRK5 can be detected (see 
Materials and Methods) in a. HEp2 cells but not b. Cos-7 cells. The immunofluorescence observed in 
HEp2 cells (a) can be blocked by addition o f the GRK5 antibody blocking peptide during 
immunolabelling (c) (see Materials and Methods). Scale bars, lOfiM. D. Western blot analysis shows 
the presence o f endogenous GRK5 in HEp2 but not COS-7 cell lysates.
A similar uniform distribution o f GRK5 was observed in a number o f  other cell lines 
including HeLa, HEK-293 and Cos-7 cells (Figure 3.1 A panels b-d). To confirm that 
the presence o f GRK5 in the nucleus is not an artifact o f transient overexpression, I 
used an antibody specific for GRK5 (Santa Cruz a5  (5 C20)), to determine the 
endogenous distribution o f  GRK5 in HEp2 cells. This GRK5 antibody specifically 
recognises GRK5 overexpressed in Cos-7 cell lysates, but not GRKs 4 or 6, as 
determined by Western blot analysis (Figure 3 .IB). Antibodies specific for GRKs 4 
(Santa Cruz a 4  (4 H64)) and 6 (Santa Cruz a6  (6 C20)) demonstrate the expression 
o f these GRKs in the relevant transfected Cos-7 cell lysates (Figure 3 .IB). 
Immunolocalisation o f endogenous GRK5 using the GRK5 specific antibody reveals 
that GRK5 is localised throughout the cytoplasm and nucleus in HEp2 cells (Figure 
3.1C a). That this antibody specifically recognises endogenous GRK5 in HEp2 cells 
is indicated by the observation that no immunostaining is observed following prior 
incubation o f the antibody with the antigenic (blocking) peptide (Figure 3.1C c). 
Furthermore, endogenous GRK5 cannot be detected by immunostaining in Cos-7 
cells (Figure 3.1C b). Using the same antibody, endogenous GRK5 is detected by 
Western blot in HEp2 cell lysates but not in Cos-7 cell lysates (Figure 3 .ID). These 
observations indicate that the immunofluorescence observed in HEp2 cells using the 
anti-GRK5 antibody (Santa Cruz a5  (5 C20)) does indeed represent the distribution
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of endogenous GRK5. This data reveals that GRK5 is present in the nucleus o f a 
range o f commonly used immortalised cell lines.
3.2. GRK5 contains nuclear localisation and export 
sequences
Nuclear import and export o f macromolecules has been studied in great detail. 
Molecules larger than 40kDa in weight require active import in order to enter the 
nucleus (Tran and Wente, 2006). Active import/export o f macromolecules is 
regulated by nuclear import receptors called importins and export receptors called 
exportins (Tran and Wente, 2006). Importins and exportins bind to NLS and NESs 
respectively in cargo molecules and then this complex is transported through the NPC 
via a Ran GTPase-dependent mechanism (Moroianu, 1999; Quimby and Corbett, 
2001). Since GRK5 is a 65kDa protein it seemed unlikely that GRK5 was present in 
the nucleus o f cells on the basis o f simple diffusion across the nuclear membrane. In 
an attempt to account for the differential cellular distribution o f the GRK2 and 4 
subfamilies, we searched for potential NLSs in the GRKs using PredictNLS. This 
database contains NLS consensus sequences from reported nuclear proteins and 
predicts NLSs by comparing protein sequences to known consensus NLSs (Cokol et 
al., 2000). Using PredictNLS a putative NLS was identified between residues 388- 
395 in the catalytic domain o f GRK5 (388RKEKVKRE395, Figure 3.2A underlined 
residues) but not GRK2 (Cokol et al., 2000). I mutated basic amino acids in the 
putative NLS o f GRK5 to alanine residues (388AAEAVAAE395, Figure 3.2A bold 
residues and shown as a schematic in Figure 3.2B), this results in the nuclear 
exclusion o f the mutant kinase (GRK5ANLS) when expressed in HEp2 cells
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(compare Figure 3.2C panels a & b). The cytoplasmic distribution o f  the GRK5ANLS 
mutant suggests that GRK5 contains a functional NLS and points towards potentially 
distinct functions o f the 2 and 4 subfamilies o f GRKs.
A.
Putative NLS & NES of GRK5 
NLS:
GRK5: 384PFR G RKEKVKREEVDRR400
NES:
GRK5 
GRK2
B.
254 270E TKDALCLVLTIMNGGD 
262HTPDKLSFILDLM NGGD268
NES NLS
WT: 259L C L V L T I265 WT : 388RKEKVKRE395
Mutant : 259ACAAATA265 Mutant : 388AAEAVAAE395
CaM  
AUTO (-)
G R K5 —• Ca M  RH -  Catalytic PKC
PIP2
BINDING
PL PL 
AUTO BINDING
(+)
c.
GRK5 GRK5ANLS GRK5ANES
GRK2 GRK2ANESput
Figure 3.2. GRK5 contains a functional NLS and NES.
121
A. Sequence (underlined) o f the putative NLS and NES of GRK5 together with the homologous 
sequence in GRK2. Residues mutated in mutant enzymes are indicated in bold. Numbers indicate 
amino acid location. B. Domain structure o f GRK5 showing the location and amino acid sequence o f  
the putative NLS and NES (Adapted from Penela et al., 2003). CaM, Calmodulin binding domain; RH, 
Regulator o f G-protein signalling (RGS) homology domain; PL, phospholipid; P, Phosphorylation site; 
Auto, autophosphorylation; PK.C, Protein kinase C. C. Confocal microscopy o f overexpressed (a) 
GRK5, (b) GRK5ANLS, (c) GRK5ANES, (d) GRK2 and (e) GRK2ANESput (putative). Scale bars, 
lOpM. The images shown are representative o f those obtained on at least three separate occasions.
Since GRK5 contained an NLS, a m otif required for active import into the nucleus, 
we used the NetNES 1.1 search program to look for putative NESs in GRK5 (la Cour 
et al., 2004). NetNES 1.1 is a database o f experimentally validated leucine-rich NESs 
collected from the literature. A putative NES was identified in GRK5 and included 
residues 259-265 o f GRK5 (259LCLVLTI265, Figure 3.2A underlined residues) located 
within the catalytic domain o f the enzyme 129 amino acids N-terminal to the NLS 
(Figure 3.2B). Mutation o f hydrophobic residues in this sequence to alanine 
(259AC A A AT A265, Figure 3.2 A bold residues and shown schematically in Figure 
3.2B) resulted in a mutant form o f GRK5 (GRK5ANES) that is predominantly 
confined to the nucleus when expressed in HEp2 cells. In contrast wildtype GRK5 is 
distributed throughout the nucleus and cytoplasm (compare Figure 3.2C, panels a & 
c). These observations imply that GRK5 contains a functional NES. NetNES 1.1 (la 
Cour et al., 2004) failed to identify a consensus NES sequence in GRK2. Indeed, 
mutation o f hydrophobic residues in GRK2 corresponding to the NES of GRK5 
(Figure 3.2A, residues in bold) had no effect on the subcellular distribution o f this 
kinase (Figure 3.2C, panel d and e). To date I have failed to identify a NES in GRK2.
Together these results suggest that possession o f an NLS and NES distinguishes
122
GRK5 from GRK2 and may indicate distinct cellular functions for these two GRKs. 
These findings are somewhat surprising since no nuclear substrates or functions for 
the GRKs have been identified to date.
3.3. Calcium ionophore treatment promotes the nuclear 
export of GRKS
As described in Section 1.4 o f the introduction, GRKs are subject to a wide range o f 
regulatory mechanisms that control their activity and subcellular distribution. I next 
wanted to determine if  the nuclear localisation o f GRK5 is modulated by extrinsic 
signals. Initially, I examined if  GRK5 subcellular distribution was altered when co­
overexpressed in HEp2 cells with the P2AR (data not shown). I also subjected HEp2 
cells expressing GRK5 to serum starvation (data not shown), PMA treatment (data 
not shown) or Ca2+ ionophore (A23187) treatment. O f these extrinsic signals, only 
treatment with Ca2+ ionophore resulted in a change in GRK5 subcellular localisation 
as compared to its basal distribution. A23187 is a cell permeable mobile ion-carrier 
that forms stable complexes with divalent cations and therefore causes an increase in
94-intracellular Ca levels. A23187 treatment o f cells stimulated nuclear export o f 
GRK5 (compare Figure 3.3A, a & b and c & d). Both transfected and endogenous 
GRK5 display similar subcellular distributions and Ca ionophore-dependent nuclear 
export. Quantification o f nuclear export reveals that 93±1.9% o f GRK5 transfected
'y,
cells have nuclear GRK5 (Figure 3.3B). After treatment with Ca ionophore only 
10±3% o f the transfected cells contain GRK5 in the nucleus (Figure 3.3B). Taken 
together these results indicate that both transfected and endogenous GRK5 is 
exported from the nucleus in a Ca -dependent fashion. As expected, ionophore
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treatment o f  HEp2 cells expressing GRK5ANLS or GRK5ANES (Figure 3.3C) does 
not alter the localisation o f  these mutants confirming that GRK5 does contain both a 
functional NLS and NES. Since the GRK5ANES mutant is still predominantly 
nuclear after a rise in intracellular Ca2+, this suggests that Ca2+ is involved in 
promoting nuclear export o f  GRK5 via its NES. I will discuss this further in Chapter 
5.
A. B.
Control
Endogenous Transfected 
GRK5 GRK5
i
+A23187 &
UNTREATED +A23187
c.
GRK5ANLS GRK5ANES
Control
+A23187
Figure 3.3. GRK5 exhibits calcium-dependent nuclear export.
A. Effect o f calcium ionophore A23187 treatment on the cellular distribution o f endogenous and 
transfected GRK5 in HEp2 cells. HEp2 cells were either untreated (a and c) or treated with the calcium
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ionophore A23187 prior to fixation as described in the Materials and Methods. Scale bars, lOpM. B. 
Quantification o f  the percentage o f  cells with nuclear transfected GRK5 as shown in A with and 
without ionophore treatment. ***, PO.OOl. C. GRK5ANLS and GRK5ANES cellular distribution 
following calcium ionophore A23187 treatment. Scale bars, lOpM. The images shown are 
representative o f those obtained on at least three separate occasions.
3.4. The nuclear export of GRK5 is calmodulin-dependent
The cellular actions o f Ca2+ are largely mediated through a family o f Ca2+ binding 
proteins, o f which CaM is the major Ca2+ sensor. Since GRK5 binds Ca2+/CaM with 
high affinity (Kd ~ 8nm) (Levay et al., 1998) I investigated a potential role for CaM 
in mediating the Ca2+-dependent nuclear export o f GRK5. Two EYFP-tagged 
peptides encoding the CaM-binding sequence o f rabbit skeletal muscle myosin light 
chain kinase (Figure 3.4A) were used to sequester CaM in the cell (Li et al., 2003; 
Wang et al., 1995). The first peptide is unmodified and sequesters nuclear CaM since 
the sequence contains a NLS (CaMBP/n). The second peptide is posttranslationally 
modified by palmitoylation, S-linked addition o f the fatty acid palmitate to cysteine 
residues. Palmitoylation targets the peptide to the membranes and therefore 
sequesters cytosolic/membrane bound CaM (CaMBP/m). These reagents have been 
described previously (Li et al., 2003; Wang et al., 1995). Ca2+-dependent nuclear 
export o f transfected GRK5, is unaffected by co-expression o f CaMBP/m. Figure 
3.4B shows the subcellular distribution o f co-expressed GRK5 and CaMBP/m in 
untreated (a & c), or ionophore treated (b & d), cells. In contrast to cytosolic CaM 
sequestration, expression o f CaMBP/n, and thereby sequestration o f nuclear CaM, 
inhibits ionophore-dependent nuclear export o f GRK5 (Figure 3.4C, a & b show, 
respectively, the distribution o f GRK5 in untreated and ionophore treated cells and c
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& d CaMBP/n expression in these same cells). These results indicate that Ca2+/CaM  
• 2+mediates Ca ionophore-dependent nuclear export o f  GRK5 and suggests that the
I
interaction o f  nuclear Ca /CaM with nuclear located GRK5 is required for this 
process.
A.
Protein Sequence of C a^+/CaM  Sequestrants:
CaMBP/m: MLCCMRRTKQVEKNDEDQKI-EYFP-KRRWKKNF1AVSAANRFKK 
CaMBP/n: EYFP-KRRWKKNFIAVSAANRFKK
B.
Expressed: GRK5 + CaMBP/m
Detected: GRK5 CaMBP/m
C.
Expressed: GRK5 + CaMBP/n
Detected: GRK5 CaMBP/n
Control
+A23187 +A23187
Figure 3.4. The nuclear export of GRK5 is regulated by nuclear Ca2+/CaM.
A. Protein sequence o f  the Ca2+/C aM  sequestrants used in B. C aM B P/m ; The N -term inal 20 am ino 
acids o f  neurom odulin (w hich contains a signal for posttranslational palm itoylation o f  cysteines 3 and 
4 that targets the fusion protein to m em branes) is fused to yellow -green fluorescent variant o f  the 
enhanced green fluorescent protein (EY FP) and R abbit skeletal m yosin light chain k inase (M LC K ) 
CaM  binding sequence. C aM B P/n; EY FP fused to unm odified rabbit skeletal M LC K  CaM  binding 
peptide w hich contains a N LS. B. Sequestration o f  cytosolic CaM  does no t affect the C a2+-dependent 
nuclear export o f  G RK 5. H Ep2 cells w ere cotransfected  w ith GRK 5 and Y FP-tagged C aM B P/m . 
T w enty-four hours post transfection , cells w ere either left untreated (a and c) o r treated w ith A 23187 
(b and d), and expressed proteins w ere v isualised as described in M aterials and M ethods. C. 
Sequestration o f  nuclear CaM  inhibits C a2+-dependent nuclear export o f  G RK 5. H Ep2 cells 
cotransfected w ith GRK5 and Y FP-tagged C aM B P/n w ere treated as described for panel B. Panels a 
and c show  the distribution of, respectively, GRK 5 and C aM B P/n in untreated  cells, and panels b and d 
show  the distribution  o f  G RK 5 and C aM B P/n in ionophore-treated cells. Scale bars, lOpJM. The
Control
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images shown are representative o f  those obtained on at least three separate occasions.
3.5. B inding o f C a2+/C aM  to the am ino-term inal 
calm odulin-b inding site o f GRK5 is required for 
nuclear export
Two CaM binding sites have been identified in GRK5 located between residues 20- 
39 in the N-terminus and residues 540-578 in the C-terminus o f the kinase (Figure 
3.5A, Levay et al., 1998). These regions o f the kinase contain clusters o f basic and 
hydrophobic residues characteristic o f CaM-binding sites identified in other CaM 
target proteins (Rhoads and Friedberg, 1997).
A.
N TPB C TPB
WT: 21G K R K G K SK K W 30 WT: ^ P K K G L L Q R L F K R Q 558
M u tan t: 21G A A A G A SA A W 30 M utan t: 546PA A G LL Q A L FA A Q 558
CaM 
AUTO (-)
GRK5-CCaM! RH - ] i:C a ta M i^ B ^ ^ C a M K p^_-PKC
PIP2 PL PL
BINDING AUTO BINDING
(+)
B. 
GRK5 GRK5NTPB GRK5CTPB GRK5K215R
Control
+A23187
Figure 3.5. The nuclear export of GRK5 requires the interaction of Ca2+/CaM with the N-
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terminal CaM-binding site of the kinase.
A. Schematic showing the domain structure o f GRK5. GRK5 contains two Ca2+/CaM binding sites, 
one at its N-terminus (residues 20-39) and one at its C-terminus (residues 540-578). Mutants o f  these 
two Ca2+/CaM binding sites GRK5NTPB (N-terminal polybasic) and GRK5CTPB (C-terminal 
polybasic) have been described previously (Pitcher et al., 1996) (Schematic adapted from Penela et al., 
2003). CaM, Calmodulin binding domain; RH, Regulator o f G-protein signalling (RGS) homology 
domain; PL, phospholipid; P, Phosphorylation site; Auto, autophosphorylation; PKC, Protein kinase C.
B. The cellular distribution o f  (a) GRK5, (c) GRK5NTPB, (e) GRK5CTPB, and (g) GRK5K215R 
(kinase dead) expressed in HEp2 cells was visualised by fluorescence confocal microscopy as 
described in Materials and Methods. Where indicated, cells were treated with calcium ionophore 
(A23187) prior to fixation (b, d, f, and h). Scale bars, lOpM. The images shown are representative o f  
those obtained on at least three separate occasions.
To determine if  Ca2+/CaM-mediated nuclear export o f GRK5 is dependent on the
04-direct interaction o f activated CaM with GRK5, the Ca -dependent nuclear export o f 
previously described mutant GRK5 constructs lacking the N-terminal polybasic 
(GRK5NTPB) or C-terminal polybasic (GRK5CTPB) CaM binding sites was 
examined (depicted schematically in Figure 3.5A) (Pitcher et al., 1996). Mutation of 
basic residues in the N-terminal (GRK5NTPB, Figure 3.5B, c & d), but not C- 
terminal (GRK5CTPB, Figure 3.5B e & f) CaM binding site o f GRK5, results in a 
mutant form o f the kinase which is almost exclusively nuclear and whose distribution 
is unaffected by ionophore treatment. These findings suggest that the interaction o f 
Ca2+/CaM with the N-terminal CaM-binding site o f GRK5 is responsible for 
mediating nuclear export. A role for CaM in mediating nuclear export has also been 
proposed for Ca2+/CaM dependent protein kinase I-a  where it promotes binding of 
the kinase to the CRM1 nuclear export complex in vitro (Stedman et al., 2004). The 
more nuclear localisation o f GRK5NTPB as compared to wildtype GRK5 in
04 -untreated cells suggests, that under basal conditions, endogenous Ca /CaM binding
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to this site may contribute to the ubiquitous distribution o f  the wildtype kinase 
(compare Figure 3.5B a & c). However, it is also possible that the ubiquitous 
distribution o f overexpressed GRK5 is determined by other molecules which also 
bind to the N-terminal CaM binding region o f  GRK5. These include PIP2 , actin, and 
the actin binding protein, a-actinin (Freeman et al., 1998; Freeman et al., 2000; 
Pitcher et al., 1996). Since all four ligands bind to the same region o f GRK5 it is 
conceivable that not only CaM, but also PIP2 , actin and a-actinin might retain GRK5 
in the cytoplasm. Since GRK5NTPB is mutated in this region, it cannot bind these 
molecules and therefore be anchored in the cytosol, restricting its localisation to the 
nucleus. To rule out the possibility that GRK5 nuclear export is kinase dependent or 
requires a specific 3D conformation, which is disrupted by mutations in the NTPB 
domain, the ability o f GRK5, GRK5ANLS, GRK5NTPB, GRK5CTPB and 
GRK5K215R to phosphorylate light activated rhodopsin (Figure 3.6A) and tubulin 
(Figure 3.6B) was assessed using partially purified Cos-7 cell lysates expressing these 
kinases. As shown in Figure 3.6A & B, GRK5NTPB, although approximately 50% 
less active than wildtype GRK5, has a similar activity against both substrates as 
GRK5CTPB, a mutant form o f the kinase which exhibits ionophore-dependent 
nuclear export. These results suggest that impaired CaM-binding, rather than 
impaired kinase activity, most likely explains the inability o f GRK5NTPB to exit the 
nucleus in a Ca2+-dependent fashion (Figure 3.5B, c & d). Indeed, the catalytically 
inactive mutant o f GRK5 (GRK5K215R) (Figure 3.6A & B) is exported from the 
nucleus following ionophore treatment (Figure 3.5B, g & h), demonstrating that 
Ca2+/CaM-dependent nuclear export o f GRK5 does not require kinase activity.
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Furthermore, the observation that GRK5ANLS has comparable kinase activity to 
wildtype GRK5 (Figure 3.6 A & B) suggests that the nuclear exclusion of this mutant 
enzyme (Figure 3.2C, c) is not simply a consequence of mutation-induced gross 
structural abnormalities in the NLS.
A. B.
Figure 3.6. Rhodopsin and tubulin kinase activities o f wild-type and mutant GRK5s.
Partially purified Cos-7 cell lysates expressing GRK5, GRK5ANLS, GRK5NTPB, GRK5CTPB, and 
GRK.5K215R were assayed for their ability to phosphorylate (A) the GPCR substrate rhodopsin and 
(B) the soluble substrate tubulin as described in Materials and Methods. The results shown for each 
enzyme represent the average activities ± standard errors o f the means for three separate transfections 
and partial purifications that were subsequently pooled and assayed in triplicate. Assays were 
performed using equivalent amounts o f GRK5 protein as determined by quantitation o f Western blots, 
using a densitometer.
3.6. Activation o f a G q-coupled receptor prom otes the 
nuclear export o f G RK5
Given that Ca2+/CaM regulates GRK5 sub-cellular localisation, I hypothesised that 
GPCRs that increase intracellular levels of Ca2+ may promote the nuclear export o f 
GRK5. To this end, the distribution of GRK5 was examined in CHO cells stably 
expressing the Gq-coupled M3MR (CHO-M3MR) and transiently expressing GRK5
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(Figure 3.7). Agonist stimulation o f M3MR with ACh (100|iM) promotes the rapid 
and reversible nuclear export o f GRK5 (Figure 3.7A, left hand panels show M3MR 
and right hand panels GRK5 staining). Within 0.5 min o f ACh treatment, GRK5 is 
exported from the nucleus (Figure 3.7A d compared to b) but re-enters the nucleus 
after 20 min o f ACh stimulation (Figure 3.7A j compared to b). Three lines o f 
evidence indicate that M3MR-mediated nuclear export o f GRK5 is Ca2+/CaM- 
dependent. Firstly, use o f a PLC inhibitor, U73122, which has been shown to inhibit 
PLC-dependent processes in platelets, neutrophils, and a neuroblastoma cell line 
(Bleasdale et al., 1990; Smith et al., 1990; Thompson et al., 1991) inhibits M3MR- 
dependent nuclear export o f  GRK5 (compare Figure 3.7B, c & d (+ ACh), with e & f  
(+ ACh + U73122)). These results suggest that Gq-mediated increases in cellular Ca 
levels are important for this process. Secondly, co-expression o f GRK5 and the 
nuclear CaM sequestrant (CaMBP/n) in this M3MR expressing cell line prevents 
agonist-dependent GRK5 redistribution (Figure 3.7B g, h & i). Thirdly, 
GRK5NTPB, a mutant form o f the kinase lacking the N-terminal CaM-binding site, 
fails to exit the nucleus following M3MR activation (Figure 3.7B, j  & k). Together 
these results indicate that activation o f a Gq-coupled GPCR can induce the 
cytoplasmic redistribution o f GRK5 via a mechanism that requires the interaction of 
Ca2+/CaM with the N-terminal CaM-binding site o f GRK5.
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Expressed: M3MR + GRK5 + CaMBP/n
Detected: M3MR GRK5 CaMBP/n
CaMBP/n
Expressed: M3MR + GRK5NTPB
Detected: M3MR GRK5NTPB
0.5 min
2.5 min
ACh
+
U73122
10 min
20 min
Expressed: M3MR + GRK5
Detected: M3MR GRK5
Control
Expressed: M3MR + GRK5
Detected: M3MR GRK5
Control
Figure 3.7. Muscarinic-M3 receptor activation promotes the nuclear export of GRK5.
A. CHO-M3MR cells were transfected with GRK5 and treated with ACh for the indicated times (min). 
M3 MR and GRK5 in coexpressing cells were visualised by immunofluorescence. Asterisks indicate 
cotransfected cells. Scale bars, 10 pM. B. CHO-M3MR cells were transfected with GRK5 (a to f), 
GRK5, and CaMBP/n (g, h, and i) or GRK5NTPB (j and k). Transfected cells were subsequently left 
untreated (Control) or treated with ACh for 5 min, and GRK.5 and M3MR were detected as previously 
described. Where indicated (U73122), cells were pretreated with 1 pM U73122 for 1 h prior to agonist 
treatment. Asterisks indicate cotransfected cells. Scale bars, 10pm.
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3.7. GRK5 binds DNA in vitro
In an attempt to elucidate a potential role for nuclear GRK5, the functions o f proteins 
containing NLSs o f similar sequence were examined (Figure 3.8A). Somewhat 
surprisingly, the NLS o f GRK5 shares sequence homology with the DNA-binding 
NLSs o f  homeobox containing transcription factors (Cokol et al., 2000). The 
homeodomain is a conserved DNA-binding domain found in eukaryotic DNA- 
binding proteins (Billeter, 1996). Whilst GRK5’s NLS shows some homology to 
homeodomains, it does not contain all the conserved residues characteristic o f 
homeodomain-containing transcription factors and thus cannot be classified as such. 
132 proteins were identified by PredictNLS as containing a NLS conforming to the 
same consensus sequence as that found in GRK5 (R[R/K]x[K/R]x[R/K]2 [D/E]) 
(Cokol et al., 2000). All these proteins contained a homeodomain and o f the 119 
demonstrated to bind DNA, 116 contain the NLS as part o f the DNA-binding site 
(Cokol et al., 2000). To assess if  GRK5 binds DNA in vitro Cos-7 cell lysates 
expressing GRK5, GRK5ANLS and GRK2 were incubated with native DNA- 
cellulose, single stranded DNA (ssDNA)-cellulose or poly(A)-4B-sepharose. 
Following extensive washing, the amount o f GRK retained on the resin was 
determined by western blot analysis as shown in Figure 3.8B. The blot was scanned 
on a densitometer and the amount of GRK bound (B l-3, Figure 3.8B) relative to the 
load (L, Figure 3.8B) was determined.
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A.
* Predicted GRK5 consensus NLS R[RK]X [ KR]X 1 RK{ 2, }?[DEJ
NLS-containing proteins conforming to consensus 132
No. proteins containing NLS consensus which bind DNA 119
No. protein DNA binding which bind via NLS 116
Function of consensus 
containing proteins
Honieobox-containing transcription factors 119
Transcriptional co/activators & co/repressors 12
* Format for NLS motifs:
IKR| read KorR
G{3} read GGG
x{3,5} read between 3 and 5 x
where 'x' stands for 'any amino acid'
B.
B1 B2 B3
GRK5
GRK5
GRK2
ANLS
1  35
g 30 
5
|  g 20
I d 15
S j t  10
£ 5 S 0 1.1
<3
I f ,X3!O
Xo
Native DNA- 
Cellulose
ssDNA-
Cellulose
Poly(A)-4B-
Sepharose
Figure 3.8. The NLS of GRK5 binds DNA in vitro.
A. Table detailing the putative NLS in GRK5. Data on proteins containing this same consensus NLS 
are given. B. GRK5, but not GRK5ANLS or GRK2, binds DNA in vitro. Lysates o f cells expressing 
GRK5, GRK5ANLS, or GRK2 were incubated with native DNA-cellulose, ssDNA-cellulose, or 
poly(A)-4B-Sepharose, and after extensive washing the amount of bound GRK was determined by 
Western blot analysis. A representative Western blot o f one such experiment is shown. L, 25% of total 
lysate loaded; B l, native DNA-cellulose-bound GRK; B2, ssDNA cellulose-bound GRK; B3, poly(A)- 
4B-Sepharose-bound GRK. Quantification o f Western blot analyses from multiple experiments is 
represented graphically. The y-axis represents the percentage o f loaded GRK5 that remained bound to 
the resin. The data shown represent the mean values ± standard errors o f the mean for at least three 
experiments. * * ,/><0.01.
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The blot reveals that GRK5, but not GRK5ANLS or GRK2, binds native and ssDNA- 
cellulose in vitro (Figure 3.8B). Quantification of a minimum of three separate 
experiments indicates that approximately 25% of the applied GRK5 was retained on 
both native and single stranded DNA cellulose (Figure 3.8B). In marked contrast, 
very little GRK5ANLS and GRK2 bound these resins (~4% o f the load, Figure 3.8B). 
No significant binding to poly(A)-4B-sepharose was detected for any o f  the kinases 
(Figure 3.8B) suggesting that a non-specific ionic interaction is unlikely to account 
for the binding o f GRK5 to DNA.
To address whether GRK5 DNA-binding is specific I repeated the assay but added 
exogenous DNA or RNA during incubation with DNA-cellulose (See Materials & 
Methods Section 2.4.5). Addition o f exogenous DNA, but not RNA, inhibits the 
binding o f GRK5 to native DNA-cellulose (Figure 3.9A). The addition o f 20pg o f 
DNA or RNA to the binding assay results in, respectively, an 80±8% and a 22±15% 
reduction in binding o f GRK5 to immobilised DNA (p<0.01). No detectable binding 
o f  GRK5 to the cellulose support was observed under these conditions (Figure 3.9A), 
suggesting that the interaction o f GRK5 with DNA is specific. Together, the results 
shown in Figure 3.8B and 3.9A indicate that GRK5 binds specifically to DNA in 
vitro and that the NLS o f GRK5 is required for this interaction. Since cell lysates 
expressing GRK5 were used for these experiments, however, I could not exclude the 
possibility that the binding o f  GRK5 to DNA is indirect.
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Figure 3.9. GRK5 DNA binding is specific and direct.
A. DNA, but not RNA, inhibits the interaction o f GRK5 with native DNA-cellulose. Lysates (lOfig) o f  
Cos-7 cells overexpressing GRK5 were incubated with native DNA-cellulose, following a 30-min 
preincubation with the indicated amounts o f  DNA or RNA. Additionally, the interaction o f GRK5 with
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cellulose was examined. After extensive washing, the amount o f resin-associated GRK5 was 
determined by Western blot analysis (a representative blot is shown; L, 25% lysate). The amount o f  
GRK5 bound to native DNA-cellulose in the absence o f DNA or RNA addition, 24% o f the total 
GRK5 loaded, was normalised to 100%. The data shown represent the means ± standard errors o f  the 
means for at least four separate determinations. **, P<  0.01. B. Purified GRK5 binds directly to DNA. 
Assays were performed as described for panel A, except that 150 ng o f purified GRK5 rather than 10 
jig o f  GRK5-expressing cell lysate was used in the binding assay (a representative blot is shown; L, 
25% lysate). The amount o f  GRK5 bound to native DNA-cellulose in the absence o f DNA was 
normalised to 100% and was 40% o f the total GRK5 loaded. The results shown represent the means ± 
standard errors o f  the means for at least five experiments. *, P<  0.05; ***, P<  0.001. C. DNA inhibits 
GRK5, but not GRK5ANLS, activity. Cos-7 cell lysates expressing GRK5 or GRK5ANLS were 
assayed for their ability to phosphorylate light-activated rhodopsin in the presence o f the indicated 
amounts o f DNA (black columns) or RNA (shaded columns). Kinase assays were performed as 
described in Materials and Methods. The activities o f  the wild-type and mutant kinases in the absence 
o f DNA or RNA were equivalent and were normalised to 100% activity. The results shown represent 
the means standard errors o f  the means for three experiments. *, PO.OS; **, P<0.01; ***, P<  0.001. 
D. DNA inhibits the kinase activity o f  purified GRK5. Kinase assays were performed as described for 
panel B and in Materials and Methods, with the exception that purified GRK5, rather than a GRK5- 
expressing cell lysate, was used as the source o f  the kinase activity. The amount o f purified GRK5 
added to the assay was adjusted such that its rhodopsin kinase activity in the absence o f DNA addition, 
100% activity, was similar to that observed with GRK5-expressing lysates under similar conditions. 
The results shown represent the means ± standard errors o f the means for three experiments. **, 
P<0.05; ***, P<0.001. E. Coomassie gel o f purified GRK5 (~ 93% pure).
To address this issue, the interaction o f purified GRK5 (approximately -93%  pure, 
Figure 3.9E) with native DNA-cellulose was examined. As shown in Figure 3.9B 
purified GRK5 binds specifically to native DNA-cellulose and its binding is inhibited 
more potently by DNA than RNA. These results suggest that GRK5 binds DNA not 
only specifically but also directly. To determine the functional consequence o f GRK5 
DNA-binding Cos-7 cell lysates expressing GRK5 or GRK5ANLS were assessed for 
their ability to phosphorylate light activated rhodopsin in the presence o f  increasing 
concentrations o f DNA or RNA. As shown in Figure 3.9C, when assayed at
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equivalent rhodopsin kinase activities, GRK5 is more potently inhibited by DNA than 
its mutant counterpart (Figure 3.9C, black columns). The addition o f 150ng o f  DNA 
inhibits GRK5 activity by 93±0.2% and GRK5ANLS activity by 28±5% (p<0.001), 
results which suggest that DNA-binding is mediated by the NLS o f GRK5. RNA is a 
much less effective inhibitor o f GRK5 activity than DNA, 150ng o f RNA inhibits 
GRK5 activity by 58±4% (Figure 3.9C, left hand side, shaded columns). GRK5ANLS 
activity is unaffected by RNA addition over the range o f concentrations used (Figure 
3.9C, right hand side, shaded columns). Consistent with the results obtained using 
lysates expressing GRK5, DNA potently inhibits the kinase activity o f purified GRK5 
(Figure 3.9D, black columns). RNA proved a much less effective inhibitor o f the 
purified enzyme, the addition o f 200ng o f DNA or RNA resulting in, respectively, a 
93±1% and a 55±3% inhibition o f kinase activity (p<0.001) (Figure 3.9D, shaded 
columns). Overall these results demonstrate that GRK5 binds directly to DNA in vitro 
via its NLS and provocatively suggest hitherto unsuspected functions for this enzyme.
3.8. Summary
In summary, the data in this Chapter provide evidence that both overexpressed GRK5 
in a range o f tissue culture cells lines and endogenous GRK5 in HEp2 cells is located 
in the nucleus. GRK5 nuclear localisation appears to be regulated by the presence o f 
both a functional NLS and NES. Mutation o f these motifs results in kinases that are 
exclusively cytosolic or nuclear respectively.
GRK5 nuclear localisation is regulated by nuclear Ca2+/CaM binding to the N- 
terminus o f the kinase. Application o f Ca2+ ionophore does not induce nuclear export 
o f a mutant form of GRK5 that cannot bind to CaM at its N-terminus. Furthermore,
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Ca2+ ionophore treatment does not alter the cellular distribution o f the NLS and NES 
mutants o f GRK5 confirming the functionality o f these motifs. The M3MR, 
activation o f which increases intracellular Ca2+ levels via Gq, also promotes Ca2+- 
dependent nuclear export o f GRK5. This can be inhibited by inhibiting PLC 
activation, downstream o f Gq, or by sequestering nuclear CaM.
The literature suggests that the M3MR is not a substrate for GRK5-mediated 
phosphorylation in cells (Tsuga et al., 1998; Willets et al., 2002; Willets et al., 
2003b). Consistent with this, I did not observe agonist-induced M3MR internalisation 
when co-expressed with GRK5 in CHO cells (Section 3.6 and Figure 3.7A left hand 
panels). Despite this, activation o f the M3MR induces GRK5 nuclear export, 
presumably negatively regulating its nuclear function rather than activating its GPCR 
kinase function. This might suggest that GRK5 not only functions as a GPCR kinase 
but also has novel nuclear functions.
Sequence homology o f the NLS o f GRK5 suggests that this particular m otif might 
bind DNA. Evidence supporting this is that GRK5 binds DNA in vitro via its NLS 
motif. GRK5 DNA-binding appears to be direct and specific since DNA-binding o f 
both purified GRK5 and GRK5 in cell lysates is inhibited more potently by addition 
o f DNA than RNA. GRK5 DNA-binding via its NLS appears to inhibit kinase 
activity suggesting again that GRK5 DNA-binding is direct and specific, and that 
GRK5 might well be catalytically inactive when bound to DNA in the nucleus. This 
data tentatively points towards a nuclear role for GRK5, perhaps in the regulation o f 
transcription.
The implications o f the results presented in this and the following Chapters will be
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discussed in more detail in Chapter 6.
4. The presence of nuclear localisation and 
nuclear export sequences is a common feature 
of the GRK4 subfamily members
In the last Chapter I described the discovery o f nuclear localisation and export 
sequences in GRK5, in this Chapter I investigate whether possession o f an NLS and 
NES is specific to GRK5 or if  it is a common feature o f the GRK4 subfamily o f 
GRKs. The ability o f G RK 4a, (3, y and 8; GRK5 and GRK6A, B and C to bind DNA 
in vitro and the regulatory mechanisms controlling their nuclear localisation are also 
investigated.
4.1. GRKs of the GRK1 and GRK4 subfamilies contain 
putative NLSs
As described in Chapter 3, GRK5 can be detected in the nucleus o f HEp2 cells when 
assessed by indirect immunofluorescence (Figure 4.1 A). GRK5 contains a NLS, 
located between amino acids 388 and 395 (388RKEKVKRE395) and a leucine rich 
NES, located between amino acids 259 and 265 (259LCLVLTI265), which regulate the 
nuclear localisation o f  this kinase (Johnson et al., 2004). There are three GRK 
subfamilies (Figure 1.1). The GRK1 subfamily contains GRK1 and GRK7. The 
GRK2 subfamily contains GRKs 2 and GRK3. The third subfamily and the focus o f 
this Chapter, is the GRK4 subfamily, which contains three kinases, GRK4, GRK5 
and GRK6. Four splice variants o f human GRK4 (a , p, y, 8) and three o f GRK6 (A, B 
and C) have been identified (Figure 4. IB).
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A.
GRK2 GRK3 GRK 4a GRK5 GRK6 A
B.
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c.
Putative NLS of the G R K s
GRKl: 216YACKKLNKKRLKKRKGYQGA235
NLS Consensus KXLKKRK
GRK7: 217YACKKLDKKRLKKKGGEKMA236
NLS Consensus KKLXKKXXKKK
GRK4a/Y: 213YACKKLQKKRIKKRKGEAMA232
NLS Consensus QKXXXKKRK
GRK4|3/8; 181YACKKLQKKRIKKRKGEAMA200
NLS Consensus QKXXXKKRK
GRK5: 381GQSPFRGRKEKVKREEVDRR400
NLS Consensus RKXKXKRE
GRK6: 381GQSPFQQRKKKIKREEVERL400
NLS Consensus QRKXKXKRE
Putative NES of the G R K 4 subfam ily
GRK5 : 254ETKDALCLVLTIMNGGD270
GRK4a: 255ETKDALCLVLTIMNGGD271
GRK6 A: 254ETKDALCLVLTIMNGGD270
Figure 4.1. Members of the GRKl and -4, but not GRK2, subfamilies contain putative NLSs.
A. The subcellular localisation o f GRK family members when overexpressed in HEp2 cells as 
determined by fluorescence confocal microscopy. Scale bars, lOpM. B. Schematic representation o f  
the GRK4 subfamily members and their splice variants. Relative localisation o f putative NLSs and
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NESs are shown (Adapted from Penela et al., 2003). C. Regions o f the catalytic domains o f  GRK 
subfamily members containing putative NLSs and NESs, indicated in bold. The consensus NLS or 
NES sequences are shown below each GRK sequence. Amino acid numbering is indicated. Note the 
NLS o f  GRKs 4, 1 and 7 are more N-terminal than that o f  GRKs 5 and 6 . The putative NES is located 
in the same region o f  all members o f  the GRK4 subfamily.
All members o f the G RK l and GRK4, but not GRK2, subfamilies are predicted to 
contain putative NLSs using the NLSPredict search engine (Cokol et al., 2000), the 
relative positions o f these are shown in Figure 4 .IB & C. Consistent with this 
prediction GRK5, G R K 4a and GRK6A, but not GRK2 or GRIG, can be detected in 
the nuclei o f HEp2 cells expressing these kinases (Figure 4.1 A). The NLS o f GRK5, 
located towards the C-terminus o f the catalytic domain o f the enzyme, is essentially 
identical in position (Figure 4. IB) and sequence (Figure 1.4C) to the putative NLS of 
GRK6, suggesting that GRK6 may also contain a functional DNA-binding NLS. In 
contrast, the predicted NLS o f GRK4 is distinct from that o f GRKs 5 and 6, and is 
located within the N-terminus of the catalytic domain (Figure 4. IB & C). The NLS o f 
GRK4 is homologous to the predicted NLS o f the GRKl subfamily rather than the 
NLS o f GRKs 5 and 6 (Figure 4. IB). The putative NLS o f GRK4, like that o f GRKl 
and 7, is not predicted to bind DNA (Cokol et al., 2000). Human G R K 4a shows 64% 
and 65% homology to human GRKs 5 and 6A respectively. Interestingly, human 
G R K 4a shows 45% and 44% homology to human GRKs 1 and 7 respectively. Whilst 
G RK 4a clearly has more sequence homology to GRKs 5 and 6 it is not completely 
dissimilar from the GRKl subfamily in terms o f homology and features such as the 
sequence o f  its NLS. This might suggest a rationale for GRK4, the most divergent 
member o f the GRK4 subfamily, being grouped with the GRKl subfamily. The fact
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that GRK2 and 3 are excluded from the nucleus, and do not contain a NLS, suggests 
divergent functions for the GRK2 and GRK1/4 subfamilies.
Furthermore, the NES o f GRK5 is conserved in all the GRK4 subfamily members, 
GRKs 4, 5 and 6 (Figure 4 .IB & C) suggesting that the possession o f a NES is a 
common feature o f this subfamily o f GRKs. NetNES 1.1 predicts that GRK7 contains 
a Leucine at residue 332 in its sequence that may form part o f a NES (la Cour et al.,
2003). The corresponding sequence in GRKl is dissimilar from GRK7 and NetNES
1.1 does not predict that this sequence would contain a NES.
4.2. Nuclear localisation is a common feature of the GRK4 
subfamily of GRKs.
To determine if  the putative NLS o f GRKs 4 and 6 is functional, I mutated basic 
amino acids present in these motifs to alanine residues (Figure 4.2A). This resulted in 
the nuclear exclusion o f  all the splice variants o f GRK4 and GRK6 when transfected 
into HEp2 cells and visualised by immunofluorescence (Figure 4.2B, compare 
wildtype to ANLS mutants). These data confirm that all members o f the GRK4 
subfamily contain functional NLSs. Confirmation that the putative NES o f GRKs 4 
and 6 is functional remains to be established.
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Figure 4.2. The GRK4 subfamily contain functional NLSs.
A. Regions o f the catalytic domains o f  GRKs 4, 5 and 6  containing putative NLSs as predicted by 
PredictNLS (Cokol et al., 2000). The position of amino acids mutated to Alanine in GRKANLS 
mutants (indicted in bold) is shown. B. The putative NLSs o f the GRK4 subfamily members are 
functional. GRK5, GRK6 A, B and C, and GRK4a, p, y and 8 , together with their respective ANLS 
mutants were expressed in HEp2 cells and visualised by indirect immunofluorescence as described in
WT ANLS
GRK4a
GRK4y
1 4 5
Materials and Methods. Scale bars 1 OjiM. The images shown are representative o f those obtained on at
least three separate occasions.
4.3. GRK5 and GRK6, but not, GRK4 bind DNA in vitro
GRK5 binds DNA in vitro and DNA-binding is mediated by its NLS (Chapter 3 and 
Johnson et al., 2004). To determine if  the other GRK4 subfamily members contain 
DNA-binding NLSs, Cos-7 cell lysates expressing wildtype or ANLS mutant kinases, 
were incubated with native DNA-cellulose and the amount o f GRK bound to the resin 
determined by Western blot analysis. Quantification o f the Western blots, as shown in 
Figure 4.3A, reveals that all the GRK6 splice variants bind to DNA-cellulose in vitro 
(A; 22.7 ± 3.5%, B; 22.6 ± 3.8%, C; 20.1 ± 3.4%). That this represents specific 
binding to DNA is indicated by the observation that GRK6 does not bind cellulose 
(A; 0.3 ± 0.1%, B; 1.1 ± 0.6%, C; 0.2 ± 0.2%) (Figure 4.3A). GRK6A-, B- and C- 
ANLS mutants fail to bind DNA (A; 0.5 ± 0.4%, B; 3.2 ± 1.8%, C; 0.3 ± 0.1%) 
(Figure 4.3A), suggesting that the NLS o f GRK6 is part o f its DNA-binding site. 
GRK6A, B and C thus appear similar to GRK5 in that they bind specifically to DNA 
via a DNA-binding NLS. In marked contrast, none of the splice variants o f GRK4 
bind DNA (a; 5.6 ± 1.4%, P; 2.7 ± 0.4%, y; 6.3 ± 1.7%, 8; 1.7 ± 1.5%) (Figure 4.3A). 
The amount o f GRK4 bound to DNA-cellulose was not significantly different from 
that bound by the cellulose support. The observation that GRKs 5 and 6, but not 4, 
bind DNA in vitro suggests distinct nuclear functions for these enzymes.
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Figure 4.3. GRKs 5 and 6  bind DNA in vitro.
1 4 7
A. G RK 5 and  G R K 6, bu t no t G R K 4, b in d  D N A  cellulose. Cos-7 cell lysates (~15 jig) expressing 
G R K 5, G R K 6A , B and C, o r G R K 4 a , (3, y  and  8, and ANLS m utants thereof, w ere incubated  w ith 
native D N A -cellu lose or cellu lose, after ex tensive w ashing  the am ount o f  bound  G R K  w as determ ined 
by  W estern  b lo t analysis. B lo ts w ere quan tified  as described in M aterials and M ethods. T he data 
show n represent the m ean values +  standard  errors o f  the m ean for at least three separate 
determ inations. **, P < 0 .01 ; ***, P < 0 .0 0 1 . B. R epresen tative W estern blots o f  the D N A  bind ing  show n 
in A. L, 25%  L ysate; C , G R K  b ound  C ellu lose; D , G R K  bound  D N A  cellulose. C. G R K 6A  binds 
d irectly  and specifically  to  D N A . P urified  G R K 6A  (150 ng) w as incubated w ith native D N A -cellulose 
fo llow ing a  30 m in incubation  w ith  the  ind ica ted  am ounts o f  D N A  or RNA . Purified  G R K 6A  w as also 
incubated  w ith cellu lose. T he am oun t o f  G R K 6A  re tained  by the resin  w as determ ined as described in 
A. The data  show n rep resen t the m ean  values +  standard  errors o f  the m ean for at least three separate 
determ inations. **, P<0.01.
GRK5 binds DNA directly (Chapter 3 and Johnson et al., 2004). To determine if 
GRK6 binding to DNA is direct and specific I repeated the in vitro DNA-binding 
assay shown in Figure 4.3A using purified GRK6A (see Materials & Methods). 
Approximately 23 ± 1.7% o f the purified GRK6A (150ng) incubated with native 
DNA-cellulose was retained by the resin (Figure 4.3B). Preincubation o f the purified 
kinase with 5fig DNA, but not RNA, inhibited binding to DNA-cellulose. This is 
depicted graphically in Figure 4.3B, 23% o f the purified GRK6A loaded onto DNA 
cellulose bound, in comparison only 9%  o f the loaded GRK6A bound following 
preincubation with DNA. This suggests that GRK6A, like GRK5, binds directly and 
specifically to DNA.
4.4. The nuclear localisation of the GRK6 splice variants is 
differentially regulated
Since the location, sequence and DNA-binding properties o f the NLS o f GRK6 
closely resembles that o f  GRK5 I investigated if  the nuclear localisation o f these
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kinases was similarly regulated. Nuclear export o f GRK5 requires CaM binding to the 
N-terminal CaM-binding domain o f the kinase (between residues 20-39) (Johnson et 
al., 2004). The N-terminal CaM binding site is conserved in GRK6A, B and C but has 
an approximately 3-fold lower affinity for CaM than GRK5 (Pronin et al., 1997). To 
establish if  GRK6 nuclear export is regulated by Ca2+, HEp2 cells transiently 
transfected with GRK5, 6A, 6B or 6C were treated with Ca2+ ionophore, A23187 
(25pM, 15min), and the subcellular distribution o f the kinases assessed by indirect 
immunofluorescence (Figure 4.4A).
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Figure 4.4. Differential regulation of the GRK6  splice variants by calcium.
A. HEp2 cells overexpressing GRK5, 6A, 6B or 6C w ere left untreated or treated with the calcium 
ionophore A23187 (+ A23187; 25p.M, 15min). The subcellular distribution o f  the transfected GRKs 
was subsequently visualised by indirect im m unofluorescence. Scale bars, 10|iM . The im ages shown 
are representative o f  those obtained on at least three separate occasions.B . Quantification o f  A 
perform ed as described in M aterial and Methods. The data shown represent the m ean values + standard 
errors o f  the m ean for at least three separate experim ents. ***, P<0.001.
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Quantification o f the subcellular distribution shown in Figure 4.4B reveals that GRKs 
5, 6B and 6C are exported from the nucleus in a Ca2+-dependent fashion. 
Approximately 90% of GRK5, 76% o f GRK6B and 78% o f GRK6C expressing 
HEp2 cells exhibited a cytosolic distribution following ionophore treatment (Figure 
4.4B). In contrast, the subcellular distribution o f GRK6A was unchanged following 
ionophore application, with only 27% o f the GRK6A expressing cells showing a 
cytosolic distribution following ionophore treatment (Figure 4.4A and B).
GRK6A differs from GRK6B and C at its C-terminus, shown schematically in Figure 
4.5A. Features unique to GRK6A include the presence o f a C-terminal PSD-95, Dig, 
ZO-1 homology (PDZ)-binding m otif (amino acids 574TRL576). The PDZ of GRK6A 
has previously been shown to bind the Na+/H+ Exchanger Regulatory Factor 
(NHERF-1), and is required for GRK6-mediated NHERF phosphorylation (Hall et 
al., 1999). Additionally, one or more C-terminal cysteine residues C561, 562, and 565 
are palmitoylated in GRK6A, these residues are not conserved in GRK6B or C 
(Figure 4.5A and Loudon and Benovic, 1997; Stoffel et al., 1994). Palmitoylation of 
GRK6A has been shown to increase its kinase activity towards both membrane bound 
and soluble substrates (Stoffel et al., 1998). It is possible therefore that GRK6A 
requires to be catalytically active (promoted by palmitoylation) in order to be 
exported from the nucleus.
To assess the role o f the PDZ-binding m otif in inhibiting Ca2+-dependent nuclear 
export o f GRK6A I used a C-terminal flag tagged version o f GRK6A. To confirm the 
disruption o f the PDZ-binding domain o f GRK6A by addition o f the flag tag I 
demonstrated the inability o f this mutant form o f the enzyme to interact with S-tag-
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NHERF-1 as assessed by an overlay assay (Figure 4.5B & C) (Hall et al., 1999) As 
shown in Figure 4.5C, GRK6A and GRK6A-flag lysates were subject to Western blot 
analysis and purified S-antigen-NHERF-1, shown in Figure 4.5B, overlaid on the blot 
(See Materials & Methods).
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Figure 4.5 GRK 6 A but not GRK 6 A-flag binds to NHERF.
A. Schematic representation o f GRK6 A (Adapted from Penela et al., 2003). GRK6 A differs from 
splice variants B and C at its C-terminus, it contains three potential palmitoylation sites (cysteines 561, 
562, 565) and a NHERF-binding PDZ interacting domain (Hall et al., 1999; Stoffel et al., 1994). B. 
Coomassie gel o f Purified 6 -His/S-tag NHERF. C. Overlay western blot. Cos-7 cell lysates expressing 
the indicated GRKs were subject to SDS-PAGE and Western blot and purified 6 -His/S-tag NHERF 
overlaid onto the blot. NHERF binds only to GRK6 A and not GRK6 -Flag or other GRK controls. D. 
The amino acid sequence o f the C-terminal o f GRK6 A. Potential sites of palmitoylation are 
underlined. The C-terminal sequence o f the non-palmitoylated mutant form of GRK6 A (GRK6 A- 
3C3A) is also shown.
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GRK6B as detected by W estern blot in cell lysates appears as a doublet whereas 
GRK6A and C appear as single bands (Figure 4.5C). A similar observation was made 
by Hall et al (Hall et al., 1999). These results suggest, either, that GRK6B is 
differentially post-translationally modified or is more susceptible to proteolysis than 
GRK6A or B. Binding o f N HERF-1 fusion protein to GRK6 was detected by probing 
for the bound fusion protein using S-protein-HRP. NHERF-1 bound to GRK6A but 
not GRK6A-flag (Figure 4.5C). This confirms that the PDZ domain o f GRK6A is 
abolished in the C-terminally flag tagged GRK6A mutant. Immunofluorescence of 
this mutant in HEp2 cells demonstrates that GRK6A-flag behaves like wildtype 
GRK6A and is not excluded from the nucleus following A23187 treatment (Figure 
4.6A). Quantification o f this data (Figure 4.6B) shows GRK6A-flag is present in the 
nucleus o f 84% o f cells expressing this mutant before and after A 23187 treatment. 
These results demonstrate that the PDZ-binding domain of GRK6A is not responsible 
for conferring insensitivity to Ca2+-dependent nuclear export.
A previously characterised mutant o f GRK6A in which three C-terminal cysteine 
residues (C561, 562 and 565) are mutated to alanine (GRK6A-3C3A), was used to 
determine if  palmitoylation o f the kinase explains its refractory nature to ionophore 
treatment (Figure 4.5 A) (Stoffel et al., 1998; Stoffel et al., 1994). 
Immunofluorescence reveals that this mutant o f GRK6 is excluded from the nucleus 
even in the absence o f ionophore treatment (Figure 4.6B and C) and A23187 
treatment has no effect on its subcellular distribution (Figure 4.6B and C). This was a 
surprising result since inhibition o f palmitoylation has previously been reported to 
promote the nuclear localisation o f R7 binding protein and scramblase I (Song et al.,
153
2006a; Wiedmer et al., 2003).
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Figure 4.6. Palmitoylation of GRK 6 A is required for nuclear localisation and DNA-binding.
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A. Mutation o f  all potential sites o f  palmitoylation results in the nuclear exclusion o f GRK6 A. HEp2 
cells expressing GRK6 A, GRKA6 -flag (a mutant lacking the PDZ-binding domain) or GRK6A-3C3A 
(in which potential sites o f  palmitoylation are removed) were left untreated (upper panels) or were 
treated with A23187 (lower panels, + A23187; 25|iM , 15min). The subcellular distribution o f the 
transfected kinases was subsequently visualised by indirect immunofluorescence. Scale bars, lOpM. 
The images shown are representative o f  those obtained on at least three separate occasions. B. Cells 
transfected with GRK6 A, or mutants thereof, were scored for their nuclear localisation as described in 
Materials and Methods. The data shown represent the mean values + standard errors o f the mean for at 
least three separate determinations. ***, PO.OOl. C. Cos-7 cell lysates (-15  (ig) expressing GRK6 A, 
GRK6 A-flag or GRK6A-3C3A were incubated with native DNA-cellulose or cellulose, after extensive 
washing the amount o f bound GRK was determined by Western blot analysis. Blots were quantified as 
described in Materials and Methods. The amount o f GRK.6 A bound to DNA-cellulose (-24% ) was 
normalised to 100%. The data shown represent the mean values + standard errors o f the mean for at 
least three separate determinations. **, P<0.01.
In an attempt to explain the cytosolic distribution o f GRK6A-3C3A I compared the 
ability o f GRK6A, GRK6A-flag and GRK6A-3C3A to bind DNA in vitro. GRK6A- 
flag binds DNA similarly to GRK6A (Figure 4.6C). GRK6A-3C3A however, 
displays an impaired ability to bind DNA in vitro as compared to the wildtype 
enzyme (Figure 4.6C).
When considered together the subcellular distribution and DNA-binding properties of
GRK6-3C3A suggest that palmitoylation may be required for efficient binding o f
GRK6A to DNA and that DNA-binding is required for nuclear localisation o f the
kinase. Alternatively, palmitoylation o f GRK6A may be responsible for maintaining
the kinase in a conformation in which its DNA-binding NLS is exposed. Since
palmitoylation is a reversible modification, it is tempting to speculate that nuclear
localisation o f GRK6A may be modulated by dynamic regulation o f its
palmitoylation status. That the nuclear localisation o f the splice variants o f GRK6 is
differentially regulated raises the possibility that distinct extracellular cues modulate
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their putative nuclear functions.
4.5. Summary
The data in this Chapter hints towards novel roles o f the GRK4 subfamily in the 
nucleus. In Chapter 3 I reported that GRK5 contains a DNA-binding NLS. I have 
now shown that the two other members o f the GRK4 subfamily, GRK4 and GRK6, 
also contain functional NLSs. The NLS o f GRK4 is different in sequence and 
location to that o f GRKs 5 and 6 suggesting that this kinase is the most divergent of 
the group and is actually more similar in terms o f NLS identity to the GRK1 
subfamily. GRK4 and 6 also possess a putative NES, with the same sequence and 
location as the NES o f GRK5. I have not confirmed that this putative NES is 
functional in GRKs 4 and 6 but since all GRK4 subfamily members contain an 
identical sequence I would predict that possession o f a functional NES is a conserved 
feature o f this GRK subfamily.
Interestingly, the GRK4 subfamily members show differential DNA-binding 
properties, perhaps suggesting that GRKs 5 and 6 (which bind DNA in vitro) may 
have different nuclear functions to GRK4 (which does not bind DNA in vitro). Since 
GRK6 shares the most sequence homology with GRK5, I investigated whether this 
kinase was regulated by Ca2+ in a similar fashion. Interestingly, GRK6B and C are 
subject to nuclear export in the presence o f Ca in a similar fashion to GRK5, but the 
nuclear localisation o f GRK6A appears to be refractory to this regulatory mechanism. 
The C-terminal PDZ m otif o f GRK6A does not appear to account for this difference 
between the GRK6 splice variants. Palmitoylation at the C-terminus o f GRK6A is 
however required for nuclear localisation. These data indicate that the GRK4
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subfamily o f kinases contain NLSs but appear to be differentially regulated. This may 
suggest that these kinases might have roles in the nucleus distinct from their classical 
involvement in GPCR desensitisation.
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5. GRK5 DNA-binding ability and kinase 
activity is required for inhibition of 
hypertrophy in myocytes
In this Chapter, I identify the structural determinants o f GRK5 required for DNA- 
binding in vitro and nuclear localisation in cells. Using isolated rat neonatal 
myocytes, I demonstrate that GRK5 overexpression inhibits the hypertrophic 
phenotype observed following cxAR or PLC activation. GRK5-mediated inhibition of 
hypertrophy requires both the DNA-binding ability and kinase activity o f GRK5 
suggesting a direct role for this enzyme in regulating gene transcription.
5.1. Structural determinants of GRK5 required for nuclear 
localisation and DNA-binding
GRK5 contains a DNA-binding NLS and is present in the nucleus o f HEp2 cells both 
endogenously and when transiently overexpressed (Chapter 3 and Johnson et al.,
2004). Whether GRK5 binds DNA in a cellular setting and the functional 
consequences o f this interaction have, however, not been explored. I reasoned that a 
clear demonstration o f  a nuclear function for GRK5 would rely on the use o f mutant 
forms o f the enzyme that have distinct subcellular localisations and differ in their 
DNA-binding properties.
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5.1.1. GRK5 nuclear localisation is dependent on the NLS and 
NES motifs
The identification o f both a NLS and NES in GRK5 (discussed in Chapter 3) suggests 
that its nuclear localisation may be regulated. In Chapter 3 I examined, using confocal 
immunofluorescence, the subcellular localisation of a range o f GRK5 mutants, 
including GRK5ANLS, GRK5ANES, GRK5NTPB, GRK5CTPB and GRK5K215R, 
before and after calcium ionophore treatment (A23187). This data revealed GRK5 
structural domains that contribute to the regulation o f its nuclear localisation. A 
schematic o f the mutant constructs o f GRK5 used (Figure 5.1 A) and confocal 
immunofluoresence o f these mutants (Figure 5 .IB) is recapitulated here in this 
chapter for purposes of clarity.
I introduce here one further GRK5 mutant which has not been previously discussed in 
this thesis, GRK5AP. Inhibition o f GRK5 autophosphorylation (GRK5AP) (Figure
5.1 A) does not seem to alter the subcellular distribution o f GRK5 compared to the 
wildtype kinase, being uniformly distributed throughout the cell including the nucleus 
(Figure 5. IB compare panel g and a). This suggests that whilst regulation o f kinase 
activity and GRK5 autophosphorylation status are important in governing GRK5 
activity in the cell, these modifications do not contribute directly to modifying its 
subcellular localisation.
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Figure 5.1. Structural determinants of GRK5 required for calcium-mediated nuclear export.
A. Schematic representation o f GRK5 mutant constructs shown by immunofluorescence in panel B 
(Adapted from Penela et al., 2003). 1. ANLS, mutation o f basic residues in the NLS (residues 388-395) 
to alanine; 2. ANES, mutation o f hydrophobic residues in the NES (259-265) to alanine; 3. NTPB (N- 
terminal polybasic), mutation o f basic residues between residue 22 and 29 to alanine in the N-terminal 
PIP2 and CaM binding sites o f GRK5; 4. CTPB (C-terminal polybasic), mutation o f basic residues 
between residues 547 and 557 to alanine in the C-terminal phospholipid and CaM binding region of  
GRK5; 5. K215R, kinase dead GRK5 mutant; 6, AP, autophosphorylation deficient GRK.5 resulting 
from mutations S484A and T485A. CaM, Calmodulin binding domain; RH, Regulator of G-protein 
signalling (RGS) homology domain; PL, phospholipid; P, Phosphorylation site; Auto, 
autophosphorylation; PKC, Protein kinase C. B. Confocal microscopy showing cellular distribution of  
GRK5 and GRK5 mutants thereof, overexpressed in HEp2 cells. Scale bars are lOpM. The images 
shown are representative of those obtained on at least three separate occasions.
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The identification o f an NLS and NES in GRK5, together with previously 
characterised mutants o f this kinase (Chapter 3 and Johnson et al., 2004 and Figure
5.1), provides a panel o f GRK5 constructs that vary in their subcellular localisation 
and nuclear export characteristics. As shown in Figure 5 .IB wildtype GRK5 (a), 
GRK5CTPB (e) and GRK5K215R (a catalytically inactive mutant) (f) are uniformly 
distributed throughout the cytoplasm and nucleus. In contrast, GRK5ANES (c) and 
GRK5NTPB (d) are localised to the nucleus whilst GRK5ANLS (b) is cytoplasmic.
5.1.2. The structural determinants of GRK5 required for DNA- 
binding i n  v itr o
GRK5 binds DNA in vitro and this requires an intact NLS (Johnson et al., 2004). To 
examine if  other structural features regulate DNA-binding, the panel o f GRK5 
mutants shown in Figure 5.1, were assessed for their ability to bind DNA in vitro 
(Figure 5.2). Consistent with previous findings wildtype GRK5 bound DNA-cellulose 
(27.8±2.3% of the load bound) but not the cellulose support (0.7±0.2%) (Johnson et 
al., 2004). GRK5ANLS failed to bind DNA (5.2±1.5%), confirming that an intact 
NLS is required for this interaction (Johnson et al., 2004). Analysis o f the DNA- 
binding properties o f the other GRK5 mutants shown in Figure 5.2 reveals that the 
DNA-binding ability o f GRK5ANES (22±6.9%) is identical to that o f the wildtype 
enzyme (Figure 5.2, ANES) while that o f GRK5NTPB (6±2.5%) (Figure 5.2, NTPB) 
is similar to that o f GRK5ANLS. Thus despite having a similar nuclear localisation, 
GRK5ANES and GRK5NTPB exhibit very different DNA-binding abilities. The 
inability o f GRK5NTPB to bind DNA suggests that, like the NLS, this region o f the 
kinase may be in direct contact with DNA. Presumably these two regions form part,
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or all, of the DNA-binding domain of GRK5.
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Figure 5.2. Structural determinants of GRKS required for DNA-binding in vitro.
GRK5 DNA-binding in vitro requires an intact NLS and N-terminal CaM binding site. A. DNA- 
binding assays, described in Materials and Methods, were performed on Cos-7 cell lysates 
overexpressing GRK5, or the mutant GRK5 constructs indicated. The results shown represent the 
mean values + standard errors o f the mean for at least three separate determinations. Statistical 
significance is determined relative to wildtype GRK5. **, PO.Ol; ***, PO.OOl. B. Representative 
western blots o f mutant GRK5 DNA binding. L, GRK Lysate (25%); C, GRK bound to Cellulose; D, 
GRK bound to DNA-Cellulose.
GRK5CTPB, GRK5K215R and GRK5AP bind DNA more avidly than their wildtype 
counterpart, respectively, 78±6.6%, 62±9.3% and 44±5.9% of the load bound (Figure
5.2). GRK5 undergoes phospholipid stimulated autophosphorylation (Figure 5.1 A) at 
serine 484 and threonine 485, the residues mutated in the GRK5AP mutant (Kunapuli 
et al., 1994). Additionally, the binding of CaM to the C-terminal CaM binding site of 
GRK5 stimulates autophosphorylation at sites distinct from these ‘classical’ 
phospholipid stimulated autophosphorylation sites (Pronin et al., 1997). Although the 
sites phosphorylated in the presence of CaM remain to be definitively mapped they
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reside in the C-terminus o f the kinase between residues 579 and 585, i.e. at a site 
more C-terminal than phospholipid stimulated autophosphorylation sites (Pronin et 
al., 1998; Pronin et al., 1997). The observation that GRK5 mutants lacking kinase 
activity (GRK5K215R) or regulatory sites o f autophosphorylation (GRK5AP and 
GRK5CTPB) bind more avidly to DNA than the wildtype kinase suggests that the 
addition o f negatively charged phosphate groups to serine/threonine residues in the C- 
terminus o f GRK5 reduces its affinity for DNA (Figure 5.2). That GRK5CTPB binds 
most avidly to DNA (Figure 5.2) may reflect an additional direct effect o f CaM 
binding at this C-terminal site to reduce DNA-binding affinity.
5.1.3. Model of regulation of GRK5 nuclear localisation and 
DNA-binding
Analysis o f the subcellular localisation and DNA-binding properties o f the seven 
GRK5 mutants used in this thesis suggests a potential model, depicted schematically 
in Figure 5.3, whereby GRK5 nuclear localisation may be regulated.
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Figure 5.3. Model illustrating potential mechanisms regulating DNA-binding and nuclear export 
of GRK5.
1. GRK5 resides in the nucleus, free o f  CaM , in a conform ation in w hich its NLS is exposed and NES 
hidden. DNA -binding is m ediated, at least in part by its NLS and N-term inal CaM  binding domain 
(N TPB). 2. CaM  binding to the N -term inus o f  GRK5 exposes the NES o f  GRK5 facilitating its 
nuclear export. C aM -binding to the C-term inal C aM -binding site o f  GRK5 induces 
autophosphorylation o f  the kinase at multiple sites w ithin its C-term inus, although not directly 
prom oting nuclear export, facilitates dissociation o f  GRK.5 from DNA. I f  CaM  rem ains bound to 
GRK5 in the cytoplasm , CaM  will inhibit GRK5 receptor association and phosphorylation. GRK5 can 
associate w ith a num ber o f  m olecules w hich com pete w ith CaM to bind to the N -term inus o f  GRK5 
that m ay prom ote its cytosolic retention: 3. PIP2 , which prom otes receptor phosphorylation 4. a -actin in  
(a -ac t), w hich prom otes phosphorylation o f  soluble substrates and 5. actin, w hich inhibits GRK5 
catalytic activity.
The wildtype kinase is distributed throughout the cytoplasm and nucleus of 
transfected cells suggesting two populations of GRK5 in which, respectively, the
1 6 4
NES or NLS are exposed. GRK5ANLS is cytosolic and GRK5ANES nuclear 
suggesting an obligate requirement for these two motifs in establishing, respectively, 
a nuclear or cytosolic location (Figure 5.3). Endogenous Ca2+/CaM may be 
responsible for exposing the NES in the cytosolic pool of transfected wildtype GRK5 
since GRK5NTPB, which lacks the N-terminal CaM binding site, is almost entirely 
nuclear (Figure 5 .IB panel d). The observation that both GRK5ANES and 
GRK5NTPB are not exported from the nucleus in a Ca2+/CaM-dependent fashion 
(Chapter 3) further supports this contention since it demonstrates that CaM-dependent 
nuclear export is both NES and CaM-dependent. NES unmasking has been reported 
for other nuclear proteins, such as p53, which contains a NES in its tetradimerisation 
domain (Stommel et al., 1999). Once cytosolic, CaM bound GRK5 is unable to 
associate with plasma membrane located receptors and thus GRK5-mediated GPCR 
desensitisation is inhibited. Even in the absence o f Ca2+/CaM GRK5 may be retained 
in the cytosol by binding to other ligands that associate with the N-terminal polybasic 
domain including PIP2/a-actinin/actin (Figure 5.3). The functional consequences of 
these binding events are be predicted to be complex, resulting in forms o f the kinase 
with different substrate specificities (illustrated in Figure 5.3).
The nuclear pool o f wildtype GRK5 is postulated to be free of CaM. In the nucleus 
GRK5 may be bound to DNA. DNA-binding requires both an intact NLS and N- 
terminal CaM binding site since mutation o f either o f the sites prevents DNA-binding 
in vitro (Figure 5.2). Binding o f CaM to the N-terminal CaM binding site o f GRK5 
may thus serve, not only to expose the NES o f GRK5, but may also contribute 
directly to its dissociation from DNA. GRK5K215R, GRK5AP and GRK5CTPB all
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exhibit an enhanced DNA-binding ability in vitro as compared to the wildtype 
enzyme. This suggests that phosphate addition, and potentially CaM binding, to the 
C-terminus o f the kinase contributes to reduce its affinity for DNA. These 
modifications do not, however, result in NES exposure since these mutant forms o f 
the enzyme show a subcellular distribution identical to that o f wildtype GRK5 
(Figure 5 .IB).
Overall these studies suggest a complex mechanism for regulating the conformation 
o f GRK5 via interaction with regulatory proteins (CaM) or by post-translational 
modifications (autophosphorylation). Altering conformation is postulated to modulate 
NLS/NES exposure thereby affecting nuclear localisation and DNA-binding 
properties o f GRK5. aPKCA, (Perander et al., 2001), and MAPK-activated protein 
kinase 2 (MK2) (Engel et al., 1998) also contain both a NLS and NES. In comparison 
to GRK5 however, which does not necessarily need to be catalytically active in order 
to be present in or exported from the nucleus, aPKCX and MK2 phosphorylation- 
dependent activation is required to expose their NLS/NES and alter their nuclear 
localisation. Active aPKCX enters, whilst active MK2 exits, the nucleus (Engel et al., 
1998; Perander et al., 2001).
5.2. GRK5 activity and the ability to bind DNA are 
required for inhibition of cardiac hypertrophy ex vivo
Determining the DNA-binding properties o f wildtype and mutant GRK5 constructs 
(shown in Figure 5.1) provides valuable tools for investigating potential nuclear 
functions o f  GRK5 in a cellular setting. For example, both wildtype and catalytically 
inactive GRK5 (GRK5K215R) are located throughout the cell and both bind DNA,
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whereas the ANLS and N-terminal CaM binding (NTPB) mutants o f GRK5 do not 
bind DNA but are cytosolic and nuclear in distribution, respectively.
5.2.1. GRK5 DNA-binding and kinase activity is required to 
rescue phenylephrine-induced cardiac hypertrophy
Adaptation o f the heart to pressure or stress results in cardiac hypertrophy, where
myocytes increase in cell size, enhance protein synthesis and heighten organisation o f
the sarcomere (Reviewed in Frey et al., 2004). Initiation o f the fetal gene program is
observed since genes required for induction of hypertrophy are typically those
expressed during development (Frey et al., 2004). Although hypertrophy initially
compensates for cardiac stress it is eventually linked to an increased risk o f HF (Frey
et al., 2004). In transgenic mice, cardiac specific overexpression o f a constitutively
active mutant o f the ocibAR induces cardiac hypertrophy (Eckhart et al., 2000).
Hypertrophy is however inhibited in mice expressing both the mutant receptor and
GRK5. Coupling o f the ocI bAR  to Gq is not affected under these conditions,
suggesting that GRK5 is not simply acting to desensitise the receptor (Eckhart et al.,
2000). I hypothesised that this GRK5-mediated inhibition o f hypertrophy reflects a
novel, potentially nuclear, function of GRK5 and sought to recapitulate this
observation ex vivo.
Application of PE to rat neonatal cardiac myocytes in culture activates ARs and
induces cardiac hypertrophy. This is evident by an increase in cell size and increased
organisation o f a-actinin as shown in Figure 5.4A. As a measure o f hypertrophy I
determined cell area (|iM 2). Treatment o f cardiac myocytes for 48h with 200pM PE
results in an increase in cell area from approximately 530pM2 to 1180pM2, a 2.2 fold
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increase (Figure 5.4A and B).
A .
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Figure 5.4. GRK5 overexpression rescues cardiac hypertrophy in myocytes.
A. Induction o f cardiac hypertrophy ex vivo induces myocyte cell growth and reorganisation o f a-  
actinin. Rat neonatal myocytes plated on coverslips were left untreated (untreated) or were treated with 
PE (200|i.M, 48h) (+ PE). oc-Actinin organisation was subsequently visualised by indirect 
immunofluorescence. Scale bars are lOpM. B. The DNA-binding ability o f GRK5 and its kinase 
activity are required for GRK5-mediated inhibition o f hypertrophy. The extent o f PE (200pM, 48h) 
induced hypertrophy in rat neonatal myocytes transfected with various GRK5 constructs was 
determined by measuring cell area (pM2) as described in the methods. GRK5, the wildtype enzyme;
ANES, GRK.5ANES; ANLS, GRK5ANLS; NTPB, GRK5 N-terminal CaM binding site mutant;
K215R, catalytically inactive GRK5. The data shown represent the mean values + standard errors o f  
the mean for at least three separate determinations. Statistical significance is determined relative to
values obtained for wildtype GRK5 + PE. **, P<0.01.
Nucleofection and expression o f  GRK5 did not alter cell area per se (P=0.3), but did
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inhibit PE-dependent hypertrophy (P<0.01, Figure 5.4B). PE treated, GRK5 
expressing myocytes, were significantly smaller than their untransfected counterparts 
(P=0.0029). Similarly, nucleofection and expression o f GRK5ANES rescued PE- 
induced hypertrophy (Figure 5.4B). Cells expressing this mutant, which is exclusively 
nuclear and binds DNA in vitro, were significantly smaller than untransfected 
controls (P=0.0035). In marked contrast overexpression o f GRK5ANLS, which is 
excluded from the nucleus o f transfected HEp2 cells and does not bind DNA in vitro, 
fails to significantly inhibit PE-induced hypertrophy. These results suggest that either 
the nuclear localisation o f GRK5 or its ability to bind DNA is required to inhibit 
hypertrophy. Nucleofection o f cardiac myocytes with GRK5NTPB was used to 
distinguish these two possibilities. GRK5NTPB, a mutant enzyme that lacks the N- 
terminal CaM-binding site o f GRK5, is present in the nucleus o f HEp2 cells but, like 
GRK5ANLS, fails to bind DNA in vitro. GRK5NTPB expression did not inhibit PE- 
induced hypertrophy. This observation suggests that GRK5-dependent inhibition of 
PE-induced hypertrophy requires the DNA-binding ability o f GRK5. The kinase 
activity o f GRK5ANLS and GRK5NTPB is similar to that o f wildtype GRK5, when 
assessed in vitro using rhodopsin as a substrate (Johnson et al., 2004). This suggests 
that GRK5-dependent rescue o f hypertrophy is a bona fide affect o f DNA-binding 
and is likely not explained by reduced kinase activity o f the non-DNA-binding GRK5 
mutants. GRK5CTPB binds to DNA with a higher affinity thann wild type GRK5 as 
assessed by the in vitro DNA binding assay (Section 5.1.2 and Figure 5.2). I thus 
hypothesised that this mutant would, like its wild type counterpart, inhibit PE-induced 
hypertrophy ex vivo. However, expression o f GRK5CTPB in myocytes resulted in
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cell death, although the significance o f this observation is not known, it may indicate 
an important functional role for the DNA-binding ability o f GRK5 ex vivo. Notably 
however, expression o f GRK5K215R, a catalytically inactive mutant o f GRK5, failed 
to rescue PE-induced hypertrophy (Figure 5.4B). Together these results point to a role 
for both the DNA-binding ability o f GRK5 and its kinase activity in regulating gene 
expression during hypertrophy.
As GRK5 is exported from the nucleus following activation o f the Gq-coupled 
M3MR (Chapter 3 and Johnson et al., 2004) it is tempting to postulate that Gq 
coupled cxAR activation may similarly affect GRK5 and thus act to inhibit nuclear 
functions o f this enzyme, parr - 1  has recently been reported to translocate to the 
nucleus upon 8 -opioid receptor activation and promote gene transcription by 
recruiting the histone acetylase p300 to the promoter o f specific genes (Kang et al.,
2005). Perhaps Nuclear GRK5 might act to repress gene transcription. Following Gq- 
coupled GPCR activation and nuclear export o f GRK5 this repression may be 
relieved. A consequence o f overexpressing GRK5 in cardiac myocytes may be 
restoration o f the DNA-binding and kinase-dependent inhibitory effect o f GRK5 on 
gene transcription.
Although GRK5ANLS and GRK5NTPB are active kinases in vitro the possibility 
remains that they are not active in a cellular setting. I thus sought to confirm that the 
activity requirement for GRK5-mediated inhibition o f cardiac hypertrophy 
represented a novel function o f this enzyme rather than desensitisation o f ARs and 
termination o f the hypertrophic signal. To address this problem, I took two 
approaches, firstly, to show that GRK5 can rescue hypertrophy in myocytes induced
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by receptors which are not known to be substrates for GRK5 in vivo and secondly, 
and perhaps more convincingly, by activating hypertrophy downstream of GPCRs 
using a PLC activator, ra-3M3FBS.
5.2.2. GRK5 rescues hypertrophy induced by EGF and Angll
Since the kinase activity as well as DNA-binding ability o f GRK5 is required to 
rescue hypertrophy in rat neonatal cardiac myocytes, I sought to confirm that this 
rescue was not simply due to GRK5-mediated desensitisation o f the am AR and 
therefore termination o f hypertrophic signalling. Angll stimulation is known to 
increase cardiac myocyte cell size by transactivating the EGFR which in turn 
activates MAPKs (Shah and Catt, 2003). Overexpression o f GRK5 in the hearts o f 
mice does not alter the contractile response to Angll stimulation suggesting that 
GRK5 does not contribute to desensitisation of ATRs in cardiac tissue in vivo 
(Rockman et al., 1996).
The tyrosine kinase receptor, EGFR, as is typical for this class o f receptor, is 
desensitised by degradation by the proteasome following ubiquitination. To date, 
GRK2, but not GRK5, has been shown to bind to and phosphorylate this receptor 
tyrosine kinase, a non-GPCR substrate. The functional significance o f this event is 
unknown since GRK2 phosphorylation does not appear to induce desensitisation of 
this receptor (Freedman et al., 2002; Gao et al., 2005). Stimulation o f the EGFR 
results in a hypertrophic response mediated by p38 stimulation o f STAT5 
transcription (Rebsamen et al., 2000).
Activation o f hypertrophy via the AT iAR/EGFR pathway is thus unlikely to be
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rescued by GRK5-mediated receptor desensitisation. Inducing hypertrophy in 
myocytes using EGF or Angll results in an increase in cell area o f  approximately 
4 2 ± 1 1% and 48±3% respectively in control cells (Figure 5.5). As was observed with 
the induction o f  hypertrophy using PE, GRK5 expression inhibits both EGF- 
(167mM, 48h) and A ngll- (200nM, 48h) dependent hypertrophy (Figure 5.5). This 
suggests that GRK5 mediated rescue o f  the increase in cell area is due to its DNA- 
binding ability and not its ability to desensitise plasma membrane located receptors. 
Presumably kinase activity is required to phosphorylate a nuclear substrate and not a 
receptor. This hypothesis is supported by the observation that GRK5ANLS is present 
in the cytosol but not the nucleus and exhibits wildtype catalytic activity, cannot 
rescue PE-induced hypertrophy.
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Figure 5.5. GRK5-dependent phosphorylation of GPCRs is not required for rescue of 
hypertrophy.
A. GRK5 overexpression rescues hypertrophy induced by receptors that are unlikely to represent 
substrates for this kinase in vivo. Induction o f hypertrophy in rat neonatal cardiac myocytes in culture 
by EGF (167mM, 48h) or Angll (200nM, 48h) caused cell area to increase by approximately 42% and 
48% respectively. Overexpression o f GRK5 prevented this induction o f hypertrophy. The data shown 
represent the mean values ± standard errors o f  the mean for at least three experiments. Control cell area 
was normalised to 100% and other values calculated as a percentage o f this size. P  values compared to 
untreated control cells. **, / ?< 0 .01; ***, P<0.001. B. GRK5 overexpression rescues hypertrophy 
induced downstream o f  GPCRs. GRK5 inhibits hypertrophy induced by activation o f signalling 
pathways downstream o f  GPCRs. The PLC activator W-3M3FBS (lOOnM, 48h) was used to induce 
hypertrophy in isolated myocytes and the effect o f GRK5 or GRK5 mutant expression on cell area 
quantified. The data shown represent the mean values ± standard errors o f the mean for at least three 
experiments. Untransfected unstimulated myocyte cell area was normalised to 100% and other values 
calculated as a percentage o f  this value. Statistical significance is determined relative to values 
obtained for wildtype GRK5 + W-3M3FBS. ***, RO.OOl.
5.2.3. GRK5 rescues hypertrophy in myocytes induced by PLC 
activation
I conducted experiments to show more definitively that GRK5-dependent rescue of
hypertrophy in myocytes is indeed due to DNA-binding ability and nuclear kinase
activity and not simply GRK5-mediated desensitisation o f PE stimulated ARs. I
induced hypertrophy by activating signalling pathways downstream o f GPCRs and
examined the ability o f GRK5, and mutants thereof, to inhibit this process. M-
3M3FBS is a cell permeable specific activator o f all PLC isotypes, which increases
intracellular Ca2+ via 1,4,5-trisphosphate (IP3) production without having any effect
on heterotrimeric G proteins (Bae et al., 2003). Application of the PLC activator, m-
3M3FBS (lOOnM) for 48h causes a modest, but significant, increase in cardiac
myocyte cell area o f 37±4% as compared to untreated cells (Figure 5.5B). Cells
overexpressing GRK5 did not exhibit this hypertrophic phenotype (Figure 5.5B). In
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contrast, and consistent with results obtained using PE, GRK5ANLS or GRK5K215R 
expression did not inhibit m-3M3FBS-induced hypertrophy (Figure 5.5B, ANLS and 
K215R). That a kinase deficient mutant o f GRK5 fails to inhibit m-3M3FBS-induced 
hypertrophy strongly suggests that phosphorylation o f non-GPCR nuclear substrates 
is required for GRK5-mediated inhibition of hypertrophy. Combined with the data 
from Section 5.2.2, I believe this demonstrates that GRK5-dependent inhibition of 
hypertrophy is due to its DNA-binding ability and catalytic activity and is not simply 
due to its ability to desensitise ARs.
5.3. Summary
In this Chapter I have made a step towards understanding how GRK5 nuclear 
localisation and DNA-binding ability is regulated by structural determinants. This 
data allows me to propose a model o f how the DNA-binding ability and nuclear 
localisation o f GRK5 may be regulated. The NLS and NES o f GRK5 control nuclear 
and cytosolic localisation o f the kinase. GRK5 DNA-binding ability depends upon an 
intact NLS and N-terminal CaM binding region. It may be that CaM binding to the N- 
terminus o f GRK5 sterically hinders DNA-binding and exposes the NES o f GRK5 
since nuclear export o f the kinase is NES and CaM dependent. Phosphate addition at 
the C-terminus o f GRK5 inhibits DNA-binding since a kinase dead mutant o f GRK5 
(GRK5K215R) and an autophosphorylation (GRK5AP) or C-terminal CaM binding 
mutant (GRK5CTPB) all show an increased affinity for DNA in vitro as compared to 
the wildtype enzyme. CaM binding at the C-terminus o f GRK5, apart from 
stimulating inhibitory autophosphorylation may also serve to directly inhibit DNA- 
binding. However, GRK5 catalytic activity is not required for nuclear export and
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appears to solely affect the ability o f GRK5 to bind DNA.
In order to attempt to understand the functional significance o f GRK5 nuclear 
localisation I recapitulated ex vivo published work that reported GRK5-mediated 
rescue o f hypertrophy in vivo (Eckhart et al., 2000). In rat neonatal cardiac myocytes, 
PE-induced cardiac hypertrophy is prevented by overexpression o f GRK5 and this 
effect requires both the DNA-binding ability and kinase activity o f this enzyme. 
GRK5 overexpression also rescued hypertrophy induced by Angll and EGF, agonists 
which activate receptors likely to be refractory to GRK5-mediated desensitisation 
events. Furthermore, GRK5 expression prevents hypertrophy induced by a PLC 
activator which stimulates signalling pathways downstream o f GPCRs and 
heterotrimeric G proteins. The molecular mechanisms whereby GRK5 inhibits 
myocyte hypertrophy ex vivo represents an exciting area o f future research.
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6. Discussion
GRKs phosphorylate and desensitise activated GPCRs and thereby play an important 
role in regulating intracellular signal transduction cascades. The identification o f non­
receptor substrates for these kinases, suggests that they may play a more diverse, and 
direct, role in regulating signalling than previously appreciated (Penela et al., 2006). 
In this thesis, I have shown that the GRK4 subfamily o f GRKs are not only 
membrane bound/cytosolic kinases but are also present in the nucleus. GRKs 4, 5 and 
6  possess functional nuclear localisation signals for nuclear import, and by homology 
with GRK5 all are predicted to contain NESs. GRKs 5 and 6 , but not 4, bind DNA in 
vitro suggesting that they may have differential nuclear functions. The nuclear 
localisation o f GRK5 and 6 A is differentially regulated by Ca2+/CaM indicating that a 
potentially common function o f these GRKs may be subject to distinct regulatory 
mechanisms. I have also shown ex vivo that GRK5 overexpression inhibits cardiac 
hypertrophy, and that this requires both the DNA-binding ability and kinase activity 
o f GRK5.
6.1. GRK5 is a nuclear protein
In Chapter 3 I demonstrate that GRK5, a member o f the GRK4 subfamily o f GRKs is 
a nuclear protein and contains a DNA-binding NLS. Furthermore, nuclear 
localisation o f GRK5 is regulated in a GPCR-dependent fashion. Agonist-occupancy 
o f the M3MR, which elevates intracellular Ca2+ levels and activates the Ca2+ sensor 
protein, CaM, promotes NES-dependent nuclear export o f GRK5. The binding o f 
activated CaM to the N-terminus o f GRK5 is required for this export event. It is
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possible, since a-actinin and phospholipids also bind to the same site as CaM that 
these molecules regulate GRK5 DNA-binding and nuclear export. However, since 
CaM is abundantly expressed in the nucleus, particularly in heart, and since I have 
shown that CaM sequestrants inhibit nuclear export this seems unlikely (Chin and 
Means, 2000; Maier et al., 2006). By regulating the nuclear localisation o f GRK5, 
and thus, the ability o f  the kinase to bind DNA in cells, Gq-coupled GPCRs could 
inhibit potential nuclear functions o f this kinase.
6.1.1. GRK5 contains both a NLS and NES
Using two search engines which predict NLS and NES sequences in proteins, I 
identified a monopartite NLS, which has homology to the NLS found in DNA- 
binding proteins such as the homeobox-containing proteins, along with a Leucine rich 
NES (Cokol et al., 2000; la Cour et al., 2004). Homeobox-containing proteins are 
DNA-binding transcription factors which all contain a DNA-binding homeodomain 
and regulate transcription o f a multiplicity o f genes during development (Billeter,
1996). The homeodomain containing transcription factor Csx/Nkx2-5 is highly 
expressed in the heart during murine embryogenesis and throughout adulthood 
(Komuro and Izumo, 1993). Csx/Nkx2-5 deficient mice showed a reduction in 
expression o f ANF and MLC2v genes, amongst others, indicating that Csx/Nkx2-5 
plays a crucial role in regulating transcription o f cardiac-specific genes essential for 
cardiac differentiation (Tanaka et al., 1999). Whilst GRK5 and 6  knockout mice 
develop to adulthood (Gainetdinov et al., 2003; Gainetdinov et al., 1999), it would be 
interesting to determine if  a GRK5/6 double knockout mouse showed any signs o f 
irregular cardiac development.
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In a similar fashion to the GRK 2 and 4 subfamilies, the two ubiquitously expressed 
members o f the arrestin family (parr- 1 and 2 ) also show distinct subcellular 
localisations when expressed in a variety o f cell lines (Benmerah et al., 2003). parr-1, 
like the GRK4 subfamily, is uniformly distributed throughout the cell and is found 
both in the cytoplasm and nucleus. In contrast parr-2, like the GRK2 subfamily of 
GRKs, is cytosolic, parr-2, but not parr-1, contains an NES and shuttles through the 
nucleus. The nucleocytoplasmic shuttling o f parr-2 results in the cytoplasmic 
retention o f nuclear parr-2-binding partners, such as Mdm2 and activated JNK, 
thereby indirectly regulating gene transcription (Benmerah et al., 2003; Lefkowitz 
and Whalen, 2004). Like GRK5, parr-2, other proteins required for receptor 
endocytosis such as epsinl, epsl5 and clathrin assembly lymphoid myeloid 
leukaemia (CALM) exhibit nucleocytoplasmic shuttling (Benmerah et al., 2003). 
Epsl5 exhibits transcriptional activity in GAL4 reporter assays, suggesting a potential 
role for this protein in regulating gene expression (Benmerah et al., 2003). Many 
membrane localised proteins which function in receptor desensitisation and 
internalisation thus appear to have multifunctional cellular roles including nuclear 
signalling. Like the majority o f proteins that contain an NES, the GRK4 subfamily 
NES does not conform to the classical NES consensus sequence (L-x(2,3)-[LIVFM]- 
x(2,3)-L-x-[LI]) (Kutay and Guttinger, 2005; la Cour et al., 2004). The critical 
residues conform but the spacing o f these residues differs from the classical NES 
consensus. Only one ‘x ’ residue rather than 2 or 3 residues spaces the critical 
residues. Although to date I have failed to identify an NES in GRK2 the ability of this 
kinase to shuttle through the nucleus warrants further investigation.
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6.1.2. GRK5 nuclear export is regulated by CaM
In Chapter 3, transfected and endogenous GRK5 was detected in the nuclei o f HEp2 
cells using fluorescent confocal microscopy (Figure 3.1). Similarly, Yi and 
colleagues have reported endogenous GRK5 in the nuclei o f rat cardiac myocytes (Yi 
et al., 2002). Treatment o f these cells with 12-o-tetradecanoylphorbol-13-acetate 
(TPA), a strong PKC activator, results in a more pronounced nuclear localisation of 
the endogenous kinase (Yi et al., 2002). GRK5 is itself a PKC substrate (Pronin and 
Benovic, 1997) and PKC-mediated GRK5 phosphorylation inhibits GRK5 receptor 
phosphorylation. I attempted to recapitulate this result by transiently overexpressing 
GRK5 in HEp2 cells however in this model system TPA treatment did not 
reproducibly induce nuclear accumulation o f GRK5. This warrants further 
investigation in rat neonatal cardiac myocytes. However, Yi and colleagues (Yi et al.,
2002), utilised six-month old adult rats in their studies and perhaps, since GRK5 has 
homology with homeodomain containing TFs which are known to be crucial for 
cardiac development, GRK5 has a different nuclear function(s) during heart 
development and maturation compared to that in terminally differentiated myocytes 
during adulthood. Conversely, in Chapter 3 the binding o f Ca2+/CaM to the N- 
terminal CaM-binding site o f GRK5 is demonstrated to result in nuclear export o f the 
kinase (Figure 3.5B). Combined, these observations suggest, that multiple regulatory 
mechanisms control the intracellular, and specifically nuclear, localisation o f GRK5. 
Similarly to TPA-mediated PKC phosphorylation o f GRK5, the binding o f Ca2+/CaM 
to this kinase potently inhibits GRK5-mediated GPCR phosphorylation (ICso~50nM) 
(Sallese et al., 2000a). However, Ca2+/CaM binding, in contrast to PKC
179
phosphorylation o f GRK5, specifically prevents the interaction o f GRK5 with 
phospholipids and activated receptors without directly affecting catalytic activity 
(Sallese et al., 2000a). O f the two identified CaM-binding sites in GRK5, the C- 
terminal site appears principally responsible for Ca2+/CaM-mediated inhibition of 
membrane located substrate phosphorylation. Deletion o f the C-terminal CaM 
binding site attenuates CaM-mediated inhibition of GRK5 phosphorylation o f ROS in 
vitro. Whereas, mutation o f the N-terminal site has no effect on CaM-mediated 
inhibition o f GRK5 catalytic activity (Levay et al., 1998; Pronin et al., 1997). My 
thesis suggests an alternative role for the N-terminal CaM-binding site o f GRK5; 
CaM-dependent nuclear export o f the kinase (Chapter 3).
Mutation o f this N-terminal CaM binding site (GRK5NTPB) results in nuclear 
retention o f the mutant GRK5 (Chapter 3, Figure 3.5B). This indicates that CaM 
binding at the N-terminus o f the kinase may retain GRK5 in the cytosol. Notably 
however, the N-terminal CaM-binding site o f GRK5 is coincident with binding sites 
for PIP2 and actin/a-actinin and the interaction o f these ligands with GRK5 is likely 
to be competitive (Freeman et al., 1998). Indeed, a role for PIP2 , actin or a-actinin in 
retaining GRK5 in the cytosol seems likely since sequestration o f 
membrane/cytosolic CaM does not result in the nuclear import o f wildtype GRK5 
(Chapter 3, Figure 3.4).
6.1.3. GRK5 nuclear export is regulated by the Gq-coupled MS- 
Muscarinic receptor
As described previously, Ca2+/CaM-binding to GRK5 inhibits GRK5-mediated
GPCR phosphorylation by inhibiting membrane localisation o f the kinase.
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Additionally, Ca2+/CaM-binding stimulates autophosphorylation o f GRK5 inhibiting 
kinase activity and further contributing to impaired receptor phosphorylation (Pronin 
and Benovic, 1997). The effects o f CaM-binding on GRK5-mediated GPCR 
phosphorylation coupled with the observation that PKC-mediated GRK5 
phosphorylation directly inhibits the catalytic activity of the kinase (Pronin and 
Benovic, 1997) suggests that agonist-occupied Gq-coupled receptors, and thus the 
M3 MR, represent poor substrates for this kinase. Three lines o f evidence are 
consistent with this hypothesis. Firstly, overexpression o f catalytically inactive 
GRK 6 , but not GRK5, inhibits M3 MR receptor desensitisation induced by 
endogenous GRKs in human neuroblastoma SH-SY5Y cells (Willets et al., 2003b). 
Secondly, mice lacking the GRK5 gene exhibit no difference in M3MR-mediated 
agonist-induced contraction o f airway smooth muscle, when compared to wildtype 
littermates (Walker et al., 2004). Thirdly, overexpression o f GRK5 in CHO cells 
stably expressing the M3MR fails to promote agonist-dependent internalisation o f the 
receptor (Figure 3.7A, left hand panels). Although apparently not a GRK5 substrate 
the M3 MR does, however, play a role in regulating the subcellular localisation of 
GRK5. Following activation o f the M3MR GRK5 is translocated to the cytosol 
(Figure 3A); potential nuclear functions o f this kinase may thus be negatively 
regulated by this receptor or perhaps less specifically Gq-coupled receptors.
6.2. The GRK4 subfamily are all localised to the nucleus
Since GRK5, a GRK4 subfamily member, but not GRK2, a GRK2 subfamily member 
is present in the nucleus o f a range o f tissue culture cells when transiently 
overexpressed, I sought to determine if  this was a common shared feature o f the
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GRK4 subfamily. The data in Chapter 4 revealed unsuspected diversity within the 
GRK4 subfamily as well as highlighting the differences and similarities between the 
GRK subfamilies. Perhaps even questioning the rationale for grouping the GRKs into 
their current subfamilies.
6.2.1. The GRK4 subfamily all contain nuclear localisation 
sequences
In Chapter 4 I show that all members o f the GRK4 subfamily contain functional 
nuclear localisation signals and that the NLS o f GRK6  like that o f GRK5, but not 4, 
bind DNA via this sequence. This data may suggest nuclear function(s) for GRK4 
distinct from that o f GRKs 5 and 6 . GRK4 is the most divergent member o f the 
GRK4 subfamily (Premont et al., 1999). In addition, the NLS o f GRK4 is most 
similar in sequence and location to predicted putative NLSs in GRK1 and GRK7 
rather than the DNA-binding NLSs o f GRKs 5 and 6  (Figure 4.1) (Cokol et al., 2000).
O f the 4 splice variants o f GRK4 only G RK4a has been shown capable o f 
phosphorylating receptor substrates in vitro (ROS and p 2ARs). Interestingly, a fourth 
splice variant o f GRK 6  has been identified in mouse, GRK6 D, which is catalytically 
inactive and entirely nuclear in localisation (Vatter et al., 2005). The GRK2 
subfamily does not contain putative NLSs, as assessed by the PredictNLS search 
engine, suggesting that these kinases may be the only GRK family members without 
nuclear functions.
Data from Chapter 4 highlights both a structural diversity between the GRK2 and
GRK4 subfamilies o f GRKs and a functional diversity within the GRK4 subfamily.
Additionally, it raises the provocative possibility that the GRK4 subfamily o f GRKs
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has signalling roles in the nucleus distinct from their characterised role o f mediating 
GPCR desensitisation at the plasma membrane. Recent evidence has suggested that 
GPCRs are located in the nucleus (Gobeil et al., 2006), raising the intriguing 
possibility that since the GRK4 subfamily members are localized to the nucleus that 
they could also be regulating the activity o f nuclear GPCRs as part o f their nuclear 
function(s).
6.2.2. Differential localisation and DNA-binding properties of the 
GRK4 subfamily
In Chapter 3 I discovered that the nuclear export o f GRK5 is promoted by Ca2+, in 
particular by CaM, a ubiquitous Ca2+ sensor known to be a regulator o f GRK function 
both at the membrane and in the cytosol. I examined whether the nuclear localisation 
o f the other GRK4 subfamily members was also regulated by Ca2+. Like GRK5, 
nuclear export o f GRK 6 B and GRK6 C is Ca2+-dependent however GRK6 A appears 
to be refractory to this regulatory mechanism (Chapter 4.4). This observation suggests 
that, like GRK5, the nuclear localisation o f GRK6 B and C could be promoted by 
activation o f a Gaq-coupled GPCR, although this has yet to be demonstrated. CaM 
activation fails to promote nuclear export o f GRK 6 A even though GRK6 A-mediated 
rhodopsin phosphorylation is inhibited by CaM (Pronin et al., 1997). Investigating the 
features o f GRK6 A responsible for conferring insensitivity to Ca2+-dependent nuclear 
export suggests a role for palmitoylation o f the kinase in this process. Mutation of 
three C-terminal cysteine residues, previously shown to encompass the palmitoylation 
site(s) o f GRK6 A (GRK6A-3C3A), leads to the nuclear exclusion o f the mutant 
enzyme (Chapter 4.4). GRK6A-3C3A also displays a reduced ability to bind DNA as
compared to wildtype GRK 6 A. This is a somewhat surprising finding since similar 
mutations in other membrane associated proteins, including the R7 family-binding 
protein and phospholipid scramblase I, are associated with their release from the 
plasma membrane and nuclear accumulation (Song et al., 2006a; Wiedmer et al., 
2003). Additionally, palmitoylated GRK6 A has previously been reported to be 
associated with membranes (Stoffel et al., 1994). In these studies, however, the 
methodology used to prepare the membrane fraction would be anticipated to result in 
nuclei contamination (Stoffel et al., 1994). A potential explanation o f my results is a 
conformational dependence o f GRK6 A on palmitoylation i.e. palmitoylation may be 
responsible for maintaining GRK6 A in a conformation in which its DNA-binding 
NLS is exposed and NES hidden. Consistent with a role for palmitoylation in 
regulating GRK 6 A conformation is the observation that a non-palmitoylatable mutant 
o f GRK 6 A has impaired kinase activity, against both receptor and soluble substrates, 
as compared to its wildtype counterpart (Stoffel et al., 1998; Stoffel et al., 1994). 
However, since palmitoylation o f GRK 6 A has been shown to increase its catalytic 
activity (Stoffel et al., 1998), perhaps GRK6 A requires kinase activity in order to be 
exported from the nucleus. This is not true for GRK5 since GRK5NTPB is 
catalytically active, exclusively nuclear, but incapable o f nuclear export (Chapter 3). 
That the nuclear export o f the splice variants of GRK6  is differentially regulated 
suggests that a potentially common nuclear function for these enzymes may be 
affected differently upon activation o f a specific GPCR.
Mechanisms regulating the nuclear localisation o f GRK4 splice variants remain to be 
investigated. In HEp2 cells the wildtype, but interestingly not the ANLS, versions of
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these kinases are relatively poorly expressed making such studies difficult to 
quantify. Differences between the effects o f ionophore treatment on the nuclear 
localisation o f GRK4a, (3, y and 8  might, however, be anticipated. GRK4oc, by 
homology with GRKs 5 and 6  is predicted to contain both N and C-terminal CaM- 
binding sites, and has been shown to bind directly to CaM in vitro (Sallese et al.,
1997). In contrast, GRK4p is predicted to contain just the N-terminal CaM binding 
site and GRK4y the C-terminal CaM binding site. GRK48 is not predicted to bind 
CaM. If, as is the case with GRK5, CaM-binding to the N-terminal CaM-binding site 
causes the nuclear export o f  these enzymes then GRK4 a  and (3, but not y and 8 , may 
be sensitive to ionophore treatment. Therefore, it might be envisaged that whilst CaM 
might promote nuclear export o f GRK 4a and p, other regulatory mechanisms might 
regulate the other splice variants or indeed all o f them.
6.3. Nuclear functions for the GRK4 subfamily?
The principle question raised by this thesis is what, if  any, nuclear function is 
performed by the GRK4 subfamily o f GRKs? I discuss in more detail putative 
functions o f GRK5 in the nucleus in Section 6.4, but first I will address potential 
nuclear functions for GRKs 4 and 6 .
6.3.1. Potential nuclear functions for GRK4
GRK4 exists as four alternatively spliced variants, a , P, y and 8 , and represents the 
least studied member o f the GRK4 subfamily o f GRKs. Since GRK4 shows limited 
tissue distribution in brain, kidney and testes/spermatocytes (Premont et al., 1996; 
Sallese et al., 1994; Sallese et al., 1997; Virion et al., 1998), work on GRK4 has
185
focused largely on examining the ability o f GRK4 to phosphorylate and mediate 
desensitisation o f GPCRs coexpressed in these tissues. Relatively few substrates for 
GRK4 have been identified, certainly in a physiological setting. GRK4a, but not 
p, yand  8 , has been shown to phosphorylate rhodopsin in vitro (Sallese et al., 1997). 
All GRK4 splice variants however exhibit, to varying extents, desensitisation of the 
rat luteinizing hormone/chorionic gonadatrophin receptor in HEK293 cells as 
determined by a decrease in cAMP (cyclic adenosine monophosphate) signalling 
(Premont et al., 1996). G R K 4a overexpression also causes desensitisation o f the 
metabotropic glutamate receptor I (Sallese et al., 2000b), the Ca2+-sensing receptor 
(Pi et al., 2005) and the phosphorylation independent desensitisation of the GAB A B 
receptor (Perroy et al., 2003) in HEK293 and cerebellar granule cells. Purified 
G RK 4a has been shown to phosphorylate purified P2AR in vitro (Premont et al., 
1996). GRK48 may have a role in desensitizing human M2MR as identified in Cos-7 
and BHK21 cells (Tsuga et al., 1998). GRK4y has been shown to contribute to 
development o f hypertension (Felder et al., 2002). A SNP identified in human 
GRK4y results in a ligand-independent increase in catalytic activity o f this splice 
variant in CHO cells and in a transgenic mice overexpressing the GRK4y SNP (Table
1.1). This leads to increased desensitisation o f the D IR  in proximal tubule cells in the 
kidney resulting in defective sodium excretion from the body and consequently 
development o f hypertension (Felder et al., 2002). A role for D IR  in regulating the 
nuclear localisation o f GRK4 in specific cell types such as neurons, kidney tubule 
cells and sperm thus warrants investigation.
The consensus NLS o f GRK4 has been identified in ten nuclear proteins (Cokol et al.,
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2000) including histone H2B from a variety o f species including human, p53 in fish 
and heat shock factor protein in yeast. This consensus NLS is also found in the cell 
growth regulating nucleolar protein found in immature spermatocytes in mouse testis, 
a putative oncoprotein which promotes cell growth (Su et al., 1993). I might therefore 
tentatively suggest a role for GRK4 in cell growth or in cell cycle control. Indeed, a 
kinase RNAi screen in HeLa cervical carcinoma cells identified GRK4 as one kinase 
responsible for promoting cell survival (MacKeigan et al., 2005).
6.3.2. Potential nuclear functions for GRK6
The consensus NLS o f GRKs 5 and 6  is found in a large number o f sequence-specific 
homeobox-containing transcription factors and transcriptional DNA-binding co­
factors in a range eukaryotes (Cokol et al., 2000), potentially suggesting these GRKs 
regulate transcription.
GRK6 A, which contains a C-terminal PDZ-binding domain, binds to and 
phosphorylates the PDZ containing protein NHERF-1. NHERF-1 is an adaptor 
protein that was originally identified as a regulator of the Na+/H+ exchanger 
(Weinman et al., 1995). GRK6 A phosphorylation o f NHERF-1 maintains this adaptor 
in a hyperphosphorylated state which has been suggested to promote its 
oligomerisation and thus allows it to act as a cofactor to inhibit Na+/H+ exchange 
(Hall et al., 1999; Lau and Hall, 2001). In contrast cyclin-dependent kinase 2 
phosphorylates NHERF-1 during mitosis and inhibits its oligomerisation and 
heteroligomerisation with NHERF-2 as well as with other binding partners (He et al.,
2001). Cyclin-dependent kinase-mediated NHERF-1 phosphorylation thus 
presumably inhibits its function as a Na+/H+ exchanger regulatory co-factor. In the
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hepatocellular carcinoma (HCC) cell line, NHERF-1 has been localised to the nucleus 
(Shibata et al., 2003). Furthermore, in HCC and a colorectal cancer cell line NHERF- 
1 increases p-catenin and T-cell factor dependent transcription (Shibata et al., 2003). 
NHERF-1 has also been reported to be required for cystic fibrosis transmembrane 
conductance regulator-dependent expression o f the chemokine RANTES (Estell et al.,
2003). Thus it appears that NHERF-1 participates in both cytosolic and nuclear 
signalling pathways. An NLS has not been identified in NHERF-1, perhaps GRK6 A 
by binding to the PDZ domain o f NHERF-1, regulates its nuclear localisation and 
function(s). This requires further investigation.
The crystal structure o f GRK 6 A has recently been solved and suggests that this 
kinase may exist as a dimer (Lodowski et al., 2006). This is in contrast to the crystal 
structure elucidated for GRK2 that suggests a monomeric structure for this kinase 
(Lodowski et al., 2003a). The relative positions of the DNA-binding domains of 
GRK6 A, the NLS (Chapter 4) and, by homology with GRK5 (Chapter 5), the N- 
terminal CaM binding region o f GRK 6  are shown in Figure 6.1. Lodowski and 
colleagues report that the region containing the NLS o f GRK6 , located between the 
oeF-aG loop (Figure 6.1), blocks the peptide binding channel o f GRK6 , which 
accommodates protein residues phosphorylated by this kinase (Lodowski et al.,
2006). This suggests that exposure o f the NLS o f GRK6  may be regulated by 
substrate binding. Exposure o f the NLS o f GRK 6  would allow DNA binding. When 
GRK6  is a dimer, the two NLSs are located at the extremity o f the protein (Figure
6.1) and might allow the dimer to wrap itself around DNA. Mutations o f GRK6 A, 
predicted to inhibit dimerisation, had no effect on GRK6 A-mediated phosphorylation
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o f  rhodopsin in vitro (Lodowski et al., 2006). It is thus possible that dimerisation is 
required for other, perhaps nuclear, functions o f GRK6A. DNA-binding of many 
transcription factors/co-regulators is dimerisation-dependent (Kohler et al., 1999; 
Lee, 1992). It would thus be o f interest to examine whether the dimerisation o f  
GRK6A is required for DNA-binding (discussed further in Section 6.6.1). Potentially 
palmitoylation o f  GRK6A may promote the nuclear localisation o f this kinase and its 
interaction with DNA by regulating its dimerisation status. It has been reported that 
lipid modification, in particular, palmitoylation is required for efficient 
oligomerisation o f  sphingosine kinase type lb, Post-synaptic density protein 95 and 
VIP21-caveolin (Christopherson et al., 2003; Kihara et al., 2006; Monier et al., 1996). 
Determination o f the crystal structures o f  GRK5 and GRK4 that, respectively, do and 
don’t bind DNA might elucidate whether the ability to dimerise is a feature specific 
to the DNA-binding GRKs (GRKs 5 and 6) or is a common feature o f the GRK4 
subfamily o f GRKs.
site
NLS
N-terminal CaM binding
N-terminal CaM binding site
Figure 6.1. Crystal Structure of GRK 6  homodimer.
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GRK6 forms a homodimer at the surface o f  the RH domain. The relative positions o f the proposed 
DNA binding regions o f GRK6, the NLS and N-terminal CaM binding region (by homology to 
GRK5), are indicated. Mg2+ AMPPNP is bound within each active site. Nitrogen atoms are coloured 
blue, oxygen is red, phosphate is green and magnesium black. Carbon atoms are coloured according to 
the domain in which they are found except for those in AMPPNP that are grey (Reproduced from 
Lodowski et al., 2006).
6.4. GRK5 inhibits hypertrophy in cardiac myocytes
6.4.1. Structural determinants of GRK5 regulate its DNA-binding 
and nuclear export
I used a panel o f GRK5 mutants in Chapter 5 to determine what function(s) GRK5
might have in the nucleus. Characterisation o f these mutants also revealed
information about how GRK5 may bind to DNA, at least in vitro and, how DNA-
binding ability and nuclear export o f GRK5 may be regulated by CaM.
Ca2+/CaM binding to GRK5 is postulated to inhibit DNA-binding in two ways. 
Firstly, the NTPB domain o f GRK5 binds both DNA and CaM, the binding of these 
two ligands is thus likely to be competitive. CaM-binding to this region o f the kinase 
would thus be anticipated to impair binding o f  GRK5 to DNA. Secondly, since the 
CTPB mutant binds DNA more avidly than its wildtype counterpart, Ca2+/CaM 
binding to the C-terminus o f GRK5 (CTPB) might physically hinder DNA-binding or 
alter the 3D-confomational structure o f GRK5, by inducing inhibitory 
autophosphorylation, such that it is unable to bind DNA. Furthermore, Ca2+/CaM 
regulation o f nuclear export is dependent not only on CaM binding to the N-terminus 
o f the kinase as described in Chapter 3, but is also dependent on exposure o f the NES 
(Chapter 5.1.1). Perhaps CaM binding to GRK5, which inhibits DNA-binding also
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results in exposure o f its NES promoting its nuclear export. CaM and other Ca2+ 
sensing proteins, such as Calreticulin, have been shown to contribute to the nuclear 
export o f other DNA-binding nuclear proteins. Calreticulin, a Ca2+ binding protein 
originally identified in the lumen o f  the endoplasmic reticulum (ER), binds directly to 
the DNA-binding domain o f glucocorticoid receptors (DeFranco, 2001). This 
interaction inhibits DNA-binding and mediates nuclear export o f the nuclear hormone 
receptor (DeFranco, 2001). In a similar vein, Ca2+/CaM binds to the DNA-binding 
domain o f members o f the basic-helix-loop-helix (bHLH) family o f transcription 
factors to inhibit their interaction with DNA (Comeliussen et al., 1994; Hermann et 
al., 1998; Onions et al., 1997; Onions et al., 2000; Saarikettu et al., 2004). Regulation 
o f nuclear-protein export by Ca2+ signalling thus appears to be a common mechanism 
whereby TF activity might be inhibited. As discussed in Chapter 5, upon nuclear 
export o f GRK5, a range o f molecules including phospholipids (e.g. PIP2), actin/a- 
actinin and CaM could compete for binding to the NTPB o f GRK5, regulating its 
catalytic activity towards either membrane bound/receptor (PIP2 ) or soluble substrates 
(actin/oc-actinin and CaM).
In order to attempt to address the question o f what function(s) GRK5 may be carrying 
out in the nucleus, I turned to the literature in an attempt to identify leads that might 
suggest putative nuclear roles for this kinase. Notably, there is some evidence linking 
GRK5 expression to changes in gene expression (Eckhart et al., 2000). Cardiac 
hypertrophy, the physiological response o f the heart to an increased work load, is 
associated with transcriptional activation of genes encoding embryonic markers, 
including ANF, a-skeletal actin and (3-MHC (reviewed in Chien, 1999). Transgenic
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mice expressing a constitutively activated mutant of the am A R in the heart exhibit 
myocardial hypertrophy and have elevated DAG content and ventricular ANF 
expression (Eckhart et al., 2000; Milano et al., 1994). Interestingly, concomitant 
expression o f GRK5 did not affect myocardial DAG content but did significantly 
attenuate constitutively active mutant-oti eAR-induced hypertrophy and ANF 
expression (Eckhart et al., 2000). Thus the cardiac overexpression of GRK5 whilst 
not affecting amAR/Gq-coupling does apparently inhibit cardiac gene transcription. 
It is tempting to speculate that the ability o f GRK5 to bind DNA may explain its 
differential effects on receptor function and gene transcription in this model system.
Endogenous GRK5 displays a more nuclear localisation in cardiac myocytes derived 
from spontaneously hypertensive heart failure (SHHF) rats than in age-matched 
control animals (Yi et al., 2002). The SHHF rat represents a genetic model for cardiac 
hypertrophy and the more nuclear localisation o f GRK5 in these cells may reflect 
either, a role for GRK5 in hypertrophic gene expression, or alternatively, an adaptive 
response to hypertrophy. This second explanation would serve to reconcile the results 
obtained using SHHF rats with those obtained using transgenic mice expressing 
constitutively active ocibAR in the heart, where co-expression o f GRK5 inhibits gene 
expression. Since Parr- 1  translocates to the nucleus upon 8 -opioid receptor activation 
and is found in complex with the histone acetyltransferase p300 (Kang et al., 2005), it 
is tempting to speculate that GRK5 is in a similar signalling complex temporally and 
spatially regulating transcription by modifying chromatin. In the case o f GRK5, 
however, GRK5-dependent changes in chromatin structure may be anticipated to 
inhibit gene transcription. Interestingly, parr-1 does not contain a NLS or NES yet
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has been shown to have a nuclear function (Kang et al., 2005). Perhaps GRK2 which 
also does not contain a NLS or NES, as far as I have been able to assess to date, 
might also function in the nucleus, gaining import by binding to a protein which 
contains nuclear import/export sequences. Since GRK2 is known to be involved in 
progression o f heart disease this would be a new and interesting line of enquiry.
6.4.2. GRK5 nuclear catalytic activity and DNA-binding ability 
are required for rescue of cardiac hypertrophy
In Chapter 5 , 1 recapitulated the published finding that GRK5 can rescue PE-induced
cardiac hypertrophy in rat myocytes ex vivo by overexpressing GRK5 or
GRK5ANES, both o f which are present in the nucleus and can bind DNA in vitro
(Eckhart et al., 2000). Moreover, I went on to demonstrate that this rescue requires
kinase activity and the ability o f GRK5 to bind DNA. Importantly, I demonstrate that
GRK5 inhibits hypertrophy induced by the activation o f signalling pathways
downstream of the GPCR, since GRK5 inhibits hypertrophy induced by a PLC
activator. This data suggests that it is not GRK5-dependent desensitisation o f GPCRs
that is responsible for GRK5-mediated inhibition o f hypertrophy. Kinase activity
however, appears to be essential as a kinase dead mutant o f GRK5 cannot rescue
hypertrophy. The DNA-binding ability o f GRK5 is also required to rescue
hypertrophy since the ANLS mutant o f GRK5, which does not bind DNA in vitro,
does not inhibit hypertrophy progression ex vivo (Chapter 3). Similarly,
overexpression o f GRK5NTPB, which is catalytically active (although reduced
compared to wildtype) but does not bind DNA in vitro (Chapter 3), cannot rescue
hypertrophy. Unexpectedly perhaps, it seems that GRK5 kinase activity and DNA-
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binding ability are both necessary for impeding advancement o f hypertrophy in 
myocytes. The potential nuclear substrates o f GRK5 and functional consequences of 
GRK5 DNA-binding are not yet understood, but merit further investigation.
Cardiac hypertrophy frequently deteriorates into congestive HF and a wealth of 
literature implicates a role for the GRKs in the development o f HF phenotypes. Both 
GRK5 and GRK2 are upregulated in animal models o f HF, and elevated GRK2 levels 
are associated with congestive HF in humans (Penela et al., 2006). Coronary artery 
ligation in rats reveals, however, that whereas myocardial GRK2 levels increase early 
after induction o f myocardial infarction, GRK5 upregulation occurs at a later stage 
(Vinge et al., 2001). Furthermore, immunohistochemical analysis o f myocardial 
tissue reveals that GRK2 is predominantly found in endothelial cells whereas GRK5 
is found mainly in myocytes (Vinge et al., 2001). This suggests that GRKs 2 and 5 
may be required for different events in the myocardial remodelling process leading to 
HF. Consistent with this hypothesis the subcellular distribution o f GRK2 and 5 in 
myocytes from SHHF rats as they progress, with age, from concentric to eccentric 
hypertrophy and to congestive HF, is very different (Yi et al., 2005). GRK2 becomes 
progressively localised to the intercalated discs whilst GRK5 redistributes from the 
cytoplasm to the nucleus (Yi et al., 2005). These observations are consistent with the 
data reported here showing that GRK5, but not GRK2, contains a NES and a DNA- 
binding NLS. Notably, the nuclear redistribution of GRK5 observed in the myocytes 
from SHHF rats precedes myocyte lengthening and shows a similar time course to 
ANF expression. Thus, these authors postulated a role for GRK5 in positively 
regulating hypertrophic gene transcription (Yi et al., 2005). In this thesis GRK5
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overexpression inhibits PE-induced hypertrophy o f rat myocytes ex vivo. If GRK5 
does indeed positively regulate transcription o f specific genes then the inhibition of 
hypertrophy observed here may be explained by mislocalisation o f GRK5-interacting 
transcription factors/co-regulators upon kinase overexpression. Alternatively, the 
nuclear translocation o f GRK5 observed during progression to HF in the SHHF rats 
may reflect an adaptive response to inappropriate gene expression. In this case 
overexpression o f GRK5 in rat myocytes would be anticipated to inhibit hypertrophy, 
by increasing the amount o f nuclear GRK5 and transcriptional repression. I anticipate 
that use o f the GRK5 mutants characterised in this study in isolated rat myocytes may 
ultimately lead to an understanding o f the molecular events associated with GRK5- 
mediated inhibition o f hypertrophy.
6.5. Experimental weaknesses of this thesis
In Chapters 3 and 4 I relied on the use o f immortalised cell lines overexpressing 
wildtype and mutant proteins o f interest. These systems, while quick and easy to use 
to address specific scientific questions do not always accurately reflect the subcellular 
localisation o f proteins in physiological relevant systems. Immortalised cell lines 
were however useful for initially identifying that the GRK4 subfamily localised to the 
nucleus. I was also able to determine that endogenous GRK5 is localised to the 
nucleus o f HEp2 cells. Further work is required to determine if  endogenous GRK4 
subfamily members display a nuclear localisation in other cell types. GRK5 is highly 
expressed in cardiac tissue (Yi et al., 2002), whilst GRK6  is present in lymphocytes 
(Fong et al., 2002), GRK4 shows a limited expression pattern, being expressed 
predominantly in the testes, kidney and brain (Felder et al., 2002; Premont et al.,
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1996; Sallese et al., 1994). Due to a lack o f time and access to suitable tissue- 
samples, I did not pursue this avenue further although it is important to show nuclear 
localisation o f the GRK4 subfamily members in their physiologically relevant 
settings. The use o f more physiologically relevant primary cells or tissue specific 
derived cell lines would also facilitate studies designed to investigate the regulation 
o f the nuclear localization o f GRK4 subfamily members and determine if  Ca2+ 
signalling is a bona fide  mechanism for regulating their subcellular localisation.
Due to low expression o f GRK4 when transfected in HEp2 cells I was unable to 
investigate the regulatory mechanisms controlling nuclear localisation o f this kinase. 
It might be easier to determine how GRK4 is regulated using cells expressing this 
kinase and its splice variants endogenously, e.g. in neurons. Interestingly, the ANLS 
mutants o f the GRK4 splice variants expressed well in HEp2 cells suggesting that 
nuclear localised GRK4 when overexpressed may lead to cell death.
To determine nuclear functions for GRK5 I did use experimentally relevant primary 
cells expressing endogenous ARs, rat neonatal cardiac myocytes. However, again I 
used overexpression o f mutant constructs to investigate the mechanism o f GRK5- 
mediated rescue o f hypertrophy. Whilst this was useful for determining that GRK5 
requires nuclear kinase activity and DNA-binding capability to inhibit PE-induced 
hypertrophy in myocytes ex vivo, RNAi o f endogenous GRK5, or myocytes isolated 
from GRK5 knockout mice might yield additional insights into the role o f GRK5 in 
regulating progression to a hypertrophic phenotype.
I did not address directly whether GRK5-mediated phosphorylation and therefore 
desensitisation o f ARs in myocytes contributes to the mechanism via which GRK5
196
overexpression prevents development o f  hypertrophy. Following PE activation of 
ARs in myocytes I could monitor PIP2  hydrolysis by measuring the amount of IP3 
produced to establish if  Gq-coupled signalling is attenuated when GRK5 and mutants 
thereof are overexpressed. If IP3 production is not decreased in myocytes expressing 
GRK5 compared to untransfected cells, then we can be confident that GRK5 is 
preventing hypertrophy via a nuclear mechanism rather than via desensitisation of 
ARs.
6.6. Future Directions
6.6.1. GRK6
It would be very interesting to carry out experiments to determine in more detail how 
the nuclear localization o f GRK6 is regulated. I characterised in detail the mechanism
1
of regulation o f GRK5 nuclear localisation and DNA-binding by the Ca sensor, 
CaM. I would hypothesise that since GRKs 6 B and C are exported from the nucleus 
after application o f Ca2+ ionophore that their regulation may be similar to GRK5 and 
involve CaM binding to the N-terminal NTPB. More interestingly though, GRK6 A
1
nuclear export does not appear to be regulated by Ca and therefore is unlikely to be 
mediated by CaM. Since one o f the defining features o f GRK6 A compared to it other 
splice variants is a C-terminal PDZ-binding m otif at its C-terminus, it would be 
interesting to determine if  GRK6 A has any unique nuclear binding partners compared 
to GRKs 6 B and C. This might be achieved using a Yeast two-hybrid system, or by 
immunoprecipitating GRK6  splice variants from the nucleus and identifying binding 
partners by mass spectrometry. An alternative approach would be to use fusion 
proteins o f the GRK6  splice variants over which nuclear lysates have been passed and
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again determine novel binding partners for GRK6 A by mass spectrometry. This 
might give clues regarding the nuclear function of GRK6 A. Performing these 
experiments using GRK6 A-flag, which has no functional PDZ motif, would 
distinguish nuclear binding partners that interact with GRK6 A via a PDZ interaction.
It would be interesting to determine if  GRK 6 A is present in a complex with NHERF- 
1 in the HCC cell line since these molecules have been localised to the nucleus and 
shown to increase transcription mediated by p-catenin and the T-cell transcription 
factor in these cells (Shibata et al., 2003). Moreover, using luciferase based 
transcription assays the ability o f wildtype GRK6 A (which binds DNA in vitro) or 
GRK6A-3C3A (which binds DNA poorly) to regulate NHERF-1-dependent gene 
transcription could be assessed (Hall et al., 1999; Shibata et al., 2003). 
Overexpressing GRK 6 A, GRK6 AANLS and GRK6 A-flag (ablated PDZ domain) 
with NHERF-1 might reveal whether GRK6 A regulates NHERF-1 nuclear functions 
by mediating NHERF-1 nuclear localisation since NHERF itself does not contain an 
NLS.
Overexpression of GRK 6  in myocytes to determine if  this GRK4 subfamily member 
can prevent development o f myocyte hypertrophy similarly to GRK5 would be 
worthwhile if  only to establish if  there is functional redundancy within the GRK4 
subfamily. Since mouse GRK6 D, a fourth mouse specific GRK6  splice variant, is 
nuclear and catalytically inactive, determining if  overexpression o f this splice variant 
in mouse cardiac myocytes can inhibit hypertrophy might indicate if  this kinase has a 
nuclear function even in the absence o f kinase activity. Since GRK5 appears to 
require both kinase activity and DNA-binding ability for rescue o f hypertrophy, use
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of GRK6 D, a naturally occurring splice variant, might be useful to dissect GRK6  
nuclear functions which require DNA-binding ability versus those which require 
kinase activity.
The crystal structure o f GRK 6  suggests this kinase exists as a dimer (Lodowski et al., 
2006). It would be interesting to determine if  dimerisation, which is not required for 
GPCR phosphorylation, is actually required for GRK6  DNA-binding. Preliminary 
data using mutants o f GRK6  in which dimerisation is predicted to be impaired 
suggests that indeed dimerisation may be required for DNA binding (Figure 6.2, 
DNA-binding carried out as described in Materials & Methods). In these mutants 
basic amino acids in the dimerisation domain are mutated to negatively charged, 
acidic amino acids. Thus I cannot exclude the possibility that these mutants fail to 
bind DNA simply because it too is a negatively charged molecule. Generation of 
mutants which inhibit dimerisation but do not change the overall local charge of the 
dimerisation site might address this question more convincingly. Since many 
transcription factors act as dimers in order to ‘clamp’ round DNA (Lee, 1992), this 
may not be such an inconceivable hypothesis.
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Figure 6.2. GRK6 double dimerisation mutants (I39E/I165E and I156/F527D), but not single 
dimerisation mutants, show a reduced affinity for DNA in vitro.
Lysates o f  cells expressing GRK.6 and mutants thereof (~15|ig) were incubated with native DNA- 
cellulose or ssD N A -cellulose (data not shown) and after extensive washing the amount o f bound GRK 
w as determ ined by W estern blot analysis as described in the Materials & Methods. The amount o f 
GRK6A bound to D N A -cellulose (-2 0 % ) was norm alised to 100%. The data shown represent the 
m ean values ± standard errors o f  the mean for at least three separate determinations. ***, P<0.001.
6.6.2. GRK4
GRK4 has been shown to desensitise certain neuronal metabotropic GPCRs. Confocal 
microscopy o f the cellular localisation o f GRK4 before and after stimulation o f the 
metabotropic glutamate or GABA B receptor in neurons might therefore reveal 
mechanisms whereby the nuclear localisation o f this enzyme is regulated. Since the 
NLS o f GRK4 is non-DNA-binding but found in a number o f proteins involved in 
cell growth, it would also be interesting to carry out assays to determine if  GRK4 
overexpression or RNAi alters cell growth or cell cycle progression. GRK4 was
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identified as a promoter o f cell survival in a RNAi screen in cervical carcinoma cells 
(MacKeigan et al., 2005). Apoptosis in HeLa cells was increased more than four-fold 
over control cells following GRK4 RNAi. Determining if  GRK4 is involved in 
contributing to cellular survival signals that counterbalance apoptotic signals might 
therefore be an important line o f research in understanding potential nuclear functions 
o f this kinase. Cell populations overexpressing GRK4 or specifically depleted in 
GRK4 could be assessed for DNA fragmentation, the activation state o f apoptotic 
kinases or release o f cytochrome C from the mitochondria, following stimulation of 
apoptosis by, for example, exposure to UV. I suggested in Chapter 4 that since the 
NLS o f GRK4 and the GRK1 subfamily share homology and are not predicted to 
bind DNA, that GRK4 might best be grouped with the GRK1 subfamily. Lack of 
GRK1 (rhodopsin kinase) in mice results in apoptotic retinal degeneration (Chen et 
al., 1999). It would therefore be interesting to determine if  both the GRK1 subfamily 
and GRK4 function to regulate apoptosis.
6.6.3. GRK5
Since GRK5 is the best characterised member of the GRK4 subfamily, investigation 
o f its potential role in inhibiting cardiac hypertrophy would be predicted to advance 
more rapidly than studies aimed at elucidating nuclear functions of GRKs 4 and 6 .
Following on from experiments I described in Chapter 5, it would be exciting to 
investigate the molecular mechanisms underlying the requirement for the DNA- 
binding ability and kinase activity o f GRK5 for inhibition o f hypertrophy. Nuclear 
substrates o f GRK5 may be identified by transfecting cells with wildtype and 
catalytically inactive GRK5 and subsequently labelling with [3 2P] orthophosphate.
201
Two-dimensional gel electrophoresis and autoradiography o f lysates o f the nuclei of 
these cells may reveal proteins which are specifically phosphorylated following 
GRK5 overexpression. Identification by Mass spectrometry o f potential nuclear 
substrates o f GRK5 may suggest nuclear signalling pathways regulated by this 
kinase. Initially, these experiments could be performed in cultured neonatal 
cardiomyocytes (H9C2 cells) as transfection o f these cells is more efficient than 
transfection o f cardiac myocytes.
To address the role o f GRK5 in the inhibition o f cardiac hypertrophy ex vivo the 
DNA-binding specificity o f GRK5 needs to be assessed. I tried unsuccessfully to 
identify a DNA-binding site for GRK5 using CASTing (cyclic amplification and 
selection o f targets) (Wright and Funk, 1993) and a modified chromatin 
immunoprecipitation (ChIP) technique (Weinmann and Famham, 2002; Wells and 
Famham, 2002) in CHO cells. CASTing involves mixing purified GRK5 with a 
library o f degenerate oligonucleotides flanked at each end by a defined primer 
sequence for PCR amplification. Immunoprecipitation o f GRK5, isolation o f DNA 
fragments and sequencing o f these amplified fragments could in theory reveal, after 
several rounds, the preferred DNA-binding consensus sequence o f GRK5. This 
sequence could be blasted against promoter regions o f the human genome to 
determine possible target genes that GRK5 might regulate. It would be interesting to 
see if  any o f the genes which are upregulated or downregulated during cardiac 
hypertrophy are identified from such a blast search. An alternative approach used was 
a modified ChIP technique which involves cross-linking GRK5 to chromatin in cells, 
sonicating the nuclei and purifying, by immunoprecipitation, GRK5 linked to DNA.
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Reversal o f cross-links reveals, in theory, DNA fragments which can be sequenced to 
determine the GRK5 DNA-binding consensus sequence but in addition, any protein 
binding partners o f GRK5 in the nucleus may also be identified by Mass 
spectrometry. The additional benefit o f this approach is that identification o f nuclear 
binding partners of GRK5 might indicate the nuclear role o f GRK5. Although initial 
attempts using this technique failed, in hindsight it would have been better to carry 
out these experiments in myocytes. Another approach would be to carry out a 
‘classical’ ChIP protocol, and immunoprecipitate GRK5 and probe for genes which 
are known to be upregulated in cardiac hypertrophy such as ANF, c-fos or p-MHC.
It might be useful to take a candidate approach to predict nuclear binding partners of 
GRK5. parr-1 is known to bind to the HAT p300 and recruit it to certain promoters 
where it acetylates chromatin and promotes initiation o f transcription (Kang et al., 
2005). Since GRK5 overexpression in myocytes inhibits hypertrophy perhaps GRK5 
suppresses hypertrophic transcription by regulating similar molecules (HDACs or 
HATs). I carried out some preliminary experiments to attempt to understand if  GRK5 
is involved in chromatin remodelling (Figure 6.3). I investigated histone acetylation 
states in Cos-7 cells expressing wildtype GRK5 or GRK5K215R (catalytically 
inactive GRK5). Transfected and untransfected cells were scored (positive or 
negative) for immunofluorescently labelled acetylated histone H3, H4 or 
phosphorylated histone H3, the results are represented graphically in Figure 6.3.
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■  GRK5K215R
□ GRK5K2I5R + A23187
AcH4 stained AcH3 stained P-H3 stained **  = P<0.01
Figure 6.3. Nuclear export of GRK5 inhibits acetylation of histones H3 and H4.
Cos-7 cells were transiently  transfected with wildtype GRK5 or G RK 5K215R and either left untreated 
or treated w ith calcium  ionophore, A 23187 (25pM , 15 min). Cells expressing GRK5 constructs or 
untransfected cells w ere subject to im m unofluorescent labelling as described in the M aterials & 
M ethods. T ransfected and untransfected cells were scored (positive or negative) for acetylated histones 
H3 and H4 or phosphorylated histone H3. N uclear export o f  wildtype GRK5 following A23187 
treatm ent, results in a significant reduction in acetylation o f  histone H3 and H4 com pared to 
untransfected cells. The sam e result was observed w ith catalytically inactive GRK5 (K215R) 
suggesting that GRK5 kinase activity is not required for this effect. No significant alteration in 
phosphorylated histone H3 w as observed betw een untransfected and transfected cells with or without 
A23187 treatm ent. *, P<0.05; **, P<0.01.
Following Ca2+ ionophore treatment and nuclear export o f  wildtype GRK5, I 
observed a 28% decrease in both acetyl-H3 and -H 4 staining compared to untreated 
cells (compare solid blue bars with crossed blue bars). A significant decrease in 
acetyl-H3 or -H 4 staining was not observed in untransfected cells following A 23187 
treatment (compare black bars with black crossed bars). Importantly, the same effect 
was observed in cells transfected with GRK5K215R; 41% fewer cells showed aceyl- 
H3 staining and 27% fewer cells showed acetyl-H4 staining compared to untreated 
cells (compare red bars to crossed red bars) suggesting that this effect is not mediated 
by GRK5 kinase activity. No change in the phosphorylation status o f histone H3 was
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observed following treatment. Therefore, it appears that nuclear export of 
overexpressed GRK5 in Cos-7 cells results in a decrease in histone H3 and H4 
acetylation levels but does not affect phosphorylation of histone H3. These results 
taken together with the fact that GRK5 overexpression in the nucleus of myocytes 
prevents development o f PE-mediated hypertrophy suggests that nuclear GRK5 might 
act to inhibit hypertrophy by inhibiting HDAC(s) or activating HAT(s) (Figure 6.3). 
A conceivable hypothesis that fits with this data would be that GRK5 promotes anti- 
hypertrophic gene transcription, such as the a-M HC gene, which is downregulated 
during hypertrophy.
An alternative approach to examine the role of GRK5 in cardiac dysfunction would 
be to generate GRK5ANLS and GRK5ANES knock-in mice to determine if  these 
mice exhibit resistance or susceptibility to the development o f hypertrophy and heart 
disease. Any such phenotype might aid in unraveling the molecular mechanism(s) 
whereby GRK5 modulates myocyte function. Completion o f these experiments would 
further our understanding o f the mechanisms regulating GRK4 subfamily nuclear 
localisation and function(s) in the nucleus.
6.7. Concluding remarks
In conclusion, in this thesis I present evidence that strengthens the emerging concept 
that GRKs act not only to desensitise GPCRs but are also involved in downstream 
signalling events. The list o f non-receptor substrates for GRKs is growing rapidly but 
this study provides evidence for novel properties o f the GRK4 subfamily including 
regulated nuclear localisation and DNA-binding. These studies have also revealed 
diversity among the GRK4 subfamily members and also between the GRK2 and 4
205
subfamilies. I have showed that GRKs 5 and 6  bind DNA in vitro and further work is 
required to understand the mechanism and relevance o f this finding in a cellular 
setting. Importantly, I have shown that GRK5 may play a role in regulating cardiac 
hypertrophy since it appears to represses such a phenotype in cardiac myocytes ex 
vivo. This finding suggests that GRK5 may represent a therapeutic target for the 
management o f cardiac hypertrophy and heart disease.
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